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Abstract;
The work reported in this thesis addresses the regulatory factors that function to limit 
the initiation of protective immune responses following exposure to the bacterium 
Mycobacterium  tuberculosis  (MTb).  Control  and  clearance  of  intracellular 
pathogens,  such  as  MTb,  is dependent on the cytokine Tumour Necrosis Factor 
(TNF)  and induction  of a T-helper  1   (Thl)  response,  which is  characterised by 
production of IFN-gamma driven by interleukin (IL)-12.  In other infection models 
the presence of the immunosuppressive cytokine IL-10 in the local milieu has been 
shown  to  down-regulate  Thl  responses  thus  limiting  detrimental  host  induced 
immune-pathology.
To determine a role for IL-10 following murine infection, we examined its 
function during acute and chronic infections with two strains of H37Rv obtained 
from either i) National Institute for Medical Research (NIMR) or ii) London School 
of Hygiene and Tropical Medicine (LSHTM).  IL-10 receptor blockade during the 
chronic phase of MTb  infection reduced bacterial burdens in  mice infected with 
H37Rv NIMR, but not mice infected with H37Rv LSHTM.  However, despite the 
lack of effect of IL-10 blockade on the bacterial load during chronic infection with 
H37Rv LSHTM, immune cells obtained from MTb infected mice produced elevated 
levels of IFN-gamma when stimulated in vitro in the presence of IL-10 blocking 
antibodies.  In  addition,  neutralisation  of IL-10  before  and  during  acute  MTb 
infection with H37Rv LSHTM resulted in a transient reduction in bacterial burdens 
and  enhanced  IFN-gamma  production,  suggesting  that  IL-10  plays  a  role  in 
regulating the early immune response to MTb.
Additional regulators that may function together with or in parallel to IL-10
to limit bacterial clearance such as regulatory T cells (Tregs) have been shown to be
i- Abstract -
regulators of autoimmunity, atopy and infectious disease.  Using flow cytometric 
analysis  of the  Treg  specific  transcription  factor  FoxP3,  we  observed  an  early 
increase in the  number of lung Tregs following  aerosol  MTb  infection of mice. 
However, when addressing the effect on bacterial clearance in the absence of Tregs 
by either i)  antibody depletion or ii)  adoptive transfer approaches into immuno- 
deficient mice, a suppressive role for Tregs on bacterial burdens could not be found.
Finally this work evaluated the role of plasmacytoid precursor DC  (pDC) during 
MTb infection, which is in contrast their normal function as mediators of the anti­
viral response.  Upon in vitro exposure to viable MTb, plasmacytoid pDC could not 
be infected and did not produce pro-inflammatory cytokines.  Using flow cytometry, 
we observed no increase in plasmacytoid pDC in either the lung or spleen during the 
early stages of aerosol or intravenous infection.  In addition, antibody depletion of 
plasmacytoid pDC during the early stages of MTb infection did not affect bacterial 
load.  In summary, the data suggests that plasmacytoid pDC play only a minor role 
during the early immune response to MTb.
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1.1.  Mycobacterium tuberculosis (MTb):
Robert Koch first identified MTb  as the causative agent of tuberculosis  (TB)  in 
1882, to date, TB is once more on the increase and is responsible for approximately 
8 million new cases and 2 million deaths annually (WHO, 2006).  The incidence of 
TB is commonly associated with developing economies such as those in sub-Saharan 
Africa, however, the number of reported cases in developed economies such as the 
UK (Fig. 1.1 A), has seen a dramatic 10% increase from 2004 (7,240 cases) to 2005, 
(8,027 cases) with the vast majority of cases occurring in London (Fig. 1.1B) (Health 
Protection Agency UK (HPA, 2006).
Figure 1.1:  The number of reported cases of TB are on the increase in the UK 
and more specifically in London.  (Data adapted from the HPA-UK, 2006).
On average, 90% of individuals exposed to MTb mount an efficient cell mediated 
immune response culminating in a latent infection with no visible signs of disease. 
The remaining 10% of individuals for reasons that are at not fully understood, will 
progress to active disease as demonstrated by culturable bacilli from the sputum
A B
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(Kaufmann, 2001, Frieden et al., 2003).  Over the past ten years TB has been on the 
increase worldwide.  In 2000, TB was the cause of 11% of deaths in individuals co­
infected with HIV/AIDS  and to date, in South Africa alone more than 2 million 
people are co-infected with TB and HIV/AIDS (North et al., 2004).  Globally it is 
believed that of the 45 million people infected with HIV/AIDS, approximately  15 
million are co-infected with TB  (WHO, 2006).  The close association of TB  and 
HIV/AIDS  highlights  the  importance  of CD4+  T  cells  in  mediating  anti-MTb 
immunity.
1.2.  Artillery in the fight against TB:
1.2.1.  BCG:
In 1921, the development of bacille Calmette-Guerin (BCG) was heralded as a major
breakthrough in the fight against TB  and to date still is the only current licensed
vaccine  for  TB.  The  BCG  vaccine  was  derived  from  in  vitro  passaging  of
Mycobacterium bovis, the Mycobacterium responsible for bovine TB,  on potato
slices soaked in ox gall (Kaufmann, 2006a).  During the passaging process key genes
of stimulatory molecules were shown to have been lost from BCG, such as the T cell
antigens ESAT-6 and CFP-10 from mutations in the BCG RD1  gene (Pym et al.,
2002), these antigens are readily abundant in live virulent MTb (Harboe et al., 1996).
It has been estimated that more than 3 billion doses of BCG have been administered
to date globally. (WHO, 2006).  In the UK, the vaccination of school children over a
period of 15 years has led to sharp 70% decline in the incidence of TB (Young et al.,
2006).  To date, BCG shows great efficacy in preventing childhood meningeal TB,
but  shows  extensive  variability  in protection  from  adult pulmonary  TB  that  is
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suggested to be dependent on geographical location (Fine, 1995).  The reasoning for 
this variation in the efficacy of BCG globally is not fully understood, however, it is 
believed that the pre-existing immune response in vaccinated individuals to shared 
antigens  between  mycobacterial  species  and  MTb  may  result  in  sub-optimal 
vaccination (Andersen et al., 2005).
1.2.2.  Antibiotics and drug resistance:
The  advent  of antibiotics  including  streptomycin  in  1943  was  seen  as  a  major 
breakthrough  in  the  battle  against  TB.  The  further  discovery  of  Isoniazid, 
Pyrazinamide, Ethambutol and Rifampin during  1950-1960 led to a decline in the 
number of cases of TB.  However it is believed that during the late 1970’s and early 
1980’s the cessation of treatment regimens including the closure of sanatoriums in 
developed countries, led to a resurgence in the number of cases until 1993 when the 
WHO declared TB a global emergency (WHO, 1993).
Patients displaying symptoms of active TB can be treated with a cocktail of front­
line antibiotics - Isoniazid, Ethambutol, Pyrazinamide and Rifampin (Wright, 2006). 
Although antibiotic chemotherapy is effective in reducing infectivity, treatment lasts 
for at least six months, gives  severe side effects e.g.  liver damage,  and does not 
achieve sterile cure.  In addition, the increasing failure for patients to comply with 
the long and arduous drug regimen often results in multi-drug resistant forms of TB 
(MDR-TB) (Kaufmann, 2001, WHO, 2006, Wright, 2006).  The incidence of MDR- 
TB  has  been  on  the  increase  since  the  late  1980’s  but  in  contrast to  antibiotic 
resistance associated by horizontal gene transfer, as was the case for penicillin, drug
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resistance in MTb is associated with chromosome mutations (Young, 2003). Patients 
with MDR-TB, if treatable, receive an extensive course of chemotherapy consisting 
of multiple  first and  second-line antibiotics lasting up to two years.  In latently 
infected  individuals  or  in  patients  that  have  completed  chemotherapy,  the  TB 
bacillus can persist for years  without giving  any  symptoms (Kaufmann, 2006b). 
Now in the 21st century, the increasing rise in cases of TB but more prominently the 
emergence  of  multiple  drug  resistant  strains  of MTb,  the  rising  incidence  in 
HIV/AIDS and air travel between continents means the spreading and lethality of 
MTb has never been greater.
1.3.  An overview of the immune response and its role in eradicating invading 
pathogens:
The maintenance of immune homeostasis involves the concise interplay between a 
multitude of immune cells  and their secreted biologically active  soluble factors. 
Their aim is to function harmoniously in order to regulate autoimmunity, atopy or 
eradicate infection whilst minimising host immune-pathology.  The key players in 
the immune system and more specifically with respect to mediating immunity to 
MTb infection, will be discussed below:
1.3.1.  Macrophages:
13.1.1.  Background:
Macrophages originate from circulating bone marrow derived monocytes and play a
pivotal role in the innate immune response to infection by ingesting, controlling and
eradicating  intracellular  pathogens  such  as  Listeria (Portnoy  et al.,  2002),
5- Chapter 1: Introduction -
Leishmania (Engwerda et al., 2004), Toxoplasma gondii (Gazzinelli et al., 1992) and 
MTb (North et al., 2004) through the production of anti-microbial reactive oxygen 
and nitrogen intermediates (Shiloh et al., 2000).  Macrophages can be derived from 
distinct sub-populations in lymphoid organs, but in addition can also be obtained 
from  non-lymphoid  tissues  such  as  the  lung,  liver and epidermis  (Taylor et al., 
2005).  Macrophages are normally resident at natural sites of pathogen entry e.g. the 
lung, and therefore express  a large  variety  of pathogen recognition receptors  to 
facilitate the recognition of invading organisms  or their products  and mount an 
appropriate immune response (Taylor et al., 2005).  Following stimulation with the 
toll-like receptor (TLR) ligands LPS (TLR-4) and CpG-DNA (TLR-9), macrophages 
produce Tumour Necrosis Factor (TNF), interleukin (IL)-12p40, IL-6 as well as the 
anti-inflammatory cytokine IL-10 (Boonstra et al., 2006).
1.3.1.2.  Macrophages and MTb:
The importance  of macrophages  in the immune response to MTb has been well
documented  (Armstrong et al.,  1975,  Schlesinger,  1993,  Gomes et al.,  1999,
Underhill et al.,  1999,  Gonzalez-Juarrero et al., 2003).  Upon inhalation of MTb
bacilli,  the  first  lines  of  defence  are  resident  lung  alveolar  macrophages.
Macrophages readily phagocytose the MTb bacteria and become activated producing
the cytokines  TNF and IL-12  (Kaufmann, 2001).  Once phagocytosed,  the MTb
bacillus survives and persists inside the macrophage by inhibition of phagosome-
lysosome fusion (Armstrong et al., 1971), in doing this MTb can still gain access to
essential nutrients, e.g. iron, via the early endocytic pathway (Sturgill-Koszycki et
al.,  1996, Collins et al., 2002).  Cytokine activation of macrophages by interferon
(IFN)-gamma  leads  to  enhanced  production  of  reactive  oxygen  and  nitrogen
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intermediates that  mediate mycobacterial  killing  (Chan et al.,  1992,  Chan et al., 
1995,  Flynn et al.,  1998,  MacMicking et al.,  1997).  Furthermore,  activation of 
macrophages  by  IFN-gamma  but  not  MTb,  is  dependent  on  the  intracellular 
signalling adaptor molecule MyD88 (Shi et al., 2003).
13.2.  Dendritic cells (DC):
1.3.2.1.  Background:
DC act as sentinels for pathogens, migrating through the blood to peripheral tissue to 
uptake antigens, then migrating to the lymph nodes and spleen, and processing and 
presenting antigens to T cells thus initiating immune responses (Banchereau,  1998, 
Lanzavecchia et al.,  2001,  Steinman,  1991,  Shortman et al.,  2002).  DC  can  be 
derived from the bone marrow  (BM)  after culture resulting  in  myeloid DC  and 
plasmacytoid pDC.  In the mouse, both can produce IL-12 and TNF upon triggering 
through  appropriate receptors but only plasmacytoid pDC  produce IFN-alpha in 
response to viral  infection.  DC can also be directly isolated from the spleen as 
classical  DC  (CD8a+  or  CD8a-,  CDllb+  DC)  or  splenic  plasmacytoid  pDC 
(Shortman et al., 2002).  The flexibility of different DC in response to pathogens and 
other environmental signals enables them to direct Thl or Th2 responses (Fig.  1.2) 
(Boonstra et al., 2003, Kapsenberg, 2003).  In response to microbial stimulus DC 
and macrophages produce bioactive IL-12 (more specifically IL-12p70), a cytokine 
that comprises of two subunits, a 35kDa light chain (p35) and a 40 kDa heavy chain 
(p40).  It has been shown that the IL-12 (p40) subunit can also associate with another 
molecule called pi9, to form a heterodimeric cytokine called IL-23, a key mediator 
involved in activation of long lived memory T cells (Trinchieri, 2003).  Following
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microbial  stimulus  IL-12  has  a polarising  effect on  CD4+  T  cells  driving  them 
towards a Thl  phenotype (Fig.  1.2), characterised by production of IFN-gamma 
(Robinson et al.,  2002,  Trinchieri,  2003).  In  contrast,  the  immunosuppressive 
cytokine  IL-10  can  dampen  Thl  responses  by  directly  acting  on  the  DC  and 
macrophages  to inhibit the  production of IL-12  (Fiorentino et al.,  1991b).  Thl 
responses are in contrast to Th2 responses, that are categorised by IL-4, IL-5, IL-13 
(Sher  et al.,  1992,  O'Garra,  1998)  promoting  protection  against  extracellular 
pathogens such as filarial worms (Whelan et al., 2000).
IL10: from DC, M < j> , B cells, CD4 &  CD8 T cells.
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Th2
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Figure  1.2:  IL-12  production  by  DC following  TLR  ligation  results  in  the 
development of Thl ceUs. (Medzhitov, 2001).
PAMPor
Pathogen
Pathogen
Endocytic
PRR
CD28
t  D80/B6
Dendritic
cell
8- Chapter 1: Introduction -
1.3.22.  DC and MTb:
Similar to macrophages, DC can phagocytose MTb bacilli (Henderson et al.,  1997, 
Gonzalez-Juarrero et al., 2001a) and become activated leading to the production of 
the cytokines TNF and IL-12  (Bodnar et al., 2001,  Giacomini  et al.,  2001).  In 
contrast to macrophages, DC are not able to kill intracellular MTb (Bodnar et al., 
2001, Tailleux et al., 2003).  However, DC play a key role in the uptake of MTb 
(Garcia-Romo et al., 2004) and BCG (Humphreys etal., 2006), then migrate to local 
draining lymph nodes.  It has also been reported that following instillation of DC 
(pre-treated with heat-killed MTb in vitro) into the trachea of naive mice, DC can 
subsequently be found 18 days later in the draining mediastinal lymph nodes with 
the capacity to drive Thl responses (Bhatt et al., 2004) that is in part dependent on 
IL-12p40 (Khader et al., 2006).  In line with this, the importance of DC in driving 
adaptive CD4+ T cell responses during early MTb infection has been shown by 
(Tian et al., 2005) using a pCDllc-diptheria toxin receptor/GFP transgenic mouse, 
where DC could be transiently ablated in vivo.  The study demonstrated that the 
absence of DC during early MTb infection resulted in impaired CD4+ T cell IFN- 
gamma and increased bacterial levels in the spleen and lungs.
1.3.3.  The granulomatous response to MTb: containing infection:
Following  macrophage  phagocytosis  of invading  MTb  bacilli,  a  host-pathogen 
standoff occurs where a small percentage of MTb bacilli survive by evading the anti­
microbial  mechanisms  of  the  macrophage  and  persist  within  the  un-fused 
phagosomes  giving  rise  to  a  latent  infection  (Armstrong  et al.,  1971).  The 
composition of the granuloma in human pulmonary TB has to date received little
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attention since original reports by the classical pathologists at the turn of the 20th  
century (Ulrichs et al., 2006).  In contrast, animal models such as the mouse and 
guinea pig have been the subject of intense investigation as MTb infection in animals 
slowly progresses to a disease that is both physiologically  and immunologically 
similar to human TB.
1.3.3.1.  The granulomatous response in human MTb:
Granulomas  in  human  MTb  infection  can  be  subdivided  into  a)  caseating 
(tuberculoid) granulomas (Fig.  1.3) or b) non-caseating (sarcoid) granulomas (Fig. 
1.4).  Following inhalation of MTb bacilli, a local inflammatory response mediated 
by infected alveolar macrophages and epithelial cells, gives rise to the formation of 
granulomas where bacilli are controlled and contained (Fayyazi et al., 2000).  If 
protective immunity is impaired in the infected host, tuberculoid granulomas may 
develop.  These contain a soft to firm “cheese-like” caseated centre (hence the Latin 
name caseous detritus)  comprising  largely of host cell debris, bacterial and host 
derived lipids, necrotic macrophages and fused infected epithelial cells or giant cells 
(Fig. 1.3)  (Kaufmann, 2001).  Due  to  the  caseated  composition  of  tuberculoid 
granulomas, they contain large numbers of infectious bacilli that can be released in 
aerosol  droplets  by  coughing  in  order  to  spread  infection.  However,  in  mice 
caseating tuberculoid granulomas do not occur (Co et al., 2004).  Studies in human 
TB patients have identified the presence of IFN-gamma and IL-12p40 in sarcoid 
granulomas (Fenhalls et al., 2002).  Interestingly, granulomas progressing towards a 
tuberculoid phenotype (or tuberculoid granulomas) were commonly associated with 
the production of TNF but not IFN-gamma, implying a down-modulation of T cell 
responses at this stage (Fenhalls et al., 2000).
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More recently, the presence of peripheral structures that closely resemble lymphoid 
follicles have been reported in close proximity to granulomas (Ulrichs et al., 2004). 
The peripheral follicles were located close to blood/lymphatic vessels and comprised 
predominantly of infected  antigen presenting cells  (APC),  and B  cells  with few 
CD4+ and CD8+ T cells.  The authors hypothesise that the presence of a peripheral 
lymphoid structure is to serve as a hub in order to co-ordinate the ongoing immune 
response to MTb.  The composition of peripheral lymphoid follicles is in contrast to 
the main granuloma which comprises predominantly of infected APC and CD4+ T 
cells with relatively low numbers of peripheral CD8+ T cells (Ulrichs et al., 2004).
APC
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Figure 1.3: The caseating tuberculoid granuloma during human MTb infection.
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13.3.2.  The granulomatous response in animal models of MTb:
The majority of studies on granuloma formation during MTb infection have largely 
been performed in mice as opposed to guinea pigs and rabbits.  This is largely due to 
factors such as maintenance costs, bio-safety containment space requirements and 
availability of immunological reagents.  The granulomatous response in mice does 
not progress to caseation or necrosis such as those observed in human pulmonary 
TB, often giving rise to non-caseating sarcoid granulomas (Fig.  1.4).  In addition, 
this  is  not to  say  that the  guinea pig  and rabbit models are  not useful tools  in 
dissecting the immune response to MTb, for example rabbits are the only animal 
model that following infection both caseation and cavitation are evident (Fig  1.3), 
which is phenotypically similar to the phenomenon that occurs in human pulmonary 
TB (Converse etal., 1996).
Studies  in  the  mouse  have  highlighted  the  presence  of  activated  APC  and
lymphocytes in the milieu producing cytokines such as TNF (Flynn et al,  1995a,
Bean et al., 1999) and lymphotoxin-alpha (Roach et al., 2001a) that are pivotal in the
organisation and maintenance of the granuloma.  Surrounding the granuloma centre
are macrophages producing pro-inflammatory cytokines such as TNF and IL-12 in
response  to  infection.  To  date,  DC  have  not  been  observed  directly  in  the
granuloma, however as discussed above, lung DC have been shown to be infected
with MTb in vitro  (Gonzalez-Juarrero et al., 2001a), and infection of BM derived
DC gives production of TNF and IL-12 (Bodnar et al., 2001).  DC play an essential
role  in  the  initiation  of adaptive  immune responses  as  following  mycobacterial
challenge they migrate to draining lymph nodes (Bhatt et al., 2004, Humphreys et
al., 2006), where they initiate adaptive immune responses and can give rise to the
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generation of antigen specific CD4+ and CD8+ T cells producing IFN-gamma (Feng 
et al., 1999).  Similar to human granuloma studies by Ulrichs et al., (2004), studies 
in the mouse have reported that CD4+ T cells form organised aggregates and are 
more  abundant  within  granulomas  than  CD8+  T  cells,  which  are  restricted 
predominantly to the periphery (Gonzalez-Juarrero et al., 2001b).
The presence of T cell  derived IFN-gamma optimally activates macrophages for 
anti-microbial activity by inducing compounds such as reactive oxygen and nitrogen 
intermediates (Chan et al.,  1992, Shiloh et al., 2000).  In response to stress, MTb 
switches to fatty acid metabolism in order to survive and take  advantage of the 
abundance  of  lipids  and  nutrients  in  the  granuloma  (McKinney et al.,  2000). 
Furthermore, the cytokine and chemokine  signals responsible for controlling the 
initiation of the granulomatous response in both human and animal models are at 
present poorly understood (Ulrichs et al., 2006).
The majority of granuloma studies to date have focussed on animal models of MTb.
As  discussed  earlier,  the  characteristics  of  granuloma  structure  and  function
following  MTb  infection  in  animals  may  differ  compared  to  human  hosts.
Interestingly,  many  similarities  are  evident between  human  and  animal  models
following MTb infection as following MTb exposure mononuclear cell granulomas
develop in the lung followed by strong antigen specific CD4+  and CD 8+ T cell
responses  that control  infection.  In  addition,  the  infection  persists  under tight
immunological control for many months (North et al., 2004).  However, the rabbit
model of pulmonary MTb is the only animal model similar to the human with regard
to granuloma caseation and cavitation (Converse etal.,  1996, McMurray,  2001).
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When this phenomenon occurs as a result in a breakdown of protective immunity, 
vast numbers of infectious bacilli are released in aerosol droplets.  Summarised in 
Table 1.1. are features associated with MTb infection and granuloma assembly in the 
human as compared to typical animal models: mouse, rabbit and guinea pig.
Phagosome APC
CD4+ 
T cell M T b\
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Figure 1.4: The non-caseating sarcoid granuloma during murine MTb infection.
Table 1.1: Comparison of  pulmonary MTb infection between the human host and
animal models.
Disease feature: Human: Mouse: Rabbit: Guinea Piq:
Susceptibility to MTb ++ + + +++
Extrapulmonary dissemination ++ ++ ++ ++
Hematogenous seeding of apical lobes ++ ? ? ++
Typical mononuclear cell granulomas ++ ++ ++ ++
Caseation/necrosis ++ — ++ ++
Liguifaction/cavitation ++ — ++ -
Delayed-type hypersensitivity ++ +/- ++ ++
Protection by BCG vaccine ++/- + ++ ++
BSL-3 containment space reguired NA + ++++ ++
Maintenance costs NA + ++++ ++
Immunological reagents ++++ ++++ ++ +
(adapted from McMurray, 2001)
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1.3.4.  Plasmacytoid pDC:
1.3.4.1.  Background:
Studies on human PBMC (Ronnblom etal.,  1983), and more recently in the mouse 
(Asselin-Paturel et al.,  2001,  Nakano et al.,  2001,  Bjorck,  2001),  described  a 
population of Type IIFN (IFN-alpha, -beta or -omega) producing cells with “plasma 
cell like morphology”, that were later renamed plasmacytoid pDC (Liu, 2005).  To 
date, numerous studies have shown that plasmacytoid pDC play a pivotal role in 
anti-viral immune response, as studies have shown that stimulation of plasmacytoid 
pDC  with  either  influenza  A  (Lund et al.,  2004,  Diebold et al.,  2004),  murine 
cytomegalovirus  (Dalod et al., 2003), or herpes simplex virus (HSV) (Izaguirre et 
al., 2003, Krug et al., 2004), resulted in the production of large quantities of type I 
IFN, more specifically IFN-alpha (Liu, 2005).  In the mouse, plasmacytoid pDC are 
considered  immature  DC  because  of  their  low  expression  of  co-stimulatory 
molecules and the limited ability to stimulate naive T-helper cells (Asselin-Paturel et 
al., 2001).  Because of this observation plasmacytoid pDC are regarded as classic 
innate cells that produce large amounts of type I IFN e.g. IFN-alpha following viral 
challenge.  However, upon activation plasmacytoid pDC up-regulate co-stimulatory 
molecules and can present antigen.  On the other hand, plasmacytoid pDC have been 
shown to be regulatory under conditions such as allergy (de Heer et al., 2004) whilst 
also mediating tolerance to vascularised grafts (Ochando et al., 2006).  Furthermore, 
no  studies  at  present  have  reported  the  ability  of plasmacytoid  pDC  to  either 
phagocytose  bacteria  or  play  a  role  during  bacterial  infection.  The  role  of 
plasmacytoid pDC during MTb infection will be the focus of chapter 5.
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1.3.4.2.  Type I IFN: inhibition of the anti-bacterial immune response: 
Interestingly, stimulation of mouse but not human plasmacytoid pDC with CpG- 
DNA  drives  the  production  of high  levels  of IL-12,  IFN-alpha  but  no  IL-10 
(Boonstra et al.,  2006).  Therefore  the involvement  of this  DC  subset  may  be 
important for inducing strong Thl responses.  In line with this, IL-12 is well known 
to promote protective Thl responses that are important for clearance of MTb, but its 
production  can  be  inhibited  (Cousens et al.,  1997)  or enhanced  under  certain 
conditions by type I IFN (Gautier et al., 2005).  Recent studies have shown enhanced 
immune  responses  to Listeria monocytogenes  in  the  absence  of IFN-alpha/beta 
signalling (Auerbuch et al., 2004, Carrero et al., 2004, O'Connell et al., 2004).  The 
findings by Auerbuch et al., (2004) indicated that in the absence of the Type I IFN, 
TNF production  by  phagocytic  cells  at  the  site of infection  was  enhanced thus 
promoting bacterial killing.  In conclusion, the interplay between IL-12 and type I 
IFN during infections may therefore be important for the outcome of the immune 
response to different pathogens.
13.43.  Plasmacytoid pDC, type I IFN and MTb:
As described earlier, infection studies with MTb on macrophages and BM myeloid
DC are well documented,  although the infection of plasmacytoid pDC with MTb
(addressed  in  chapter  5),  has  however  not  been  reported.  In  human  studies
plasmacytoid pDC have been shown to be present in the lymph nodes of TB patients
(Celia et al.,  1999) and are decreased in the blood of active TB  patients prior to
antibiotic chemotherapy (Lichtner et al., 2006).  Following successful completion of
chemotherapy the numbers of blood DC and plasmacytoid pDC returned to baseline
levels (Lichtner et al., 2006).  In the mouse model, injection of heat killed MTb into
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the footpad gave a 5-10 fold increase in plasmacytoid pDC induction in the knee 
draining lymph nodes (Blasius et al., 2004).  In the same study, in vitro stimulation 
of BM derived plasmacytoid pDC with heat-killed MTb did not induce IFN-alpha 
(Blasius et al., 2004), but the production of TNF or IL-12 was not examined.  In 
addition,  it has been  suggested that the hyper-virulent phenotype of the clinical 
isolate MTb HN878 in mice is due to induction of type I IFN, however, the source of 
the  Type  I  IFN  was  not  examined  (Manca et al.,  2001,  Manca et al.,  2005). 
Therefore, the role of plasmacytoid pDC as a source for Type I IFN during MTb 
infection is still at present unclear.
In  summary,  the  involvement  of plasmacytoid pDC  in  regulating  the  immune 
response to invading pathogens can be mediated, a) directly through production of 
large quantities IFN-alpha/beta  in response to  viruses,  or b)  indirectly via IFN- 
alpha/beta regulation of IL-12 as highlighted above.  Similarly, plasmacytoid pDC 
may also regulate asthmatic responses to inhaled antigens (de Heer et al., 2004) or 
tolerance to grafts (Orchando et al., 2006) through unknown mechanisms.
1.3.5.  The importance of the Thl response in immunity to intracellular 
pathogens:
IL-12 is essential for driving CD4+ T cells towards a Thl response (characterised by 
the production of IFN-gamma), which is key mediating immunity to intracellular 
pathogens  such as MTb.  However,  IL-4 production promotes the  Th2 response 
(characterised by the production of IL-4, IL-5 and IL-13), which is responsible for 
mediating protection to extracellular pathogens such as helminths, but in addition
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may also promote allergic reactions.  IL-17 producing cells  (Th-17)  are  a newly 
described subset of highly inflammatory CD4+ T cells that have been implicated in 
autoimmune  tissue  injury  leading  to  diseases  such  as  experimental  allergic 
encephalomyelitis (EAE) (Park et al., 2005, Langrish et al., 2005).  Th-17 cells are 
induced following microbial stimulus whilst in the presence of TGF-beta and IL-6 
(Mangan et al., 2006, Veldhoen et al., 2006) and their expansion requires the IL-12 
family cytokine IL-23 (Harrington et al., 2005).
13.5,1,  The  Thl  response  in  human  MTb:  lessons  learnt from Mendelian 
susceptibility cases.
The essential requirement for a Thl response for control of mycobacterial infections 
has been observed in patients exhibiting Mendelian susceptibility to mycobacterial 
diseases.  Mutations in the IL-12 receptor or related signalling molecules render 
individuals  extremely  susceptible  to  intracellular  pathogens  such  as  atypical 
mycobacteria  (Altare et al.,  1998,  Casanova et al.,  2002,  Dorman  et al., 2000), 
Salmonella (de  Jong  et al.,  1998)  and  pulmonary  TB  (Remus  et al.,  2004). 
Similarly, mutations in the IFN-gamma receptor 1  also render individuals extremely 
susceptible to pulmonary TB (Newport et al., 2003), BCG (Jouanguy et al.,  1996) 
and environmental mycobacteria (Dorman et al., 2004).  Interestingly, it has also 
shown that individuals with a polymorphism in the promoter for monocyte chemo- 
attractant protein-1   (MCP-1)  have  enhanced levels  of MCP-1  that inhibited the 
production of IL-12p40  by  monocytes  in  response  to  MTb  stimulation  (Flores- 
Villanueva et al., 2005).
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1.3.5.2.  The Thl response in mouse MTb:
1.3.5.2.1.  Cytokines:
The findings in human TB patients highlighting the importance of IFN-gamma and 
IL-12 have also been demonstrated in the mouse.  Knockout mice deficient in IFN- 
gamma (Flynn et al.,  1993,  Cooper et al.,  1993)  or  IL-12  (Flynn et al.,  1995b, 
Cooper et al., 1995, Cooper et al., 1997, Cooper et al., 2002) succumb early to MTb 
infection with high bacterial loads (Fig. 1.5).
IFNy
Class I
WT+y8'
TIME 52 WEEKS 3 WEEKS
Figure  1.5: A  simplified overview  of the  experimental studies  in  the  mouse 
highlighting the importance of CD4+ T cells, CD8 T cells,  IFN-gamma and TNF 
in the anti-MTb response,  (adapted from North et al., 2004).
The importance of a strong Thl response mediated by IFN-gamma following MTb
infection has been well documented, interestingly, studies have also shown that as
MTb infection progresses to chronicity a Th2 phenotype where the production of IL-
4 becomes apparent (Orme etal.,  1993, Hemandez-Pando etal.,  1996), which also
correlates with disease reactivation  (Howard et al.,  1999).  Studies in mice using
adoptive transfer of Thl  and Th2 cells (polarised in vitro) at the time of infection
have shown that although Thl cells mediate protection during infection, transfer of
Th2 cells was associated with enhanced lung pathology and weight loss (Wangoo et
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al., 2001).  These findings suggest that the switch to a Th2 phenotype during chronic 
in  vivo  infection  may  function  to  dampen  the  immune  response  and  limit  host 
pathology.
13.5.2.2.  The protective role of different T cell subsets in the immune response to 
MTb:
The essential role of CD4+ and to a lesser extent CD8+ T cells has also been well 
documented during MTb infection.  Mice deficient in CD4+ T cells (major histo­
compatibility complex [MHCj-ir') (Caruso et al.,  1999) or mice depleted of CD4+ 
T cells via antibody depletion (Scanga et al., 2000)  are unable to control aerosol 
challenge and rapidly succumb to infection.  However, in mice lacking CD8+ T cells 
(Beta2-microglobulin'/' or MHC-I7 ') (Flynn et al.,  1992, Sousa et al., 2000, Rolph et 
al., 2001), or mice depleted of CD8+ T cells via antibody depletion (Mogues et al.,
2001), still exhibit protection against MTb challenge but the infection is sustained at 
a higher level (1-Log1 0 ) compared to wild-type mice (Fig.  1.5).  Various hypotheses 
have been put forward identifying differing roles of CD4+ and CD8+ T cell subsets 
during infection.  Reports have suggested that CD4+ T cells play a dominant role as 
IFN-gamma producers during early infection, and CD8+ T cells serve as an essential 
source of IFN-gamma and cytolytic granules e.g. perforin, during latter stages of 
chronic infection (van Pinxteren et al., 2000, Lazarevic et al., 2005).  In contrast, 
studies by Feng et al., (1999) have observed an equal role for both CD4+ and CD8+ 
T cells during early infection.  These findings perhaps reflect the different strains of 
MTb used between the studies.  Reports on the role of gamma/delta T cells using 
knockout mice has thus far failed to identify a protective role for this T cell subset 
with regard to regulation of bacterial load.  However, mice deficient in this T cell
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subset have enhanced lung immune-pathology following aerosol infection compared 
to wild-type controls (D'Souza et al.,  1997) and recent findings by Lockhart et al., 
(2006) have shown gamma/delta T cells as major producers of IL-17 during early 
MTb infection.
13.5.2.3.  IL-23, IL-17 and mycobacterial immunity:
More  recently,  it  has  been  shown  that  the  IL-12  family  cytokine  IL-23,  can 
compensate in the  absence of IL-12p70  and function during MTb  infection  as a 
protective cytokine (Khader et al., 2005, Wozniak et al., 2006).  In addition IL-23 is 
also  essential  for  the  expansion  of  pro-inflammatory  Th-17  CD4+  T  cells 
(Harrington etal.,  2006).  IL-17  is  a  major  inducer  of  neutrophils  during  an 
inflammatory response, in line with this, Th-17 cells have been shown to play a role 
in autoimmune diseases such as EAE (Park et al., 2005, Langrish et al., 2005).  In 
mycobacterial studies, IFN-gamma production regulates the IL-17 response during 
infection  with  BCG  (Cruz et al.,  2006,  Khader et al.,  2005),  and  during  MTb 
infection, gamma/delta T cells are suggested to be the predominant producers of this 
cytokine (Lockhart et al., 2006).  The exact role of this novel IL-17 producing Th 
subset in mediating either protection or potentially pathology during MTb infection 
is at present not fully understood.
13.5.3.  The importance of TNF in controlling MTb reactivation:
The role of TNF during murine MTb infection has to date been well documented. 
Mice deficient in TNF succumb to MTb around day 30 post infection with enhanced 
bacterial  levels,  reduced  production  of  reactive  nitrogen  intermediates  and
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disorganised granulomas (Flynn et al., 1995a, Bean et al., 1999).  Similarly, TNF is 
important in mediating bacterial control during latent infection, as treatment of MTb 
infected-antibiotic  cured  mice  with  anti-TNF  antibody  resulted  in  disease 
reactivation (Scanga etal., 1999, Mohan etal., 2001).
Similar to the findings in mice, recent studies by Keane et al., (2001) during human 
MTb infection, have also highlighted the importance of TNF.  They reported that 
latent  (non-active)  TB  patients  receiving  anti-TNF  therapy  (Infliximab)  for 
rheumatoid arthritis  (RA)  or Crohn’s  disease may  develop  active TB  soon after 
initiation of Infliximab treatment.  The baseline level of TB  in RA patients in the 
USA is approximately 6 per 100,000, the incidence of TB rises to 24 per 100,000 in 
RA patients receiving Infliximab therapy (Keane et al., 2001).
1.3.6.  The role ofCDl molecules in MTb lipid presentation:
13.6.1.  CD1 expression in humans:
The role  of CD1  molecules is  to regulate immunity not only to  self, in  order to 
prevent autoimmunity, but also to initiate anti-bacterial responses upon encountering 
microbial  lipids  (Brigl et al.,  2004).  In  the  human,  CD1  molecules  can  be 
subdivided into Group 1  (CDla, CD lb and CDlc - expressed exclusively on DC and 
APC), Group 2 (CDId - expressed on DC and APC but in addition on epithelial cells 
parenchymal  cells  and  vascular  smooth  muscle  cells  in  the  liver  and  gut)  and 
intermediate molecules (CDle).  Following activation, CD1  restricted T cells can 
mediate  helper,  effector  and  adjuvant  like  functions  by  interacting  with  DC, 
macrophages, NK cells, T cells and B cells (Brigl et al., 2004).
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13.6.2.  CD1 expression in mice:
In contrast, mice only possess CD Id and present antigen to invariant Natural Killer 
(iNK) T cells (De Libero et al., 2005).  Stimulation of iNKT cells with lipid antigen 
can lead to the production of the cytokines IFN-gamma, IL-4, IL-13, TNF and GM- 
CSF along  with  cytolytic  granules,  thereby  demonstrating  an  important role  in 
linking the innate and adaptive immune response (De Libero et al., 2005).
1.3.63.  Characterisation of CD1 restricted antigens:
To date, reports characterising lipid antigens have focused on cell wall constituents 
from MTb including phosphatidylinositol mannosidase (PIM), lipoarabinomannan 
(LAM)  and didehydroxymycobactin  (DHM)  (Moody et al.,  2004).  Both  MTb 
derived PIM, LAM and DHM can be bound by CD1 molecules that are expressed 
predominantly but not exclusively  on  DC,  macrophages  and B  cells  in order to 
activate appropriate T cell responses (Winau et al., 2004a).  In addition, studies have 
identified mycobacterial cell wall constituents that are presented on specific CD1 
molecules:  CD la =  DHM;  CD lb  =  PIM  and  LAM;  CDlc  =  Mannosyl-beta-1- 
phosphomycoketide; CD Id = phosphatidyl-tetra-mannoside (De Libero et al., 2005).
1.3.6.4.  The  role  of CD1  in  the  alternative  “detour” pathway  during MTb 
infection:
Recent findings by Schaible et al., (2003), have identified a “detour” pathway for 
activation of CD8+ T cells via recognition of antigen by MHC-I and CD1.  This 
significant finding demonstrated that during MTb infection,  macrophages release 
apoptotic vesicles containing MTb antigens that can “cross prime” T cells via un­
infected bystander  DC.  Bystander DC  uptake  the  vesicles  containing  antigen,
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process and present them via MHC-I and CD1 in order to facilitate the activation of 
CD8+ T cells (Schaible et al., 2003).  During cross priming by DC, the chaperone 
type molecules called saposins, have been shown to be essential in the loading of 
MTb lipids onto CD lb molecules in human APC (Winau etal., 2004b).
1.3.6.5.  Exploiting CD1 presentation as a strategy during BCG vaccination or 
cancer immunotherapy to boost sub-optimal immune responses:
Grode  et al.,  2005  have  highlighted  the  potential  for  exploiting  CD8+  T  cell 
responses mediated through CD1 lipid presentation, in order to enhance the efficacy 
of the current BCG vaccine.  The recombinant BCG (rBCG) used expressed the 
membrane perforating factor listeriolysin (derived from Listeria monocytogenes). 
Upon phagosomal acidification in the APC, the listeriolysin would become activated 
and facilitate rBCG escape into the cytosol leading to cross priming and initiation of 
CD1 and MHC-I presentation to CD8+ T cells (Grode et al., 2005).  The benefits of 
targeting  CD1  restricted T  cells  is  not just  restricted  to  MTb  or  mycobacterial 
diseases.  It has been reported using a murine model of cancer that targeting CD Id 
restricted NK T cells via delivery of alpha-galactosylceramide in conjunction with 
pre-existing therapy led to eradication of established tumours (Silk et al., 2004).
1.4.  The role of TLR in initiating anti-microbial responses:
1.4.1.  Overview:
TLR are a diverse family of innate immune recognition receptors that are expressed
on B cells, macrophages, DC and neutrophils.  TLR recognise pathogen associated
molecular proteins (PAMP) and induce antimicrobial immune responses (Medzhitov,
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2001,  Akira et al., 2004).  PAMP bind TLR expressed on the surface of immune 
cells, in doing so adaptor molecules such as MyD88, TIRAP, TRIF and TRAM are 
activated and recruited resulting in a signalling cascade, cell activation and cytokine 
production (Fig. 1.6).
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Figure  1.6:  TLR  ligands  and  their  specific  intracellular  signalling  adaptor 
molecules.  (Adapted from Takeda et al., 2005).  TIRAP -  Toll IL-1R associated 
protein, TRIF -  TIR domain containing adaptor protein inducing Interferon 
Beta, TRAM -  TRIF related adaptor molecule.
1.4.2.  TLR expression in humans and mice:
There are 11 known TLR humans and mice.  TLR expression has been shown to be 
cell  specific,  in  humans it  has  been  reported  by  (Kadowaki et al.,  2001)  that 
monocytes express TLR-1, 2, 4, 5 and 8, CD1 lc+ immature blood DC express TLR- 
3  and plasmacytoid pDC exclusively  express  TLR-7  and TLR-9.  However,  the 
distribution of human TLR has been shown to vary and the criteria are not as rigid as 
Kadowaki et al., (2001) portrays.  For example, studies by Muzio et al., (2000) have 
shown that monocyte derived DC express TLR-3 and is therefore not exclusively
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expressed on CDllc+ immature DC. Furthermore, it is possible that TLR may be 
regulated on macrophages, DC, neutrophils and B cells during an immune response 
as recently shown for human leukocytes (Muzio et al., 2000).
The distributions of TLR in the mouse are different to that of the human.  In the 
mouse,  BM  myeloid  DC  express  TLR-2  and  TLR-4,  (comparable  to  human 
monocyte-derived  DC)  but  in  addition  express  TLR-9  (Boonstra et al.,  2003). 
Plasmacytoid pDC derived from the BM or their splenic derived equivalent are well 
documented in responding to viral infection giving rapid production of the cytokine 
IFN-alpha  and  the  Thl  inducing  cytokine  IL-12  (Asselin-Paturel etal.,  2001, 
Nakano et al., 2001, Barchet et al., 2002), but are poor at inducing proliferation of 
naive T cells (Boonstra et al., 2003).  The plasmacytoid pDC have been shown by 
Boonstra  et al.,  (2003)  to  express  largely  TLR-9  but  also  TLR-7,  therefore 
responding  strongly  to  the  TLR-9  ligand  CpG-DNA  and  TLR-7  ligand  R848 
(Imadizolquinolene) in keeping with findings in human studies.  In murine studies 
CpG-DNA is a potent inducer of pro-inflammatory cytokines including IL-12 from 
macrophages, DC and plasmacytoid pDC.  CpG is non-methylated (unlike human 
DNA) and is present in MTb as well as viruses and other organisms.  The expression 
of TLR-9 on mouse  BM  myeloid  DC  and splenic  macrophages  is  distinct from 
human since in human TLR-9 is exclusively expressed on plasmacytoid pDC and B 
cells but has been recently suggested to be up-regulated by MTb products (Muzio et 
al., 2000).
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1.4.3.  TLRinMTb:
Initial studies addressing the role of TLR during MTb infection have highlighted 
controversial roles for single TLR in mediating protective immune responses.  The 
involvement of TLR-2 and TLR-4 in mediating TNF responses during in vitro MTb 
infection have been reported using human TLR-transfected cell lines (Means et al., 
1999, Means et al., 2001).  Similar findings have also been reported in the mouse by 
Underhill et al., (1999), where TNF production by murine macrophages in response 
to MTb was dependent on TLR-2 and MyD88.  In vivo studies in TLR-4'7 ' mice have 
reported a role for this TLR in mediating protection from aerosol challenge (Abel et 
al., 2002).  However, there is evidence to  suggest that TLR-2, but not TLR-4 is 
responsible for mediating protection from aerosol MTb challenge (Reiling et al.,
2002).  These findings suggest that other factors may be involved.  More recently, 
studies by Bafica et al, (2005) have demonstrated a role for TLR-9 during aerosol 
MTb challenge.  Following MTb infection, TLR-9'7 ' mice had comparable bacterial 
levels to control mice but IL-12p40  and CD4+ T cell derived IFN-gamma were 
significantly decreased.  In the same study it was also demonstrated that multiple 
TLR can collaborate in order to regulate immunity to MTb challenge as TLR2/9 
double knockout mice had elevated bacterial  loads compared to single knockout 
controls (Bafica et al., 2005).
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1.5.  Regulatory mechanisms involved in the down regulation of the immune 
response to infection: studies from human and mouse:
1.5.1.  The role ofIL-10 in regulating immunity to invading pathogens:
1.5.1.1.  The biology of IL-10:
IL-10 is  an immunosuppressive cytokine displaying anti-inflammatory functions. 
IL-10 is produced by a variety of cell types including B cells, T cells, macrophages 
and  some  DC  (Moore et al.,  2001).  IL-10  can  inhibit  the  production  of pro- 
inflammatory cytokines such as TNF and the Thl  polarising cytokine IL-12 (Fig. 
1.7) by directly acting on DC and macrophages (Fiorentino et al., 1991a, Fiorentino 
et al., 1991b) to inhibit pathogen killing (Gazzinelli et al., 1992, Moore et al., 2001).
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Figure  1.7:  The  source  and  immunosuppressive  role  of IL-10  in  regulating 
protective immunity to infection.
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1.5.1.2.  IL-10 in infectious disease:
When  addressing  the  role  of  IL-10  in  the  mouse,  studies  using  Listeria 
monocytogenes (Wagner et al.,  1994, Dai,  1997, Silva et al., 2001a), Leishmania 
major (Belkaid et al., 2001, Belkaid et al., 2002), Leishmania donovani (Murray et 
al., 2002), Mycobacterium avium (Bermudez et al.,  1993, Roach et al., 2001b) and 
BCG (Murray et al.,  1999), have all reported an increase in pathogen clearance in the 
absence of IL-10.  Strikingly, in Leishmania major, although the absence of IL-10 
led  to  enhanced pathogen  clearance,  mice  displayed  a  loss  of immunity  to re­
infection (Belkaid et al., 2002).  This finding suggests that IL-10 does limit pathogen 
clearance, but moreover plays a key role in the maintenance of effector memory 
populations although at present the mechanism is unknown.
Studies in Mycobacterium  avium  infection have  shown that the efficacy of both
vaccination and antibiotic chemotherapy can be enhanced in the absence of IL-10
(Silva et al.,  2001b).  Similarly,  neutralisation of IL-10 enhanced chemotherapy
during chronic Leishmania donovani infection (Murray et al., 2002, Murray, 2005).
In addition, following infection with  Toxoplasma gondii (Gazzinelli et al.,  1996,
Reis e Sousa et al.,  1999,  Suzuki et al., 2000), Trypanosoma cruzi (Hunter et al.,
1997) and malaria (Li et al.,  1999), studies in the mouse have shown that IL-10 is
essential to limit fatal host immune-pathology  associated with an over-exuberant
effector  response.  Furthermore,  over-expression  of IL-10  in  various  infection
systems has also shown a regulatory role for this cytokine, as expression of IL-10 by
a recombinant strain of Mycobacterium smegmatis can inhibit activation and pro-
inflammatory cytokine production by macrophages in vitro (Marshall et al.,  1997).
Similarly,  studies  in Mycobacterium  avium  using a transgenic mouse that over-
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expresses IL-10, have shown that infected mice have enhanced bacterial levels and 
impaired macrophage function (Feng et al., 2002).  These findings above highlight 
the regulatory role that IL-10 plays in limiting protective effector responses but at 
the  same  time  inadvertently  hampering  pathogen  eradication.  The  potential 
regulatory role for IL-10 during MTb infection will be addressed in chapter 3.
I.5.I.3.  IL-10 and MTb:
1.5.13.1.  The role of IL-10 in human MTb studies:
Studies  on  PBMC  obtained  from  infected  TB  patients,  have  shown  that 
neutralisation of endogenous IL-10 increased the production of IFN-gamma and IL- 
12p40 in response to heat-killed MTb (Gong et al.,  1996).  Furthermore, studies on 
PBMC obtained from in anergic TB patients i.e. TB patients that have no positive 
purified  protein  derivative  (PPD)  skin  test  reaction,  have  demonstrated  that 
neutralisation  of  endogenous  IL-10  enhances  proliferative  responses  to  PPD 
(Boussiotis et al., 2000).  The studies by Gong et al., (1996) and Boussiotis et al., 
(2000), concluded that IL-10 was functioning to limit the immune response to MTb. 
In  addition,  Gerosa et al.,  (1999)  have  reported the  presence  of CD4+  T  cells 
producing both IFN-gamma and IL-10 in  the broncho-alveolar lavage (BAL)  of 
active TB patients.  These findings in the BAL were in contrast to CD4+ T cells 
derived from the peripheral blood that were of a Th2 phenotype producing both IL- 
10 and IL-4 (Gerosa et al., 1999).  The suppressive action of endogenous IL-10 and 
TGF-beta has been  shown  to inhibit CD4+ T cell proliferation  and IFN-gamma 
production in MTb stimulated PBMC obtained from healthy PPD+ patients although 
there  was  no  effect  on  MTb  uptake  by  monocytes  (Rojas  et al.,  1999).  In
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conclusion,  the human studies  of TB  infection  suggest that during chronic MTb 
endogenous  IL-10  may  inhibit protective  Thl  responses  via  indirect  action  on 
macrophages or DC and may ultimately be functioning to limit immune-pathology. 
However,  these  studies failed to address  the relationship between  IL-10  and its 
suppressive effect on pathogen eradication.
1.5.13.2.  The role of IL-10 in murine MTb studies:
The  literature  to  date  when  addressing  the  role  of IL-10  during  murine  MTb 
infection is controversial  with  studies focusing predominantly on IL-10 deficient 
illlO ' )  mice.  Studies  have  reported  that III O'1 ' mice  are  no  more  resistant  or 
susceptible to aerosol MTb infection than wild type mice (North,  1998, Jung et al.,
2003).  In contrast, others have reported that I1101 ' mice display a transient increase 
in resistance to aerosol MTb challenge in the first 4 weeks following infection, but 
by week 8 and 12, they were no more resistant to MTb than wild-type mice (Roach 
et al., 2001b).
Thus far, the literature suggests that endogenous IL-10 has little to no effect during 
the early phase  of MTb infection.  However during late MTb infection of IL-10 
transgenic mice, where IL-10 is under the control of the IL-2 promoter, bacterial 
burdens in transgenic mice are elevated compared to wild type mice, thus confirming 
the suppressive effect of IL-10 on the anti-MTb response.  However, this model of 
MTb  infection  by  Turner et al.,  (2002)  is not physiological,  in that not all IL-2 
producing cells in the mouse would actually produce IL-10 and secondly the IL-10 
production is not under the natural control of its own promoter.  We will address the
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potential regulatory role for IL-10 in murine  studies of both early and late MTb 
infection.
1.5.2.  TGF-beta and immune-regulation:
I.5.2.I.  Overview:
TGF-beta is an immunosuppressive cytokine produced in three distinct isoforms; 
TGF-beta 1, 2, and 3.  TGF-beta  1  is the most dominant form in lymphoid organs 
being produced by  all  leucocytes,  exerting  an  inhibitory  effect on Thl  and Th2 
responses, macrophage activation and DC maturation (Letterio et al., 1997, Li et al., 
2006a).  In addition, TGF-beta also plays an essential role in many developmental 
and physiological processes, as Tgf-Bl'1 ' mice die  at  3-4 weeks  of age due to an 
overwhelming lymphoproliferative disorder (Shull  et  al.,  1992).  TGF-beta  can 
indirectly  inhibit  the  development  of a  protective  Thl  response  e.g.  following 
Leishmania infection, by inhibiting IFN-gamma production from NK cells (Laouar 
et al.,  2005).  In  line  with  this,  TGF-beta has  also been  shown  to  decrease the 
survival  of BCG  activated  T  cells  (Hernandez-Garay et al.,  2003).  Similarly, 
regulatory T cells (Tregs) producing TGF-beta can modulate the function of effector 
cells during  colitis  (Powrie et al.,  1996,  Fahlen  et al.,  2005).  It  has  also  been 
reported that T  cell  receptor  stimulation  in  the  presence  of TGF-beta has  been 
implicated  in  the  conversion  of  peripheral  naive  CD4+CD25-  T  cells  into 
CD4+CD25+ Tregs (Chen et al., 2003, Fantini et al., 2004) that can be inhibited in 
the presence  of IL-6  (Bettelli et al.,  2006).  TGF-beta is  also an essential  factor 
involved in the maintenance of the Treg population (Marie et al., 2005).
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1.5.2.2.  The role of TGF-beta during MTb infection:
The role of TGF-beta during MTb infection has not been well documented and is 
addressed  in  chapter  4  where  we  examined  its  potential  for  down  regulating 
protective immune responses to MTb.  In human studies it has been found that TGF- 
beta is increased in the serum of TB patients (Fiorenza et al., 2005, Guyot-Revol et 
al., 2006) and can inhibit CD4+ T cell proliferation and IFN-gamma production by 
PBMC (Rojas et al., 1999).
In rodent studies, TGF-beta expression has been shown to increase in the lungs of 
aerosol infected mice (Mogga et al., 2003).  TGF-beta can also be induced in vitro 
following stimulation of MTb secretory antigen matured DC with MTb cell extract 
(Balkhi et al., 2004).  Neutralisation of TGF-beta in guinea pigs injected with heat- 
killed MTb gave enhanced TNF and reduced cellular infiltrate into the pleural space 
(Allen et al.,  2004).  However, IFN-gamma responses were unaffected following 
anti-TGF-beta neutralisation.
1.53.  Regulatory T cells (Tregs) as negative regulators of the immune response to 
invading pathogens:
I.5.3.I.  The biology of Tregs:
Tregs mediate suppressive activity either via cell-cell contact or through production 
of suppressive  cytokines  e.g.  IL-10  or TGF-beta.  The  outcome  limits  aberrant 
autoimmune responses or may dampen over-exuberant and potentially pathological 
innate  or  adaptive  immune responses  to  antigen  or  infection.  The  presence  of 
regulatory  factors  may  benefit the  host by  limiting  collateral  damage  but  may
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inadvertently promote pathogen persistence.  Tregs have been subdivided into a) 
naturally  occurring  Tregs  derived  from the  thymus  or b)  antigen  driven  IL-10 
producing  CD4+  Tregs  (IL-10  Tregs)  that  result  after  exposure  to  specific 
stimulatory conditions during infection or antigen exposure (Mills, 2004, O'Garra et 
al.,  2004,  Belkaid  et  al.,  2005).  The  role  of Tregs  and Treg  derived  IL-10  as 
negative regulators of the immune response to MTb will be addressed in chapter 4.
1.5.3.2.  Naturally occurring Tregs:
I.5.3.2.I.  Overview:
Naturally  occurring  CD4+CD25+  Tregs  were  originally  described in  the mouse 
(Sakaguchi et al.,  1995)  and more recently  in humans  (Levings et al.,  2001),  as 
essential  regulators  for  autoimmunity,  allergy  and  disease  (Hawrylowicz et al.,
2005).  Initial studies demonstrated that depletion of CD25+ cells from whole CD4+ 
T cells and then subsequently transferred into lymphopenic hosts resulted a broad 
range of autoimmune disorders including thyroiditis and gastritis (Sakaguchi et al., 
1995).  In adult mice and humans CD4+CD25+ Tregs constitute approximately 5- 
10% of peripheral CD4+ T cells and  1% of CD8 T cells (Fontenot et al.,  2005a). 
Tregs  can be isolated from humans  and naive  mice  via the  marker CD25  (IL-2 
receptor  [IL-2R]-alpha),  which  is  however  also  expressed  on  activated  T  cells 
(Shevach,  2006).  Furthermore,  recent phenotypic  analysis  of murine Tregs  has 
shown that in addition to original markers CD4 and CD25, Tregs also express the 
markers CTLA-4,  glucocorticoid TNF receptor (GITR), CD 103  (alpha-E  integrin) 
and 0X40 (Fontenot  et al.,  2005b).  Similar to CD25, these molecules  are  also 
expressed on activated T cells, which makes functional Treg depletion studies i.e. by
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anti-CD25 treatment of mice, difficult to interpret (Sakaguchi et al., 2006, Shevach,
2006).  With this observation in mind, alternative approaches such as adoptive Treg 
cell  transfer have been utilised.  More recently,  naturally  occurring Tregs  were 
shown to express the forkhead (winged helix) transcription factor forkhead box P3 
(FoxP3)  (Fontenot et al.,  2003,  Hori et al., 2003, Khattri et al.,  2003),  which  is 
fundamental for their development and function.
I.5.3.2.2.  Treg mediated suppression of auto-immunity:
Studies by Powrie and colleagues identified the presence of Tregs contained in a 
population of CD4+CD45RBl0 W  T cells.  This population of CD4+CD45RB,0 W  T cells 
have the ability to regulate Thl mediated colitis in vivo by CD4+CD45RBh ig h  T cells 
through TGF-beta (Powrie et al.,  1996, Fahlen et al., 2005), IL-10 (Asseman, 1999, 
Asseman et al., 2003) and CTLA-4 dependent mechanisms (Read et al., 2000, Read 
et al., 2006).  Furthermore, CD4+CD25+ Tregs can inhibit Thl  mediated colitis in 
SCID  mice  in  an  antigen  specific  manner  when  co-infected  with  the  parasite 
Leishmania  major (Xu  et al.,  2003),  and  is  dependent on  IL-10,  TGF-beta  and 
CTLA-4 (Liu et al., 2003).  In contrast to these observations in vivo, in vitro Treg 
suppression assays by have shown that regulation is mediated by a cell-cell contact 
dependent mechanism  and not via IL-10, TGF-beta or CTLA-4 (Thornton et al., 
1998, Vieira et al., 2004).  Therefore the mechanism of suppression utilised by Tregs 
is at present poorly understood.
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I.5.3.2.3.  Characterisation of the Treg specific transcription factor FoxP3:
As  discussed earlier,  studies by Fontenot et al.,  (2003),  Hori  et al.,  (2003)  and 
Khattri  et al.,  (2003)  identified  FoxP3  a  transcription  factor  specific  to  Tregs. 
Similar to IPEX (immune dysregulation, polyendocrinopathy enteropathy, X linked) 
syndrome in humans, scurfin or FoxP3 deficiency in mice results in a lack of Tregs 
leading to the development of a fatal lymphoproliferative syndrome 3-4 weeks after 
birth.  Expression of FoxP3 is restricted predominantly to CD4+CD25+ Tregs that 
possess regulatory properties in vitro (Fontenot et al., 2003, Hori et al., 2003, Khattri 
et al., 2003) and in vivo (Fontenot et al., 2003).  In addition, Khattri et al., (2003) 
also demonstrated that forced expression of FoxP3  in  Ctla4m '~  mice rescued them 
from a fatal lymphoproliferative disorder.  Interestingly, ectopic expression of FoxP3 
in  naive  CD4+CD25-  T  cells,  generates  a  CD4+CD25-  T  cell  with regulatory 
phenotype  that  inhibits  wasting  disease  and  inflammatory  bowel  disease  in 
lymphopenic hosts  (Fontenot et al.,  2003,  Hori et al.,  2003,  Khattri et al., 2003). 
Additionally, FoxP3  was also required for the development and function of Tregs 
(Fontenot et al.,  2003).  In  summary,  FoxP3  is  a  unique  cell  lineage  specific 
transcriptional factor responsible for the development of Tregs and as a marker of 
naturally occurring Tregs
1.5.33.  Antigen driven IL-10 Tregs:
As discussed earlier, Tregs can be derived from the thymus as naturally occurring 
Tregs  or induced  under  specific  stimulatory  conditions  to  become  IL-10  Tregs 
(Groux  et al.,  1997)  demonstrated  that repeated  stimulation  in  vitro  of murine 
DO 11.10 (OVA specific) transgenic T cells with OVA peptide in the presence of IL-
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10 could drive a distinct population of IL-10 producing Tregs.  The resulting Treg 
cells produced IL-10, little IL-2 and no IL-4 with the ability to prevent colitis in 
SCID mice re-constituted with splenic CD4+CD45RBh ig h  T cells.
Further studies in the mouse have reported that IL-10 producing Tregs can also be 
obtained following in vitro culture with the immunosuppressive drugs vitamin-D3 
and dexamethasone, the resulting homogenous IL-10 Treg population can inhibit 
EAE in vivo (Barrat et al., 2002).  These in vitro driven IL-10 Tregs share similar 
properties to naturally occurring Tregs in that they can inhibit naive CD4+ T cell 
proliferation by cell-cell contact that was independent of IL-10 (Vieira et al., 2004). 
However,  these  IL-10  Tregs  did  not  express  the  transcription  factor  FoxP3. 
Interestingly, unlike freshly isolated naturally occurring Tregs, IL-10 Tregs readily 
produced IL-10 without re-stimulation, suggesting that the importance of “seeing” 
antigen is key both in vivo or in vitro in order to drive IL-10 dependent suppression. 
Furthermore, these findings highlight the different developmental origins of Treg 
subsets.
Similarly, in vivo studies have shown that IL-10 Tregs can be obtained from mice 
anergised  with  soluble  antigens  such  as  myelin  basic  protein  (Burkhart,  1999, 
Sundstedt et al., 2003) or following infection with virus (Buer, 1998) or viral super­
antigens (Papiemik et al., 1997).  In these in vivo scenarios, antigen specific CD4+ T 
cells develop that produce DL-10, little IL-2, no IFN-gamma or IL-4.
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1.5.3.4.  Tregs in microbial infections:
1.5.3.4.1.  Overview:
The roles of Tregs in diseases such as Helicobacter hepaticus (Maloy et al., 2003), 
Listeria monocytogenes (Kursar et al., 2002), Plasmodium  (Hisaeda et al., 2004), 
Schistosoma mansoni (McKee et al., 2004), HIV (Andersson et al., 2005) and HSV 
(Suvas et al.,  2003)  have been documented.  The role  of Tregs  during parasitic 
infection,  most  notably  in  murine models  of Leishmania,  has  been  extensively 
studied to date.  The insight acquired from these Leishmania studies has aided and 
facilitated our understanding of Tregs in immune-regulation, thus enabling us to 
transfer this knowledge to other infectious diseases.
1.5.3.4.2.  Tregs in Leishmania:
1.5.3.4.2.1.  Human Leishmania studies:
In human studies of cutaneous L.  viannia  braziliensis infection, Tregs have been 
associated with promoting parasite persistence as reports have shown the presence of 
CD4+CD25+FoxP3+  Tregs  producing  large  quantities  of IL-10  and  TGF-beta 
(Campanelli et al., 2006).  In addition, these Tregs could also inhibit proliferative T 
cell responses  in  vitro.  In  contrast,  other sources of IL-10  during Leishmania 
infection have been reported.  In Leishmania donovani, splenic CD4+CD25-FoxP3- 
T cells can be isolated from patients and are the predominant producers of IL-10 
(Sacks, 2006).
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1.5.3.4.2.2.  Murine Leishmania studies:
As discussed previously, Belkaid et al., (2001) identified IL-10 as a regulator of the 
protective Thl immune response in clearance of L. major infection in mice.  Further 
analysis  using  an  adoptive  transfer  model  into  Rag'1 '  mice,  demonstrated  that 
CD4+CD25+  Tregs  accumulating  at  the  site  of infection  were  responsible  for 
promoting pathogen persistence that was mediated by IL-10 dependent and IL-10 
independent  mechanisms  (Belkaid  et al.,  2002).  In  addition,  depletion  of 
CD4+CD25+ Tregs via anti-CD25 monoclonal antibody (mAb) therapy resulted in 
enhanced clearance of L. major parasites (Mendez et al., 2004).  Similarly, following 
infection of B6 mice with a Thl resistant strain of L. major (i.e. not susceptible to a 
dominant protective Thl  response), resistance and parasite survival in the host is 
associated with the induction of CD4+CD25+FoxP3+ Tregs (Anderson et al., 2005). 
Depletion  of Tregs  with  an  monoclonal  antibody  (mAb)  targeted  against CD25 
enhanced  parasite  clearance.  In  the  same  study,  Anderson  et al.,  (2005),  also 
identified CD4+CD25- T cells  as  a major source for IL-10  during infection.  In 
summary, the source of IL-10 that limits the immune response to pathogens may 
come  from  other  non-Treg  sources  including  Thl  cells  or  Th2  cells,  B  cells, 
macrophages and DC.
1.5.3.5.  Tregs and MTb:
1.5.3.5.1.  Tregs in human MTb studies:
To date, data on the role of Tregs  during MTb infection in both the human  and
mouse model has been limited.  Recent studies of PBMC from human TB patients
have identified an increase in FoxP3 mRNA expression (Guyot-Revol et al., 2006)
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and by flow cytometry, (Ribeiro-Rodrigues et al., 2006) have reported an increase in 
the percentage of CD4+CD25+FoxP3+ Tregs that have suppressive activity in vitro. 
The  findings  suggest  that  Tregs  are  present  in TB  infected  individuals  and  are 
functioning to limit the immune response.
1.5.3.5.2.  Tregs in murine MTb studies:
Quinn  et al.,  (2006)  have  shown  by  flow  cytometry  that  following  intranasal 
infection  with  mycobacterial  BCG  there  is  an  increase  in  the  total  number  of 
CD4+CD25+FoxP3+  Tregs.  In  addition,  using  an  over  simplified  model  for 
depletion of Tregs by treating mice with the anti-CD25 mAb, showed no effect on 
bacterial burdens or histology.  However CD4+ T cell derived IFN-gamma was 
enhanced in mice that received anti-CD25 mAb.  In the same study, Quinn et al., 
(2006) also presented a limited amount of data demonstrating that depletion of Tregs 
had no effect  on clearance  of MTb.  The role of Tregs  during MTb  (which  we 
address during murine MTb infection in chapter 4), is still in its infancy and warrants 
further investigation.
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Chapter 2: Materials and Methods.
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2.1.  Mice:
Specific pathogen free BALB/c, BALB/c IL-10 deficient (BALB/c.//70'a), C57B1/6 
(B6), and B6 recombination-activating gene (Rag) 1  deficient (B6.Ragl'/), were bred 
and housed under specific pathogen  free conditions  at the National Institute for 
Medical  Research  (NIMR).  B6.111 O '*',  B  cell  deficient  (B6and 
BALBIc.Rag2'1 ' mice  were  a kind  gift from J.  Langhorne  (NIMR).  For in vivo 
experiments  with  MTb, mice  were housed under bio-safety containment level 3 
conditions.  All mice were between 8-10 weeks of age at the start of experiments.
2.2.  Reagents:
Culture medium used for all in vitro applications was RPMI  1640 (BioWhittaker) 
with the following supplements: 5% heat inactivated fetal calf serum (FCS) (Labtech 
International),  2-mercaptoethanol  (0.05  mM;  Sigma),  penicillin  (lOOU/ml; 
BioWhittaker),  streptomycin  (lOOpg/ml;  Bio  Whittaker),  L-glutamine  (2mM; 
Sigma),  sodium pyruvate (ImM;  BioWhittaker),  HEPES  (lOmM; BioWhittaker), 
GM-CSF  (lOng/ml;  Schering-Plough),  Flt3-ligand (lOOng/ml;  R  &  D  systems). 
Culture medium plus the above additives is referred to as cRPMI.
2.2.1.  TLR ligands:
To stimulate DC in vitro CpG-B DNA 1668 ISS (5 ’-TCCATGACGTTCCTGATG 
CT; Invitrogen Life Technologies) was used.  For in vivo challenge of mice CpG-B 
DNA 1018 ISS (5 ’-TGACTGTGAACGTTCGAGA; Invitrogen Life Technologies) 
was used.
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2.2.2.  Mycobacteria and Mycobacterial antigens:
All experiments using MTb were performed under bio-safety containment level 3 
conditions.  MTb  H37Rv  was  used  for in  vitro infections (H37Rv sub-strain as 
indicated), for ex vivo re-stimulations BCG (Danish strain [3.3x10s CFU/ml]; Statens 
Serum Institute (SSI) - batch #101063), Tuberculin PPD (8-10p,g/ml; SSI - Batch 
RT49) and plate bound anti-CD3 mAb (5[xg/0.5ml coated overnight; 145.2C11 BD) 
were used to stimulate cells.
2.2.3.  In vivo MTb studies:
MTb H37Rv was used for in vivo infections.  H37Rv London School of Hygiene and 
Tropical Medicine (LSHTM) strain was cultured by seeding lOOul of MTb stock in 
10ml  aliquots  of 7H9  culture  broth  (in  50ml  Falcon  polypropylene  tubes;  BD) 
supplemented with Tween-80 (0.05%) and 10% oleic acid-albumin-dextrose catalase 
(OADC; BD Difco #212240) and incubated as a static culture at 37°C.  The growth 
of MTb was monitored by optical density at 600nm (OD^) and harvested when an 
OD of approximately 0.6 was reached.  Final MTb stocks were washed twice with 
saline (25 minutes at 3000 rpm) and aliquoted as 250^1 aliquots into pre-labelled 1  
ml freezing vials then stored at -80°C.  To ascertain the number of viable colony 
forming units (CFU) in the H37Rv stock, aliquots were thawed, serially diluted then 
plated on 7H11  agar plates supplemented with OADC (10%) and read after  16-18 
days.  To determine  whether the MTb  stock  was free  from other contaminating 
organisms stocks were checked by plating 250^1 on blood agar plates (5% sheep’s 
blood; BD) for 5 days.
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Intraperitoneal (I.P.) injections of immune-modulatory antibodies were performed 
weekly (or as indicated) in sterile PBS Dulbeccos (Gibco) as listed below (Table 
2.1).
Table 2.1: Immune-modulatorv antibodies:
Antigen
recognised:
Clone: Species
origin:
IgG class Dose 1   mouse: Source:
beta-galactosidase GL113 Rat IgGl As indicated DNAX
IL-10 receptor 
(IL-10R)
1B1.3A Rat IgGl 0.5mg DNAX
CD25
(IL-2R-alpha)
PC61 Rat IgGl 0.5mg NIMR
Viral hexon TC31.27F11 Mouse IgGl 1.5mg Harlan
TGF-beta l/b2/b3 1D11 Mouse IgGl 1.5mg R&D
Plasmacytoid
pDC
120G8 Rat IgGl lmg G.
Trinchieri
2.2.4.  Cytometry reagents:
For analysis of cell surface markers from both in vitro and in vivo experiments, cells 
were pre-treated for 10 minutes with anti-FcYlI/Fcyll (anti-CD 16/CD3 2) to minimise 
aspecific antibody binding.  Staining was performed in FACS buffer (Dulbeccos 
PBS supplemented with 1%FCS, penicillin [lOOU/ml] and streptomycin [100pg/ml]) 
on ice with antibodies as described below (Table 2.2).  Cells were then washed with 
FACS buffer (1200rpm, 7 minutes) and acquired on a FACS Caliber flow cytometer 
(BD  Biosciences).  The  data  was  analysed  using  FlowJo  version  8  (Treestar) 
software.
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Table 2.2: Cvtometry reagents: concentrations, clones and origins:
Antigen
recognised
Clone Fluoro-
chrome
Species origin 
and IgG class
Working
concentration
Source
FcYin/Fcyll
(CD16/CD32)
2.4G2 Rat IgG2a k lpg/ml NIMR
CD4 RM4-5 FITC Rat IgG2a k 2pg/ml Ebioscience
B220 RA3-6B2 FITC Rat IgG2a k 5pg/ml Ebioscience
CD8 53-6.7 PE Rat IgG2a k 2pg/ml Ebioscience
CD25
(IL-2R-alpha)
PC61 PE Rat IgGl X 2pg/ml Ebioscience
CDllc HL3 PE Hamster IgGl X 2pg/ml BD
F4/80 BM8 PE Rat IgG2a k 2pg/ml Ebioscience
CDllb Ml/70 APC Rat IgG2b k lp,g/ml Ebioscience
GR-1 (Ly6C) RB6-8C5 APC Rat IgG2b k lpg/ml Ebioscience
FoxP3 FJK-16s APC Rat IgG2a k lpg/ml Ebioscience
CD25
(IL-2R-alpha)
7D4 Biotin Rat IgM k lpg/ml BD
Plasmacytoid
pDC
120G8 ALEXA-
488
Rat IgGl  k 0.5pg/ml NIMR
Isotype IgGl ALEXA-
488
Rat IgGl k As indicated NIMR
Isotype IgGl PE Rat IgGl  k As indicated BD
Isotype IgG2a APC Rat IgG2a k As indicated Ebioscience
2.2.5.  Immunoassay:
Protein analysis of supernatants from both  in vitro and in vivo experiments  were 
carried out by enzyme linked immuno-adsorbent assay (ELISA) using 96 well flat 
bottom plates (Nunc); as detailed below (Table 2.3).  For quantification of cytokine 
production, cell free supernatants were collected at the time-points indicated after 
infection/stimulation and analysed by ELISA.  A commercially available ELISA kit 
(Ebioscience) was used to determine IL-12p70 and TNF concentrations in sample 
supernatants, both cytokine ELISA’s were performed according to manufacturers 
instructions. Antibody capture and detection pairs were used for the cytokines IL-10, 
IL-12p40  and IFN-alpha.  Supernatants  that were potentially MTb contaminated 
were gamma-irradiated (20 kGrays) then plated on to 7H11  agar plates supplemented 
with 10% OADC for 4 weeks to check sterility.  In addition, Listeria monocytogenes 
was used as a fast growing control to confirm sufficient radiation exposure.
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Table 2.3: ELISA reagents: concentrations. clones and origins:
ELISA: Standards:
Starting
concentration
in()
Capture antibody: Detection
antibody:
Detection
limit
(substrate):
IL-10 rmIL-10 
(lOng/ml; DNAX)
2A5
(5ng/ml; DNAX)
SXC-1
(250ng/ml;
Pharmingen)
40 pg/ml 
(TMB)
IL-12p40 rmIL-12 
(50ng/ml; R & D 
systems)
C15.6 
(5 p.g/ml)
C17.8 
(1 ng/mi)
50 pg/ml 
(ABTS)
IL-12p70 IL-12p70 kit 
(lOng/ml; 
Ebioscience)
Monoclonal anti 
p35
Monoclonal anti 
p40
20 pg/ml 
(TMB)
TNF TNF kit 
(lOng/ml; 
Ebioscience)
IF3F3D4 MP6-XT3
MP6-XT22
20 pg/ml 
(TMB)
IFN-alpha rmlFN alpha 
(10,000 U/ml; 
DNAX)
F18
(5ng/ml; HyCult 
Biotechnology)
Polyclonal rabbit 
anti-mouse IFN 
alpha. 
(5ug/ml; PBL 
Biomedical)
40 pg/ml 
(ABTS)
23.  Derivation of mouse BM APC:
2.3.1.  Derivation of GM-CSF cultured BM DC:
CD1 lc+ DC were generated using cRPMI supplemented with recombinant GM-CSF
as described previously (Inaba et a l 1992).  Cells were isolated from the BM by
flushing femurs and tibias with  ice-cold cRPMI. Centrifuge the cells once (1400
rpm, 5 minutes) and then re-suspend in 0.83% ammonium chloride to lyse red blood
cells (0.5ml/lxl07  cells).  Wash the cells twice with cRPMI, re-suspend in  10 ml
cRPMI and count.  BM cells were then plated out in  six well tissue culture plates
(Costar) at 106  cells/ml (total 5 ml/well) in cRPMI supplemented with 10 ng/ml GM-
CSF.  After 2 days, remove the culture medium and wash each well with 5ml cRPMI
to remove non-adherent cells.  5ml cRPMI (supplemented with 10 ng/ml GM-CSF)
was  then  added to  each  well.  After 4  days  the  non-adherent  cells  were  again
discarded and 5ml cRPMI (supplemented with lOng/ml GM-CSF) was then added to
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each well.  On day 6, non-adherent cells were recovered.  Cells were then cultured 
(0.5x106 DC/ml) for a further 24hrs with cRPMI (supplemented with 10 ng/ml GM- 
CSF), subsequently harvested, counted and used in stimulations.  The purity was 
always >70% CD1 lc+ by flow cytometry.
2.3.2.  Derivation ofFlt-3L cultured BM derived DC:
Plasmacytoid pDC  were  generated  by  culturing  BM  cells  in  cRPMI  containing 
lOOng/ml Flt3-ligand at lxlO6  cells/ml in  12 well flat-bottom plates (2ml/well) for 
10  days.  On  day  5,  1ml  of  medium  was  removed  and  1ml  of fresh  cRPMI 
containing Flt3-ligand was added at a final concentration of lOOng/ml.  Plasmacytoid 
pDC were sorted on either a) CD1 lc+ CD1 lb- B220+ or b) CD1 lc+ 120G8+.  The 
purity was always >99% by flow cytometry.
2.3.3.  Derivation of macrophages fromBM:
F4/80+  macrophages  were  generated  using  cRPMI  supplemented  with  M-CSF 
derived from L-929 cell conditioned medium.  BM cells were isolated as above; the 
BM cells were cultured with cRPMI with M-CSF (20% L-929 conditioned medium) 
and plated out on bacteriological Petri-dishes at 0.5xl06 cells/ml (total volume was 
8ml  per  dish).  After  4  days,  10ml  of cRPMI  containing  M-CSF  (20%  L-929 
conditioned medium) was added to each dish.  On day 7, non-adherent cells were 
discarded; lOmls of ice cold PBS was added to each dish and then incubated at +4C 
for  15  minutes.  Macrophages  were  harvested,  counted  and  used  for  further 
experiments.  The purity was always >90% F4/80+ by flow cytometry.
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23.4.  Determination of  APC purity after culture in vitro:
The purity of GM myeloid DC generated as described above (2.3.1) was determined 
by cytometric  analysis of CD 11c expression.  Similarly, BM  macrophages were 
stained for expression of the macrophage-restricted marker F4/80.  2xl05  enriched 
cells were plated out in 96 well round bottom plates.  The cells were kept on ice 
where possible.  BM  cultured cells  were pre-treated with  anti-Ftr/U/Fcyl! (anti- 
CD 16/CD32) to minimise aspecific antibody binding.  BM myeloid DC and BM 
macrophages were stained on ice for 30 minutes with CD1 lc-PE (2pg/ml) or F4/80- 
PE (2pg/ml) respectively.  The cells were then washed with FACS buffer (2000rpm, 
20 seconds) and acquired on a FACS Caliber flow cytometer (BD Biosciences).  The 
data was analysed using Flow  Jo version 8 (Treestar) software.
2.4.  Derivation of plasmacytoid pDC from the spleen:
Splenic  plasmacytoid  pDC  for  in  vitro  stimulations  were  isolated  by  MACS 
separation from splenocyte suspensions using the Miltenyi CD1 lc+ beads.  Spleens 
were  aseptically  removed  and  collected  in  cRPMI.  Spleens  were  treated  with 
liberase Cl (30 mins, 37°C, 2% C02).  The organs were then homogenised by passing 
through a 70pm sieve with the piston from a 2ml syringe.  Centrifuge the cells once 
(1400 rpm, 5 minutes) and then re-suspend in 0.83% ammonium chloride to lyse red 
blood cells (0.5ml/lxl07  cells).  Wash the cells twice (1400 rpm, 5 minutes) and put 
into FACS buffer.  Using the Miltenyi CDllc+ beads following the manufacturers 
instructions CDllc+ cells should be positively selected.  Wash the cells and count 
and re-suspend in FACS buffer at 20xl06  cells/ml in the following antibodies B220- 
FITC (5pg/ml), CD1 lc-PE (2pg/ml), GR1-APC (1 pg/ml) for 20 mins on ice.  Wash
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the cells twice in FACS buffer (1300rpm, 7 mins).  Re-suspend at 20x106  c/ml in 
sorting buffer containing 1  pg/ml propidium iodide and to remove cell clumps pass 
through a 40 pm sieve. Splenic plasmacytoid pDC were sorted on CD1 lc+ CD1 lb- 
B220+. The purity was always >98% by flow cytometry.
2.5.  In vitro infection of APC:
2.5.1.  Infection of myeloid APC:
BM DC and macrophages were plated in antibiotic free cRPMI at 0.5xl06  cells/well 
in 48 well.  MTb was added directly to the wells at a multiplicity of infection (MOI) 
of either  1:1  or 5:1  (MTb:APC)  and the cells  incubated at 37°C  (5%  C02) until 
harvest.  The number of bacilli in the inoculum was determined by serial dilutions in 
PBS before plating on 7H11 agar plates supplemented with OADC (10%).  The MTb 
was left in the wells for the duration of the experiment.  The cells were harvested at 
the  appropriate  time-points  post  infection  and  supernatant  collected.  For 
determination of CFU in macrophages, the wells were washed twice with PBS to 
remove residual extra-cellular bacteria and lysed as described below (2.5.2).  For 
BM DC, cells were collected, spun (1200 rpm, 7 mins) and the supernatant collected. 
The pellet was washed twice (1200rpm, 7 mins) with cRPMI (without antibiotics) to 
remove residual extra-cellular bacteria. DC cell pellets were lysed and used for CFU 
determination as described below (2.5.2).
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2.5.2.  Assessment of  MTb in infected APC:
Infected cell pellets were treated with  1ml saponin (0.2%; Sigma) and left for one 
hour at room temperature.  Serial dilutions were then performed in PBS and plated 
out on 7H11  agar plates supplemented with OADC (10%) to determine CFU.  After 
16-18 days at 37°C, visible colonies could be counted and bacterial load per well 
calculated.
2.6.  In vivo MTb infections:
2.6.1.  MTb infection of mice:
MTb H37Rv was thawed from pre-aliquoted stocks and used to infect mice either 
intravenously (I.V.) or by aerosol  exposure;  the  infection  inoculum  was  serially 
diluted on the day of infection to determine the exact MTb dose.  For I.V. infections, 
mice were injected with the desired number of H37Rv CFU in a total volume of 
200pi via the lateral tail vein (as specified in Figure legends).  For aerosol infections, 
approximately lxlO7  CFU was aerosolised over a period of 30 minutes in a three-jet 
Collison nebuliser unit.  Each mouse received approximately 50-100 CFU to the 
lungs  as confirmed  by bacterial burdens  assessed  on day  1   post infection.  For 
infections using immuno-deficient mice,  BALB/c.RagT1 ' were  infected I.V.  with 
lxlO6  CFU and monitored daily for signs of disease/pathology, mice that exhibited 
signs of moderate disease were killed and the “survival” time noted.
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2.6.2.  Determination of bacterial burdens within infected organs:
For both I.V. and aerosol infections, mice were taken at the time-points indicated 
and organs prepared as described below.  Mice were killed by exposure to carbon 
dioxide and death was confirmed by cervical dislocation.  The spleen and lungs were 
aseptically removed and put into 15ml tubes (Corning) containing 5ml of PBS.  The 
organs were homogenised by passing through a 70 pm sieve with the piston from a 
2ml  syringe.  To  determine  the  bacterial  levels  within  infected  organs,  serial 
dilutions were made in PBS then 100pi of each dilution was spread onto 7H11  agar 
plates supplemented with OADC (10%).  After 16-18 days at 37°C, visible colonies 
were counted and the bacterial load per organ calculated.
2.6.3.  Neutralisation of cytokines and!or depletion of target cells by antibody 
therapy in vivo:
A  summary  of immune  modulatory  antibodies  with  concentrations,  clones  and 
origins is presented in Table 2.1 above.
2.6.3.I.  Cytokine neutralisation:
To block the IL-10R, anti-EL-lOR mAb (1B1.3A, 0.5mg/mouse in PBS) was injected 
via the I.P. route at the time points indicated.  To block TGF-beta, anti-TGF-beta 1, 
2, 3 mAb (1D11,  lmg/mouse in PBS) was injected via the I.P. route once weekly 
from the day of infection or as indicated in Figure legends.
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2.6.3.2.  Target cell depletion:
To deplete CD25+ Tregs, mice were treated with anti-CD25 (PC61, 0.5mg/mouse in 
PBS)  at day  -4,  -2,  0  and  7  post  infection.  Flow  cytometry  analysis  of Tregs 
(CD4+CD25+FoxP3+)  at  day  0  showed  a  >80%  depletion.  For  depletion  of 
plasmacytoid pDC, mice were treated with 120G8 mAb (lmg/mouse in PBS) at day 
-1, 0,  7,  and  14 post infection.  Flow  cytometry  analysis  of plasmacytoid pDC 
(CD1 lc+GRl+B220+) at day 0 showed a >80% depletion.
Control mice for all depletion experiments using anti-IL-lOR (1B1.3A), anti-CD25 
(PC61)  and  120G8  were  given  the  same  antibody  regimen  and  received  an 
appropriate dose of irrelevant rat IgGl  mAb (GL113; anti-beta-galactosidase).  For 
neutralisation  of TGF-beta,  control  mice  given  the  same  antibody  regimen  of 
irrelevant mouse IgGl antibody (TC31.27F11; anti-viral hexon).
2.6.4.  Functional analysis of immune cells obtained  fromMTb infected mice:
All ex vivo stimulations were performed in triplicates in Costar 24 well flat bottom 
plates in a final volume of 1.5 ml.  Spleen and lung homogenates were treated with 
ammonium  chloride  (0.83%)  to  lyse  red  blood  cells.  Cells  from  the  spleen 
(5xl06 /1.5ml),  and lung  (lxl06/1.5ml)  were  stimulated  with  either  BCG  (5x10s 
CFU/1.5  ml),  Tuberculin  PPD  (8-10p,g/ml)  or  plate  bound  anti-CD3  mAb 
(5pg/0.5ml; coated overnight).  Cell cultures  were incubated at 37°C  (5%  C02). 
Supernatants  were  harvested  as  indicated  in  figure  legends  then  irradiated  as 
described above.
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2.6.5.  FACS analysis of cells fromMTb infected mice:
Where possible all staining was carried out on ice.  Whole spleen (5xl06  cells) and 
lung (lxlO6  cells) suspensions were stained in 5ml FACS tubes for 10 minutes with 
lug/ml anti-FcYHI/Fcyll (anti-CD 16/CD32).  Cells were then stained for 25 minutes 
with the appropriate concentration of cell surface antibodies in a total volume of 
200ml.  Cells  were  washed  twice  in  FACS  buffer  then  fixed  in  500ml  2% 
formaldehyde overnight and fumigated within the class  I microbiological  safety 
cabinet at room temperature.
For  determination  of  FoxP3  expression,  cells  were  stained  according  to  the 
manufacturers protocol.  Briefly, cells were  stained for CD4-FITC and CD25-PE 
then fix/permeabilised for 2 hours at 4°C with an Ebioscience fix/permeabilisation 
buffer.  Cells were then further washed with permeabilisation buffer then stained 
with FoxP3-APC for 30 minutes.  Cells were then washed twice with Ebioscience 
permeabilisation buffer and once with FACS  buffer then fixed and fumigated as 
described above.  All samples were acquired the next day on a FACS Calibur within 
the bio-safety containment level 3 suite at the LSHTM.
2.7.  T cell reconstitution:
2.7.1.  Purification ofT cell subsets:
CD4+CD25- and CD4+CD25+ T cells for adoptive transfer were isolated by MACS
separation from splenocyte suspensions using the Miltenyi CD4+CD25+ regulatory
T cell isolation kit.  Briefly, the spleens were aseptically removed and collected in
cRPMI.  The organs were homogenised by passing through a 70pm sieve with the
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piston from a 2ml syringe then treated with ammonium chloride (0.83%) to remove 
red blood cells and re-suspended in FACS buffer.  Using the Miltenyi kit; CD4+ 
cells were negatively enriched using lineage specific biotin-conjugated antibodies 
against CD8 (Ly-2), CDllb (Mac-1), CD45R (B220), CD49b (DX5), Ter-119, and 
anti-biotin MicroBeads were used.  CD25-PE and anti-PE MicroBeads were used for 
the  subsequent positive  selection  of CD4+CD25+  regulatory  T  cells  from  the 
enriched whole CD4+ fraction.  The purity  of the  enriched CD4+CD25- (>90% 
pure) and CD4+CD25+ (>95% pure) populations was confirmed by flow cytometry.
2.7.2.  T cell reconstitution of immuno-deficient Rag1 ' mice:
Rag'' mice were injected I.V. with MACS sorted CD4+CD25- T cells (>92% pure) 
alone or together in the presence CD4+CD25+ T cells (>95% pure) as specified.  All 
injections of T cells were performed in PBS the day before MTb H37Rv infection.
2.8.  Statistical analysis:
All data was analysed as indicated in figure legends using either a) Students t test or 
b) One-Way ANOVA combined with a Bonferroni multiple comparison post-test 
with differences being considered significant when P <0.05.
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Chapter 3: The Role of IL-10 in Regulating Protective 
Immunity to MTb Infection.
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3.1.  Determining a role for IL-10 in regulating immunity to MTb. aims of the 
investigation:
To address a role for IL-10 during MTb infection we sought to identify:
1) During late stages of murine MTb infection, does IL-10 play a regulatory role on 
bacterial clearance?
2) Is the early immune response to MTb enhanced in the absence of IL-10?
3) Does endogenous IL-10 regulate macrophage anti-mycobacterial effector function 
during in vitro MTb infection?
4) To determine a cellular source for IL-10 during early MTb infection.
3.2. Background:
Control and potential clearance of intracellular pathogens such as MTb requires a 
strong pro-inflammatory response  dependent on  TNF and the induction of IFN- 
gamma through the Thl polarising cytokine IL-12 (Flynn et al., 2001, Baumann et 
al., 2006).  However, this may lead to host pathology due to over-exuberant effector 
responses.  The presence  of regulatory factors  may benefit the host by  limiting 
collateral damage but may inadvertently promote pathogen persistence.  It has been 
demonstrated in  infectious diseases that the presence of IL-10 prevents pathogen 
clearance and promotes parasite persistence but can also protect against immuno- 
pathology (Moore et al., 2001).
Studies in the mouse by North et al., (1998) and Jung et al., (2003) have shown that
IL-10  has  no  apparent  role  to  control  the  immune  response  or  affect  bacterial
clearance during early MTb infection.  However, these observations are in contrast
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to Roach  et al.,  (2001b),  who  showed a transient decline in bacterial load early 
during infection in the absence of IL-10.  Turner et al., (2002) using a transgenic 
mouse model where IL-10 is under control of the IL-2 promoter, have shown that 
over-expression of IL-10 enhances bacterial burdens during the latter stages of MTb 
infection.  However, this approach may be seen as non-physiological as IL-10 is not 
under the control of its natural promoter.
In human studies, Gong et al., (1996) have shown that neutralisation of endogenous 
IL-10 in PBMC cultures from active TB patients increased IFN-gamma responses to 
the heat-killed MTb.  Similarly, Boussiotis et al., (2000) have also reported a similar 
observation on T cell proliferation  when PBMC from  anergic TB  patients  were 
stimulated with PPD in the absence of IL-10.  Gerosa et al., (1999) have shown that 
in the BAL of active TB patients CD4+ T cells  are present producing both IFN- 
gamma and IL-10.  Taken together these studies in humans suggested that IL-10 may 
suppress the clearance of MTb and contribute to chronic infection.  However, this 
cannot not be demonstrated in human studies at this stage and has only been inferred.
Thus the role of IL-10 in suppressing the immune response to MTb and affecting 
bacterial clearance can only be demonstrated in experimental models.  To resolve the 
contradictory data in the  mouse we have examined the role of IL-10 in  immune 
responses to MTb infection.  More specifically, we determined whether at an early 
(acute) or late (chronic)  stage of MTb infection, endogenous IL-10  suppressed a 
protective  Thl  response  (characterised  by  IFN-gamma),  and  consequently  the 
clearance of MTb.
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3,3.  The immune response to different strains of MTb H37Rv: diverging roles 
for.LL-10.
The conflicting murine data with regard to the role of IL-10 in regulating the early 
response to MTb  and studies by Turner et al.,  (2002) using an IL-10 transgenic 
mouse suggested a role for IL-10 late during chronic MTb infection.  We first sought 
to identify a role for IL-10 at a late stage of infection with the MTb strain H37Rv 
NIMR.  We also performed this study on an independent strain of H37Rv from the 
London  School  of  Hygiene  and  Tropical  Medicine  (LSHTM)  to  ensure 
standardisation between strains of H37Rv.  To selectively block IL-10 signalling in 
vivo, a monoclonal antibody (mAb) to the IL-10 receptor (anti-IL-lOR mAb) was 
administered after MTb infection was established.  Studies in the literature on the 
role of IL-10 in regulating the early immune response to MTb to have thus far used 
III O’1' mice  which  failed  to  establish  a  role  for  IL-10  during  the  late  stages  of 
infection.
33.1.  IL-10 functions during late MTb infection with H37Rv NIMR to regulate 
bacterial clearance:
To address a role for IL-10 in regulating the immune response to MTb at different 
stages after infection; i) BALB/c mice were infected I.V. with H37Rv NIMR for 123 
days to establish a chronic infection (Fig.  3.1 A) as demonstrated by a plateau in 
bacterial burdens within infected organs.  When a chronic infection was established 
mice were treated once weekly from day 90 post infection with either anti-IL-lOR 
mAb (0.5mg/mouse) or PBS (control) and at day 123 the experiment was terminated.
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Bacterial burdens (CFU) in the lungs and spleen were monitored during the course of 
infection  and determined as  discussed in Materials  and Methods.  Treatment of 
infected mice  with either PBS  or  an  isotype  control  IgG  (GL113),  have  shown 
similar effects on bacterial burdens in vivo (Boonstra A., O’ Garra A., unpublished 
observations).
Infection  with  H37Rv  NIMR  in  immuno-competent  mice  exhibited  an 
unconventional pattern of bacterial growth compared to the literature, where the total 
bacterial counts in the spleen and lung did not converge and stabilise during the 
latter stages of infection (Fig. 3.1 A).  When intervening with anti-IL-lOR mAb at 
day 90 post MTb infection, the bacterial loads were reduced by 2-Log10in the spleen 
(P < 0.0001) and  1.5-Log 1 0   in the lung (P < 0.0001) compared to control treated 
MTb  infected  mice  (Fig.  3.IB  and  C  respectively).  To  examine  the  effect  on 
cytokine production following IL-10 neutralisation in vivo, cell suspensions from 
infected  mAb  treated  mice  were  re-stimulated  ex  vivo  in  the  presence  of  the 
mycobacterial antigens BCG (3.3xl05  CFU/ml) or PPD (lOpg/ml). The decrease in 
bacterial load following anti-IL-lOR mAb treatment in vivo was associated with an 
increase  in Thl  cytokines  as  stimulation  of splenocytes  from  anti-IL-lOR mAb 
treated mice gave a significant increase in IFN-gamma (P < 0.05) (Fig. 3.2A and B) 
and  TNF  (Fig.  3.2C  and  D)  compared  to  MTb  infected  control  treated  mice. 
Stimulation of whole cell suspensions obtained from infected mice in the absence of 
mycobacterial stimuli did not produce any detectable levels of cytokines IFN-gamma 
or IL-12  (as demonstrated in Fig. 3.8).
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In a second experiment when intervening in BALB/c mice once weekly with anti-IL- 
10R mAb at day  165 post MTb infection (Fig.  3.3A), the bacterial burdens were 
approximately  five  fold higher  in  the  spleen  and the  lungs  as  compared to the 
previous intervention at day 90 in un-manipulated control infected mice (Fig. 3.1 A). 
The effect of anti-IL-lOR mAb treatment at this time was less pronounced giving 
only a 0.5-Log1 0  reduction in the spleen (P < 0.0001) (Fig. 3.3B) with no apparent 
reduction in the lung (Fig. 3.3C) as compared to control treated mice.  Similarly, the 
pattern of bacterial growth within infected organs (Fig. 3.3A) was identical to the 
previous study (Fig. 3.1 A), where the total bacteria burdens in the spleen and lung 
did not converge  during the  latter  stages  of infection,  as  compared to bacterial 
growth curves for H37Rv infection reported broadly in the literature (North, 2004).
To determine the cytokine responses in mice treated with anti-IL-lOR mAb, whole 
splenocyte cell suspensions were re-stimulated ex vivo with BCG or PPD.  At this 
stage during infection there was no enhancement of IFN-gamma (Fig. 3.4A and B) 
or TNF (Fig. 3.4C and D) in splenocytes derived from mAb treated mice in response 
to either BCG or PPD.  However, the levels of inducible IFN-gamma at this time 
were 20-fold higher at this late stage during infection as compared to the previous 
experiment at day 123 (Fig 3.2A and B).  In addition, the levels of IL-10 present in 
culture supernatants following ex vivo PPD and BCG re-stimulation at either day 123 
(data not shown) or day 205 (Fig.  3.4E and F) did not correlate with the levels of 
IFN-gamma.
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3.3.2.  Regulation of bacterial load during late infection with MTb H37Rv LSHTM 
strain is not dependent on IL-10:
To further evaluate a role for IL-10 in suppressing immune responses to MTb at a 
late stage of infection and the observation that the in vivo bacterial growth curves 
observed for H37Rv NIMR were in contrast to those reported in the literature, we 
verified our findings with an independent isolate of MTb named H37Rv LSHTM. 
Interestingly, both the LSHTM strain and NIMR strain had originated from the same 
source as a gift from S. Cole (Pasteur Institute, Paris).
To repeat the experiments with the H37Rv NIMR when anti-IL-lOR treatment had 
an effect on reducing bacterial levels, BALB/c mice were infected i) I.V. for 97 days 
(Fig.  3.5A) or ii)  via aerosol for 90 days (Fig.  3.5B), before mAb treatment was 
started.  Mice were treated once weekly I.P. with anti-IL-lOR mAb (0.5mg/mouse) 
or PBS (control) when at day 133 (Fig. 3.5A - I.V.) or day 125 (Fig. 3.5D - aerosol), 
mice were killed and bacterial loads in the spleen (Fig. 3.5B and E) and lungs (Fig. 
3.5C and F) were determined.
In contrast to the growth curves observed with H37Rv NIMR, the growth curves for 
H37Rv LSHTM in infected organs were similar to the infection curves published in 
the literature where both the spleen and lung converged and stabilised relatively 
early (day 30-40) after infection.  Neutralisation of IL-10 signalling late after I.V or 
aerosol  infection  with  H37Rv  LSHTM  strain  did  not  influence  the  infection 
outcome.  This finding was in contrast to anti-IL-lOR mAb treatment starting day 90
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during late I.V. infection with the H37Rv NIMR strain (Fig. 3.IB and C).  The in 
vivo bacterial growth curves observed for H37Rv NIMR and H37Rv LSHTM in our 
experiments  are compared in Fig.  3.5.  Our findings may reflect the differential 
induction  of IL-10  during  infection  or  differing  virulence  between  the  H37Rv 
strains.
3.3.3.  Does the H37Rv strain and infection dose affect the regulation by IL-10 in 
vivo?
We show here that IL-10 appears to play a role during the latter stages of infection 
with H37Rv NIMR but not H37Rv LSHTM.  The potential reasons for the observed 
differences  in  bacterial  levels  following  anti-IL-lOR  mAb  treatment  could  be 
attributed to i) H37Rv strain, or ii) that the initial infection dose of H37Rv NIMR 
was  lower  than  that  of H37Rv  LSHTM.  (However,  this  could  not be  further 
addressed with H37Rv NIMR as the collaborators original stock of H37Rv NIMR 
was no longer available).
Using a freshly grown batch of H37Rv NIMR and H37Rv LSHTM, studies within 
the laboratory have identified a vast difference in virulence between the two H37Rv 
strains NIMR and LSHTM following infection of immuno-compromised Rag1 ' mice 
(Boonstra, A., Holman, M., O’Garra, A., unpublished data).  BALB/c./tog2 A  were 
infected I.V.  with  lxlO6  CFU and monitored daily for signs of disease/pathology, 
mice that exhibited  signs  of moderate  disease were killed and the  survival time 
noted.  The differences observed between the H37Rv strains  were striking; mice 
infected with H37Rv LSHTM had a mean survival time of 25 days compared with
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46 days for H37Rv NIMR.  For the reason of reduced virulence of H37Rv NIMR, 
we focussed our studies from thence solely on H37Rv LSHTM as the growth curves 
of this isolate were more reflective of what has been reported in the literature.
To determine whether the lack of effect when neutralising IL-10 late during infection 
with H37Rv LSHTM was because the infecting dose was too high, we administered 
anti-IL-lOR mAb late after infection with different doses of H37Rv.  BALB/c mice 
were infected I.V. with A) 23,350 CFU, B)  161,000 CFU, C) 234,000 CFU and D)
1,812,000  CFU H37Rv LSHTM strain.  Starting at day 35, mice received weekly 
injections I.P. with either anti-IL-lOR mAb (0.5mg/mouse) or PBS control.  At day 
77, mice were killed and the bacterial levels in the spleen and lung were determined. 
During the latter stages of MTb infection with H37Rv LSHTM, anti-IL-lOR mAb 
treatment had no effect on bacterial burdens and was independent of the starting 
infection dose (Fig. 3.7A-D).
3.4.  IL-10R blockade during early MTb infection:
3.4.1.  Anti-IL-lOR  mAb  treatment of mice  during  early I.V.  MTb  infection 
enhances pathogen clearance and is associated with increased production of IFN- 
gamma:
Thus far we have shown that following I.V. infection with H37Rv LSHTM, IL-10 
played  no  role  on  regulating  bacterial  load  late  during  MTb  infection.  As  the 
literature to date on a role for IL-10 in regulating the immune response and hence 
bacterial clearance during early MTb infection in mice appears  controversial, we
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sought to address a role for IL-10 during early infection with H37Rv LSHTM via a) 
I.V. and b) aerosol infection.
a) Effect of anti-IL-lOR mAb intervention earlv in I.V. MTb infection:
BALB/c mice received anti-IL-lOR mAb (0.5mg/mouse) or control IgG I.P. on the 
day of MTb infection, then once weekly for four weeks (until day 28).  Following 
infection (Fig. 3.8A) we observed a decline in CFU on day 32 in the spleen of anti- 
IL-10R mAb treated mice (P < 0.05; Fig. 3.8B).  However, in the lung anti-IL-lOR 
mAb treatment resulted in a transient 0.5-Log1 0  decline in CFU at day 22 (P < 0.01), 
but by day 32 post infection this effect was less pronounced (Fig. 3.8C).  In order to 
understand the events resulting from neutralisation of IL-10 in vivo which led to this 
transient decrease in bacterial clearance, whole splenocytes from non-infected and 
MTb infected mAb treated mice were re-stimulated ex vivo with PPD (lOp-g/ml) for 
72 hours after which supernatants were collected and assayed by ELISA for IFN- 
gamma.  PPD stimulation of cells from mice treated with anti-EL-lOR mAb in vivo, 
exhibited a three-fold increase in IFN-gamma production compared to MTb infected 
control IgG treated animals (P < 0.0001; Fig. 3.8D).  As expected, un-infected mice 
did not respond to stimulation with PPD.
b) Effect of anti-IL-lOR mAb intervention earlv during aerosol MTb infection:
To address a role for IL-10 during aerosol infection with H37Rv LSHTM, BALB/c 
were treated with either anti-IL-lOR mAb or control IgG on day 0 before aerosol 
infection; mice then received the same schedule of once weekly mAb injections as 
described above for 5 weeks (until day 35).
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Mice were killed at days 27, 35 and 60 post infection and bacterial burdens in the 
lungs and spleen were determined as described in Materials and Methods.  Treatment 
of mice  with  anti-IL-lOR mAb  before (at day 0)  and once weekly after aerosol 
exposure to H37Rv LSHTM appeared to have no effect on disease progression in 
either  the  lung  (Fig.  3.9A)  or  spleen  (Fig.  3.9B)  at  the  time-points  indicated. 
Similarly, aerosol infection of III0'' mice (BALB/c.IIIO'1 '),  showed no effect on 
bacterial burdens in the lung (Fig. 3.9C), however in the spleen, a slight decrease in 
bacterial burdens was evident but failed to reach statistical significance (Fig. 3.9D).
3.5.  IL-10 blockade on ex vivo PPD stimulated cells obtained from MTb infected 
mice enhances IFN-gamma production:
Gong et al., (1996) have reported that neutralisation of endogenous IL-10 in human 
PBMC cultures restored IFN-gamma and IL-12p40 responses to PPD.  The authors 
thus  suggested that  IL-10  must be regulating the  immune response to MTb  and 
therefore limiting pathogen clearance.  However, this can only be inferred from these 
human  studies  using  ex vivo derived  cells  from  TB  patients  and  has  yet to be 
addressed in experimental models.
To address whether similar findings could be demonstrated in the mouse model, we 
used  the  same  experimental  approach  as  reported  in  the  human  studies.  Cell 
suspensions were prepared from MTb infected mice at various stages after infection 
and IL-10 activity was neutralised in vitro before stimulation with MTb antigens to 
determine whether IFN-gamma could be enhanced.  Whole splenocytes and lung 
preparations from non-infected and MTb infected mice (infected I.V. with H37Rv
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LSHTM for 32 days), were stimulated ex vivo with PPD (lOpg/ml) in the presence 
or  absence  of  anti-IL-lOR  mAb  (lOpg/ml).  Following  72  hours  of  culture, 
supernatants were collected and assayed by ELISA for IFN-gamma and DL-12p40. 
Stimulation  of  splenocytes  with  PPD  in  the  presence  of  anti-IL-lOR  gave  a 
significant enhancement of the pro-inflammatory cytokines IFN-gamma (P <0.01; 
Fig.  3.10A)  and  IL-12p40  (P <  0.05;  Fig.  3.10B)  compared  with  splenocytes 
stimulated with PPD alone.  In contrast to the stimulations using whole splenocytes, 
stimulation of lung preparations for 72 hours did not give any detectable cytokine 
production (data not shown).  Similarly, results have also been obtained within the 
laboratory using spleen preparations from mice infected with H37Rv LSHTM for 
more than 100 days.  Enhancement of IFN-gamma induced by PPD from lung cells 
could also be observed when stimulations were performed in the presence of anti-IL- 
10R mAb (Boonstra, A., O’Garra, A., unpublished data).
Our findings demonstrate that endogenous IL-10 in splenocytes obtained from MTb 
infect mice, dampens the IFN-gamma response to PPD in vitro.  This suggests that 
IL-10 may be regulating the immune response to MTb  at this  stage as was  also 
shown in the human studies by Gong et al., (1996).  However,  the  enhancement 
observed  in  IFN-gamma  production  may  not  directly  reflect  /  correlate  with 
pathogen clearance in vivo.  Since, in our mouse model of infection where mice were 
treated in  vivo  with  anti-IL-lOR  mAb  during the  latter  stages  of infection  with 
H37Rv LSHTM, IL-10 blockade had no effect on reducing bacterial load (Fig. 3.5).
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3.6.  IL-10 functions during in vitro MTb infection of macrophages to negatively 
regulate  pro-inflammatorv  cytokine  production,  but  ultimately  does  not 
influence MTb H illing;
Since  IL-10  acts  on  macrophages  and  DC  to  down  regulate  pro-inflammatory 
cytokine responses we postulated that the in vivo effect of IL-10 blockade was to 
enhance the early response to MTb infection by removing its suppressive action on 
macrophage pro-inflammatory cytokine production and bacterial killing.  To test this 
in vivo scenario, we used a simplified in vitro model for MTb infection using BM 
derived  macrophages  to  identify  whether:  a)  endogenous  IL-10  inhibits  the 
production of pro-inflammatory cytokines and b) macrophage MTb killing.
Macrophages were derived from the BM of BALB/c and BALB/c.//70 a  mice  as 
described in Materials and Methods.  BM macrophages were infected with H37Rv 
LSHTM strain at an MOI of 1:1  (MTb: Macrophage) and 5:1.  The MTb was left in 
the culture wells for the duration of the infection and cell culture supernatants were 
collected after 6, 24 and 48 hours post infection.
In vitro MTb  infection of BM  macrophages  from wild-type  BALB/c  mice for 6
hours (Fig. 3.11 A) and 24 hours (Fig. 3.1 IB) produced low levels of TNF and IL-
12p40 but no detectable levels of IL-12p70  or IL-10  (Fig.  3.1 IB).  In contrast,
H37Rv  infection of BM  macrophages from III O'1 ' mice gave  significantly higher
levels of TNF compared to wild-type macrophages at 6 hours (Fig. 3.11 A) showing
that low levels of IL-10 were induced although un-detectable.  By 24 hours, the
levels  of IL-12p70,  IL-12p40  and TNF from  BALB/c.//i0'A  macrophages  were
greatly enhanced compared to macrophages from wild-type mice (Fig.  3.1 IB)  as
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described by  others  (Hickman et al.,  2002).  In addition, the increased cytokine 
production following in vitro infection of macrophages in the absence of IL-10 was 
independent of mouse strain, as B6 and B6.111 O'1 ' mice gave comparable cytokine 
results to our findings in BALB/c and BALB/c.7/7 O'7 ' mice respectively (data not 
shown).
Macrophages from I110'1 ' mice (both BALB/c and B6) produced enhanced levels of 
pro-inflammatory cytokines in response to H37Rv LSHTM infection.  We sought to 
determine whether the enhanced pro-inflammatory cytokine production due to the 
absence of IL-10 had any effect on macrophage anti-bactericidal killing.  To address 
this, BM macrophages were prepared and infected as described above.  Macrophages 
were infected for 24 hours (Fig. 3.12A) and 48 hours (Fig. 3.12B) before cells were 
harvested  and  bacterial  burdens  were  analysed  as  described  in  Materials  and 
Methods.  MTb killing in macrophages infected with an MOI of 1:1  with H37Rv 
LSHTM, did not alter after 24 or 48 hours of infection and was independent of the 
presence  of IL-10  as  compared  to  wild-type  controls  (Fig.  3.12).  However, 
following infection with H37Rv LSHTM at an MOI of 5:1, we observed a decline in 
macrophage intracellular bacterial burdens from 24 to 48 hours post infection that 
was  not enhanced in the  absence  of IL-10  (Fig.  3.12).  This  data  suggests that 
increased pro-inflammatory cytokine production as a result of the removal of IL-10, 
does not reliably correlate with increased macrophage MTb killing.
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3.7.  Isolating the source of IL-10 during early infection with MTb H37Rv 
LSHTM:
Our data demonstrates that IL-10 appears to play a regulatory role during early but 
not late during I.V. MTb infection with H37Rv LSHTM.  It is well documented that 
IL-10 is  an  immuno-regulatory cytokine produced by a wide array of cell types 
including T cells and B cells (Moore et al., 2001).  We therefore sought to determine 
whether CD4+ T cells or B cells serve as a cellular source for IL-10 during early 
MTb infection.
3.7.1.  T cell derived IL-10 as a negative regulator of the immune response to I.V. 
MTb infection:
We examined a role for T cell derived IL-10 in regulating the immune response to 
MTb infection by adopting a number of approaches.  Firstly, we tried to identify 
CD4+ IL-10 producers using intracellular flow cytometry.  To address this, whole 
splenocytes and lung preparations were prepared from MTb infected mice and re­
stimulated ex vivo with PPD (lOpg/ml) or plate bound anti-CD3 for 12 hours.  IL-10 
could not be detected in either organ preparation after stimulation with PPD or anti- 
CD3 (data not shown), although we knew IL-10 was present in the cell populations 
from our ex vivo IL-10 blocking studies.  The inability to detect IL-10 could be due 
to  the  low  frequency  of  antigen  specific  T  cells  or  different  cell  populations 
producing IL-10.
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Therefore to address the potential role of T cell derived IL-10 in regulating the 
immune response to MTb infection an adoptive transfer model was used.  CD4+ T 
cells that contain both naive CD4+CD25- T cells and CD4+CD25+ Tregs, were 
purified by magnetic  separation from either wild-type BALB/c or BALB/c.7/70'7 ' 
mice.  Donor  cells  were  adoptively  transferred  into  immuno-compromised 
BALB/c.Rag2/' recipient mice the day before infection with H37Rv LSHTM.  At 
day 22 post infection the mice were killed and bacterial burdens in the spleen (Fig. 
3.13A) and lungs (Fig. 3.13B) were determined.  The protection afforded by CD4+ T 
cells following transfer in to BALB/c.Rag2 '' could not be enhanced in the absence of 
IL-10.  Our findings demonstrate that CD4+ T cells play a pivotal role in mediating 
protection to MTb infection as previously reported at this stage of infection (Flynn et 
al., 2001).
3.7.2.  The role ofB cells during early I.V. MTb infection:
Our data suggested that CD4+ T cells mediate protection during early MTb infection 
but are not a source of IL-10.  Therefore the potential role of B cell derived IL-10 
was addressed using B cell deficient mice on the C57B1/6 background (B6.[iMT1).
Wild-type B6  and B6.yiMT1 '  were  infected  I.V.  with  54,000  CFU  and bacterial 
burdens in the spleen  (Fig.  3.14A)  and lung (Fig.  3.14B) were monitored over a 
period of 52 days.  Following I.V. infection B6.fxMT'' displayed a transient decrease 
(0.5-Log1 0 ) in bacterial burdens in the spleen at day 23 post infection (P < 0.05; Fig. 
3.12C), but by day 52 this effect had diminished (Fig. 3.14E).  There was no effect in 
bacterial burdens in the lung at either time-point day 23 or day 52 (Fig. 3.14D and
70- Chapter 3: The role of IL-10 during MTb infection -
F).  In addition, low dose infection of B6 and B6.^MT1 ' with 2,400 CFU I.V. also 
showed no significant difference in bacterial burdens (data not shown).  Our findings 
suggest a minimal and transient role for B cells and possibly B cell derived IL-10 
during the early stages of immune response to I.V. H37Rv infection.
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Figure 3.1:  Neutralisation  of the  IL-10R  in  vivo  after infection  with  H37Rv 
NIMR enhances bacterial clearance.
(A) BALB/c mice were infected I.V. with  1.75xl06  CFU/mouse H37Rv NIMR (as 
determined by O.D.) for 123 days.  At day 90 mice were injected once weekly I.P. 
with either anti-IL-lOR mAb (1B1.3A; 0.5mg/mouse) or PBS (control).  At day  123, 
mice were killed and bacterial burdens were determined in the spleen £B] and lung 
IQ , as described in Materials and Methods (number of mice per group = 8).  Each 
point  represents  the  CFU  value  from  one  mouse  with  the  horizontal  lines 
representing the geometric means.  The effect of IL-10R mAb treatment was tested 
statistically using an unpaired Students t test (***, p <0.0001).
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Figure 3.2:  Neutralisation  of IL-10  in  vivo enhances IFN-gamma and TNF 
responses upon re-stimulation in vitro.
BALB/c  mice  were  infected  I.V.  with  1.75xl06  CFU/mouse  H37Rv  NIMR  (as 
determined by O.D.) for 123 days.  At day 90 mice were injected once weekly I.P. 
with either anti-IL-lOR mAb (1B1.3A; 0.5mg/mouse) or PBS (control).  At day 123, 
mice were killed and cell suspensions were prepared as described in Materials and 
Methods.  Whole splenocyte cell suspensions were re-stimulated ex vivo with either 
BCG (A/Cl (3.3xl05  CFU/ml) or PPD (B/Dl  (lOpg/ml).  The supernatants were 
collected  after  48  hours  post  stimulation  and  were  assayed  by  ELISA  for  the 
production  of IFN-gamma  (A/Bl  or TNF (C/D).  The  effect  of  IL-10R  mAb 
treatment was tested statistically using an unpaired Students t test (*, P <0.05).
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Figure  3.3:  Neutralisation  of IL-10  after MTb  infection  with  H37Rv NIMR 
minimally enhances bacterial clearance.
(A)  BALB/c  mice  were  infected  I.V.  with  1.4xl06  CFU  H37Rv  NIMR  (as 
determined by O.D.) for 205 days.  Bacterial burdens were monitored in the spleen 
and lungs throughout the time course.  At day 165 mice were injected once weekly 
I.P. with either anti-IL-lOR mAb (1B1.3A; 0.5mg/mouse) or PBS (control). At day 
205, mice were killed and bacterial loads were determined in the spleen (B1 and lung 
(C). as described in Materials and Methods (number of mice per group = 7).  Each 
point  represents  the  CFU  value  from  one  mouse  with  the  horizontal  lines 
representing the geometric means.  The effect of IL-10R mAb treatment was tested 
statistically using an unpaired Students t test (***, P <0.0001).
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Figure 3.4:  Blockade of the IL-10R in the latter stages of MTb infection does not 
enhance pro-inflammatory cytokine responses following re-stimulation ex vivo.
BALB/c  mice  were  infected I.V.  with  1.75xl06  CFU/mouse  H37Rv  NIMR  (as 
determined by O.D.) for 123 days.  At day 165 mice were injected once weekly I.P. 
with either anti-IL-lOR mAb (1B1.3A; 0.5mg/mouse) or PBS (control).  At day 205, 
mice were killed and cell suspensions were prepared as described in Materials and 
Methods.  Whole splenocytes were pooled from anti-IL-1 OR mAb or control treated 
mice and re-stimulated ex vivo with either BCG (3.3x105  CFU/ml) or PPD (8pg/ml). 
Supernatants  were  collected  after  48  hours  post  stimulation  and  assayed  for 
production of IFN-gamma (A/B). TNF (C/D) and IL-10 (E/F) by ELISA.  The effect 
of IL-10R mAb treatment was tested statistically using an unpaired Students t test (*, 
P <0.05).
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Figure 3.5:  The absence  of IL-10 signalling does not influence bacterial load 
following late infection with H37Rv LSHTM.
BALB/c mice were infected with H37Rv LSHTM via 1A) I.V. or  aerosol for a 
duration of 133 or 125 days, respectively.  Bacterial burdens were closely monitored 
during infection and starting from day 97 (for I.V. infection) or day 90 (for aerosol 
infection) mice were injected weekly I.P.  with either anti-IL-lOR mAb  (IB 1.3A; 
0.5mg/mouse)  or  PBS  (control).  At  day  133  (for I.V.)  or  day  125  (for  aerosol 
infection), mice were killed and bacterial burdens were determined in the  spleen 
(CV(D) and lung (EV(F). as described in Materials and Methods (number of mice 
per group = 5).  Each point represents  the  CFU value  from one  mouse with the 
horizontal lines representing the geometric means.  Results shown are representative 
of two independent experiments.
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Figure 3.6:  The bacterial growth of H37Rv NIMR and LSHTM differs greatly 
immuno-competent BALBIc mice.
BALB/c  mice  were  infected  I.V.  with  either  H37Rv  NIMR  (1.75xl06  CFU 
determined by  O.D.)  or H37Rv  LSHTM  (dose  unknown).  During the course of 
infection bacterial burdens were determined in the spleen and lung at the time-points 
indicated as described in Materials and Methods (number of mice per group H37Rv 
NIMR = 8; H37Rv LSHTM = 5).
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Figure 3.7: The effect of IL-10R neutralisation in vivo late after infection with 
H37Rv LSHTM is not dependent on initial infection dose.
BALB/c mice were infected via the  I.V. route with either: (A) 23,350 CFU, (B)
161,000  CFU, {£} 234,000 CFU or £D) 1,812,000 CFU H37Rv LSHTM.  At day 35 
post infection mice were injected weekly I.P. with either anti-IL-lOR mAh (1B1.3A;
0.5mg/mouse) or PBS (control).  At day 77, mice were killed and bacterial burdens 
were determined in the  spleen  and lung  as  described in Materials  and Methods 
(number of mice per group = 5).  Each point represents the CFU value from one 
mouse with the horizontal lines representing the geometric means.  The effect of IL- 
10R mAb treatment was tested statistically using an unpaired Students t test (*, P 
<0.05).
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Figure  3.8:  IL-10R  neutralisation  in  vivo  has  a  transient  effect  on  bacterial 
burdens during early I.V. MTb infection with H37Rv LSHTM.
£A) Female  BALB/c  mice  were  infected I.V.  with  2.2xl05  CFU H37Rv  LSHTM  strain  and 
bacterial burdens  were monitored in the spleen and lungs throughout the time course.  From 
day 0 of infection  mice  were  injected once  weekly I.P.  for 4  weeks  with  anti-IL-lOR  mAb 
(IB 1.3A;  0.5mg/mouse)  or  control  IgG  (GL113).  At  days  22  and  32  post  infection  mice 
were  killed  and  bacterial  burdens  were  determined  in  the  £Bj  spleen  and  (£Q  lung,  as 
described in Materials  and Methods  (number of mice per group = 5).  Each point represents 
the CFU value from one mouse with the horizontal  lines  representing the  geometric  means. 
On Day  32, whole splenocytes  were pooled from anti-IL-lOR mAb or control IgG (GL113) 
treated mice and re-stimulated ex vivo with PPD  (lOpg/ml) alone or in the presence of anti- 
IL-10R  mAb  (lOpg/ml).  Supernatants  were  collected  after  72  hours  post  stimulation  and 
assayed by ELISA for (Df IFN-gamma production. The effect of IL-10R mAb treatment was 
tested statistically using an unpaired Students t test (A-C) or by use of a One-Way ANOVA 
with  a  Bonferroni  multiple  comparison  post-test  (D}  (*,  P  <0.05;  **,  P  <0.01;  ***,  P 
<0.0001).  Results shown are representative of two independent experiments.
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Figure 3.9: Bacterial load  following early aerosol MTb infection is only minimally 
decreased in the absence of IL-10 signalling.
Female  BALB/c  mice  were  infected  via  the  aerosol  route  with  approximately  100  CFU 
H37Rv  LSHTM  strain.  The  bacterial  burdens  were  monitored  in  the  spleen  and  lungs 
throughout the time course.  From day 0 of infection mice were injected once weekly I.P. for 
5  weeks  (until  day  35),  with  either  anti-IL-lOR  mAb  (0.5mg/mouse)  or  control  IgG 
(GL113).  At days 27,  35 and 60 post infection mice were killed and bacterial burdens were 
determined in the lung {A)  and spleen (B}, as described in Materials and Methods (number 
of mice per group  = 5).  Alternatively BALB/c  and  B A LB /c.//70/' mice  were  infected  via 
the aerosol route and bacterial burdens were determined at day 56 post infection in the lung 
(C) and spleen (Dj (number of mice per group = 7/8).  Each point represents the CFU value 
from  one  mouse  with  the  horizontal  lines  representing  the  geometric  means.  The  effect 
attributed to  the absence  of IL-10 was  tested  statistically using an  unpaired Students  t test 
(NS = non-significant).
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Figure 3.10:  Neutralisation of endogenous IL-10 in ex vivo cultures from MTb 
infected mice enhances IFN-gamma responses.
Whole splenocytes were pooled from either naive or MTb infected mice (infected
I.V. for 32 days with H37Rv LSHTM).  Splenocytes were re-stimulated ex vivo with 
either, PPD (lOpg/ml) alone or in the presence of anti-IL-lOR mAb (both lOpg/ml). 
Supernatants were collected after 72 hours post stimulation and assayed by ELISA 
for £A) IFN-gamma or £B1 IL-12p40 production.  The effect of neutralising IL-10 
signalling was tested statistically using an unpaired Students t test (*, P <0.05; **, P 
<0.01). Results shown are representative of two independent experiments.
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Figure 3.11: Endogenous IL-10 limits macrophages pro-inflammatory cytokine 
responses to MTb infection.
Macrophages cultured from the BM of wild-type BALB/c and BALB/c.///O'7 ' mice 
and  infected  with  MTb  H37Rv  LSHTM  at  an  MOI  of  1:1  and  5:1 
(MTb:Macrophage).  Supernatants were collected after {A) 6 hours and {B} 24 hours 
then  assayed  by  ELISA  for  the  presence  of IL-12p70,  IL-12p40  and  TNF,  as 
described in Materials and Methods.
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Figure 3.12: Despite the increase in pro-inflammatory cytokines in the absence of 
endogenous IL-10, the viability of  MTb within BM macrophages is not altered.
Macrophages were cultured from the BM of wild-type and III0'1 ' mice and infected 
with MTb H37Rv LSHTM at an MOI of 1:1 and 5:1 (MTb:Macrophage).  After £A) 
24 hours and £B1 48 hours, cells were harvested and CFU performed as described in 
Materials and Methods.  Each point represents the CFU value from one tissue culture 
well with the horizontal lines representing the geometric means.
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Figure 3.13:  The protection  afforded by CD4+ T cells in a transfer model of 
infection is not regulated by IL-10.
CD4+CD25-  T  cells  were  purified  from  the  spleens  of naive  WT  BALB/c  or 
BALB/c .III O'1 ' mice as described in Materials and Methods.  BALB/c .Rag2'/' mice 
were reconstituted I.V. the day before infection with 4xl05: i) no cells (PBS), ii) WT 
CD4+, or iii) IL10'' CD4+.  Mice were infected I.V. with approximately 1x10s CFU 
H37Rv  LSHTM.  At  day  22  post  infection  mice  were  killed  and  CFU  were 
determined in the spleen (A} and lung (B). as described in Materials and Methods 
(number of mice per group = 8).  The effect of IL-10 was tested statistically using a 
One-Way ANOVA combined with a Bonferroni multiple comparison post-test (*, P 
<0.05; *** P <0.001; VS = non-significant).  Results shown are representative of two 
independent experiments.
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Figure 3.14: B6.[iMT  mice show a transient decrease in CFU during the early 
phase of I.V. infection with H37Rv LSHTM.
B6 and B6.pMT1 ' mice were infected I.V. with 5.4xl04 CFU H37Rv LSHTM strain. 
During the course of infection bacterial growth was determined in the spleen £A] and 
lungs (Bl.  At days 23 (CV(D)  and 52  (EV(F) post infection mice were killed as 
described in Materials and Methods and bacterial burdens were determined.  Each 
point  represents  the  CFU  value  from  one  mouse  with  the  horizontal  lines 
representing  the  geometric  means.  The  effect  on  bacteraemia  attributed  to  the 
absence of B  cells was tested statistically using an unpaired Students  t test (*, P 
<0.05).
85- Chapter 3: The role of IL-10 during MTb infection -
3.9.  Discussion:
The  importance  of  the  protective  Thl  response  to  MTb  infection  has  been 
highlighted  in  patients  exhibiting  Mendelian  susceptibility  to  species  of 
mycobacteria as demonstrated by defects in the cytokine signalling pathways for IL- 
12 (Altare et al., 1998; de Jong et al., 1998) and IFN-gamma (Jouanguy et al., 1996; 
Newport et al., 2003).  In addition, the mouse model has served as a valuable tool to 
further clarify and dissect these findings in mycobacteria infected human patients 
demonstrating key roles for IFN-gamma (Flynn et al., 1993; Cooper et al., 1993) and 
IL-12 (Flynn et al.,  1995; Cooper et al.,  1995; Cooper et al.,  1997; Cooper et al., 
2002) in the immune response to MTb.  The importance of other pro-inflammatory 
cytokines such as TNF in controlling the reactivation of dormant MTb, have been 
highlighted in human RA patients receiving anti-TNF therapy (Keane et al., 2003). 
These effects reported in human patients on the importance of TNF in controlling 
disease  reactivation  have  also  been  verified  in  mouse  models  by  using  TNF- 
knockout mice  or via  injection of an  anti-TNF mAb  during  late  MTb  infection 
(Flynn et al., 1995; Bean et al., 1999).
The role of immuno-regulatory factors such as IL-10 in limiting pathogen clearance 
and thus promoting MTb survival in the mouse has been reported but the findings 
are controversial.  During early MTb infection North et al., (1998) and Jung et al., 
(2003) have reported that in  the absence of IL-10 there is no effect on bacterial 
burdens  compared  to  wild-type  mice.  In  contrast,  Roach  et al.,  (2001b)  have 
reported that in the absence of IL-10 there is a transient decrease in the bacterial 
level  in  the  first 4  weeks  post  infection.  Turner  et  al.,  (2002)  using  an  IL-10
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transgenic  mouse  model,  have  shown  that  over-expression  of  IL-10  enhances 
bacterial burdens during late but not early MTb infection.  Human  studies using 
chronically  infected  TB  patients  have  suggested  a  regulatory  role  for  IL-10  in 
limiting  IFN-gamma  responses  (Gong  et al.,  1996)  and  proliferative responses 
(Boussiotis et al., 2000) to the mycobacterial antigen PPD.  Furthermore, Gerosa et 
al., (1999) have reported the presence of CD4+ T cells in the BAL of active TB 
patients that produce both IFN-gamma and IL-10.  Taken together these findings 
suggest that IL-10 affects bacterial clearance leading to chronic disease, however, 
this can only be inferred from studies in human at this stage.
Virulence between H37Rv strains:
Our data indicates a difference between the two H37Rv strains that could be linked 
to virulence.  When intervening with an anti-IL-lOR mAb late after infection H37Rv 
NIMR but not H37Rv LSHTM,  a regulatory role for IL-10 on bacterial clearance 
was revealed.  The lack of effect observed when neutralising IL-10 during infection 
with H37Rv LSHTM, was not dependent on bacterial load as mice infected with 
various infection doses of MTb before anti-IL-lOR mAb did not clear bacteria more 
effectively than MTb infected control treated mice.  When addressing the virulence 
between  H37Rv  strains  by  infection  of immuno-deficient  mice,  studies  in  the 
laboratory have revealed a vast difference in virulence, as mice infected with H37Rv 
LSHTM  and  H37Rv  NIMR  had  a  mean  survival  time  of 25  days  and  46  days 
respectively.  Finally, the in vivo growth curves for H37Rv LSHTM but not H37Rv 
NIMR were more reflective of those broadly reported in the literature.  For these 
reasons we focussed our subsequent studies solely on H37Rv LSHTM.
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A role for IL-10 during early H37Rv LSHTM infection:
We  demonstrated  that  the  timing  of  anti-IL-lOR  mAb  treatment  during  MTb 
infection  influenced  whether  an  effect  was  seen  on  bacterial  clearance.  When 
infecting I.V. with H37Rv LSHTM we found an early role for IL-10 as treatment 
with anti-IL-lOR gave a transient decrease in bacterial burdens in the lung at day 22 
and  spleen  at day  32.  When  addressing a role for IL-10 in  an  aerosol infection 
model during early MTb  infection,  we saw no effect on bacterial burdens during 
anti-IL-lOR mAb treatment.  However, infection of BALB/c .III O'1 ' mice showed a 
slight decrease in bacterial load in the spleen that was is in keeping with the findings 
by  Roach  et al.,  (2001b), but failed to reach  statistical  significance.  The  slight 
difference in bacterial burdens observed between III O'1 ' mice  and mice  that were 
treated with anti-IL-lOR mAb could be due to a) the amount and timing of antibody 
treatment, b)  the  efficiency  of antibody  receptor blocking,  c)  the  ability of the 
antibody to counteract an infection starting in the lungs or d) during the latter stages 
of mAb  treatment  mice  may  have  elicited  an  anti-antibody  response  therefore 
neutralising any potential therapeutic effect.  Following infection of III O '' mice we 
observed no effect on bacterial clearance in the lung, at day 56 post infection.  This 
may result from a transient effect on bacterial load as demonstrated by Roach et al., 
(2001b) whereby a 1-Log1 0  decrease in lung bacterial burdens was evident at day 28 
but had diminished by day 42 post infection.
The role of IL-10 in during late infection with H37Rv LSHTM:
Since all the studies to date neutralising IL-10 during MTb infection were performed
in 1110'1 'mice it has not been possible to determine a role for IL-10 during chronic
infection.  We sought to determine a role for IL-10 late after infection with H37Rv
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LSHTM using an antibody to block the IL-10 receptor as studies by Turner et al., 
(2002) using an IL-10 transgenic mouse under the control of the IL-2 promoter had 
identified a suppressive role for IL-10 late during MTb infection.  Similarly, human 
studies have suggested that IL-10 suppresses protective immune responses leading to 
chronic infection (Gong et al., 1996, Boussiotis et al., 2000).
When mice were infected via either the I.V. or aerosol routes with H37Rv LSHTM 
and treated with anti-IL-lOR mAb at a late stage after infection we did not observe a 
regulatory role for IL-10 on bacterial clearance.  This finding suggested that IL-10 
may not regulate bacterial clearance at this stage of infection.  However, IL-10 may 
be playing a role but the level of neutralising mAb may not be sufficient to reverse 
the  high  level  of infection.  To  address  this  possibility  we  infected  mice  with 
different doses of MTb before anti-IL-lOR mAb was started.  We still observed no 
effect on bacterial clearance following anti-IL-lOR mAb treatment at any infection 
dose.  With this in mind two further approaches could also be adopted to address the 
role of IL-10 during chronic  infection a) if possible an IL-10 inducible knockout 
where IL-10 could be ablated in vivo post infection, and b) chemotherapy at the peak 
of MTb infection in order to lower the bacterial load before antibody treatment is 
initiated.
Enhanced IFN-gamma production  in  ex  vivo  re-stimulations  in  the  absence  of
endogenous IL-10: new insights into interpreting human MTb studies.
In human studies it has been shown that neutralisation of IL-10 in PPD stimulated
PBMC cultures from active TB patients restores IFN-gamma production (Gong et
al.,  1996)  or  proliferative  responses  (Boussiotis  et  al.,  2000).  The  authors
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interpreted the data suggesting that IL-10 must be regulating the immune response to 
MTb and therefore limiting pathogen clearance.  Our data in a mouse model of MTb 
infection compliments the findings in the human studies, as stimulation of cells from 
MTb infected mice with PPD in vitro in the presence of anti-IL-lOR mAb enhanced 
production of IFN-gamma and IL-12p40 (Fig. 3.10).  This demonstrates that IL-10 is 
present although anti-IL-lOR mAb treatment of mice late after infection with H37Rv 
LSHTM had not effect on bacterial clearance at this stage of infection (Fig. 3.5).  As 
discussed earlier, demonstrating a role for IL-10 in regulating bacterial clearance at 
this late stage of infection may be difficult to achieve at high bacterial loads.  Our 
findings  at this  stage of infection  may  also reflect that IL-10  may only regulate 
cytokine  production  and  not  bacterial  killing  as  suggested  by  human  studies. 
Furthermore, it is necessary to improve ex vivo assays in human studies in order to 
assess the effect of immune-modulators e.g. anti-IL-lOR mAb, on bacterial killing. 
To compliment these human studies, experimental assays in the mouse also need to 
be modified to address subtler effects mediated by immune modulators.
IL-10 negatively regulates macrophage responses to in vitro MTb infection:
The data in human studies suggests that IL-10 functions to limit bacterial clearance
as  neutralisation  of IL-10  in  ex  vivo  PPD  re-stimulations  restores  IFN-gamma
responses (Gong et al.,  1996).  In order to address a role for IL-10 on MTb killing
we utilised a reductionist approach by infecting BM macrophages in vitro in absence
of  IL-10  to  determine  a) the  induction  of pro-inflammatory  cytokines  and  b)
macrophage  MTb  killing  in  vitro.  Despite  the  finding  that  pro-inflammatory
cytokine production  from III O'1 '  macrophages  was  enhanced  following  different
burdens of infection in vitro, there was no enhancement of macrophage MTb killing.
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The observation that MTb killing in vitro was not enhanced in the absence of IL-10, 
may be due to an over simplified in vitro system where T cells and NK cells were 
not present.  Alternatively, MTb could be functioning to inhibit anti-microbial killing 
via inhibition of other signalling pathways.  We are currently re-evaluating the role 
of IL-10 on macrophage activation by adding IFN-gamma to macrophage infection 
cultures to address this.
The source of IL-10 during MTb infection:
We sought to isolate a cellular source for IL-10 during MTb infection.  In contrast to 
the published human studies by Gerosa et al., (1999) and Boussiotis et al., (2001), 
using adoptive transfer of CD4+.I110'1 ' T cells into immuno-compromised Rag2',m  
recipients and intracellular flow cytometry for detecting IL-10, we failed to confirm 
CD4+ T cells  as a source for IL-10  at this  stage during MTb infection, possibly 
reflecting the  low  frequency  of IL-10  producing  antigen  specific  T  cells.  The 
inability to detect IL-10 could be due to the low number of antigen specific T cells in 
the organs investigated, the  sensitivity of the antibody or the kinetics or cellular 
origin  of IL-10  cytokine  production,  all  are  key  aspects  that  need  to  be  more 
rigorously dissected.  Besides CD4+ T cells, other cells that are involved in the 
innate and adaptive immune response have been shown to make IL-10 (Moore et al., 
2001).
With this in mind we addressed the role of B cells as a source of IL-10 by using
B6.juMrA . Following I.V. infection we could only address a transient role for B cells
during MTb infection.  Our studies compliment the findings of Bosio et al., (2000)
who also showed a transient role for B cells in limiting bacterial clearance during the
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early immune response to MTb CDC1551.  However, our data is in contrast to that 
published by Vordermeier et al., (1996) who show an increase in bacterial burdens in 
the absence of B cells following I.V. MTb infection.  The key differences that may 
explain the variability between these studies are the route of infection used, the time 
points examined and the strain of MTb, i.e. H37Rv or CDC1551.  In addition, we are 
currently addressing the role of B cell derived IL-10 on MTb bacterial clearance in 
adoptive transfer studies using B cells from III O '' donors.  Thus far CD4+ T cells 
and B  cells do not appear to  serve as  a major source for IL-10 during the early 
immune response to MTb.
However, the potential for other cell types producing IL-10 also needs investigating 
as reports have demonstrated that both DC and macrophages readily produce IL-10 
following TLR stimulation (Dillon et al., 2004, Boonstra et al., 2006) or via ligands 
that trigger non-TLR such as through DC-SIGN (Gagliardi et al., 2005) or Dectin-1 
(Rogers et al.,  2005).  Interestingly, it has also been shown that regulation of the 
innate immune response to Listeria infection is by IL-10 derived from a population 
of CD1 lb+ cells (Carrero et al., 2006).
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Chapter 4: The Potential Role for Naturally Occurring 
Regulatory T cells As Mediators of MTb Survival and
Persistence.
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4.1.  The potential role for naturally occurring regulatory T cells as mediators 
of MTb survival and persistence, aims of the investigation;
To address the role of regulatory T cells in MTb we sought to:
1) Determine the kinetics of Tregs in the lung following aerosol MTb infection.
2) Identify whether the immune response and moreover bacterial clearance, is altered 
in mice depleted of Tregs prior to infection?
3) Evaluate the immunosuppressive role of TGF-beta during MTb infection.
4) Using an adoptive transfer model:
a) Can Tregs limit the immune response following MTb infection?
b) Do Tregs mediate suppression by IL-10 dependent mechanisms?
4.2. Background:
Naturally occurring CD4+CD25+ Tregs were originally described by Sakaguchi et 
al., (1995) as essential regulators of autoimmunity.  More recently, Tregs have been 
shown to play regulatory roles in allergy (Kearley et al., 2005) and infection with 
agents such as Listeria (Kursar et al., 2002), Plasmodium (Hisaeda et al., 2004) HSV 
(Suvas et al., 2003) and Leishmania (Belkaid et al., 2002; Mendez et al., 2004).  In 
addition to the marker CD25 (IL-2R-alpha), Tregs also express high levels of CTLA- 
4, GITR, CD103 and 0X40 (Fontenot et al., 2005b).  Interestingly like CD25, all 
these markers are up regulated on all T cells following activation, thus making CD25 
in the context of infection, an unreliable marker for defining Tregs (Hawrylowicz, 
2005).  However, the  discovery  of the  Treg  lineage  specific transcription  factor 
FoxP3 has further facilitated studies on Tregs.
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The  role  of FoxP3+  Tregs  during  MTb  infection  has  only  now  been  recently 
reported.  Recent  studies  of PBMC  from human TB  patients  have  identified  an 
increase  in  FoxP3  mRNA  expression  (Guyot-Revol  et al,  2006)  and  by  flow 
cytometry,  Ribeiro-Rodrigues  et al,  (2006)  have  reported  an  increase  in  the 
percentage of CD4+CD25+FoxP3+ Tregs that have suppressive activity in vitro.  In 
the mouse model, there is limited data on the role of Tregs during MTb infection. 
Quinn  et  al., (2006)  have  shown  by  flow  cytometry  that  following  intranasal 
infection with BCG there is an increase in the total number of CD4+CD25+FoxP3+ 
Tregs.  In a model for depletion of Tregs by treating mice with the anti-CD25 mAb 
(clone PC61), they showed no effect on bacterial burdens or histology, but did show 
that IFN-gamma production by CD4+ T cells  was enhanced.  In the same study, 
Quinn  et al,  (2006)  also presented  a limited  amount of data demonstrating that 
depletion of Tregs via treatment of mice  with  anti-CD25  mAb had no effect on 
clearance of MTb.  However, it is well documented that in vivo treatment of mice 
with anti-CD25 mAb depletes a subset of naturally occurring CD4+CD25+ Tregs. 
One  caveat  of this  approach  is  that  anti-CD25  mAb  will  also  deplete  recently 
activated effector T cells that also express CD25, thus numerous studies in the field 
of Tregs utilise transfer models.  To address a role for Tregs during murine MTb 
infection, we adopted a three pronged approach utilising i) flow cytometry to track 
FoxP3 expression;  ii) antibody depletion of CD25+ cells; iii) adoptive transfer of 
specific T cell populations into immuno-compromised recipients.
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4.3.  CD4+FoxP3+ Tregs increase at the site of MTb infection following aerosol 
infection;
Although an increase in FoxP3 expression by mRNA expression and flow cytometry 
in the blood of TB patients has been  shown (Guyot-Revol et al.,  2006; Ribeiro- 
Rodrigues et al., 2006), there is no published data on FoxP3 expression following 
MTb infection in mice.  We therefore wanted to establish whether following aerosol 
infection there was  an  increase  in Tregs at the  site of infection,  as identified by 
expression  of the  markers  CD4,  CD25  and FoxP3.  However,  before  we could 
address this question  and in order to optimise the  system, we titrated the FoxP3 
antibody  (2pg/ml  down to 0.125pg/ml)  on  whole  splenocytes  suspensions  from 
naive BALB/c mice.  In addition, we also confirmed the specificity of the FoxP3 
antibody by  testing  it on  whole  splenocytes  obtained  from foxp3'''  mice  and  as 
expected they were negative for FoxP3 compared to wild type controls.
To address the influx of Tregs during MTb infection, BALB/c mice were infected 
with H37Rv  LSHTM  strain  via the  aerosol  route with  approximately  100  CFU. 
During the course of infection mice were killed, cell suspensions from the lungs and 
spleen were prepared and stained for expression of CD4, CD25  and FoxP3  (Fig. 
4.1 A).  By flow cytometry we observed a sustained increase in the percentage of 
lung CD4+ T cells from day 8 post infection compared to non-infected control mice 
(Fig.4.1B).  The observed increase in CD4+ T cells was accompanied by an increase 
in the percentage CD4+CD25+FoxP3+ Tregs and CD4+CD25-FoxP3+ Tregs from 
day  8  (Fig. 4.1C).  In  addition,  a subset of CD25lo w Fox3- expressing T cells was 
evident early on during the time-course, which could have potentially constituted a
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population of early effector T cells, but these failed to increase during the course of 
infection.
During the progression of infection (Fig. 4.2A), we observed an increase in the total 
numbers of CD4+FoxP3+ T cells in the lung from day 8 to day 29 post infection that 
was  independent  of  the  marker  CD25  (Fig.  4.2C  and  D).  This  increase  in 
CD4+CD25+FoxP3+ and CD4+CD25-FoxP3+ Tregs was in contrast to the numbers 
of effector T cells (CD4+CD25+FoxP3-), that remained unchanged until day 29 post 
infection and then increased until day 50 when the experiment was terminated (Fig. 
4.2B), which is in keeping with reports by others (Junqueira-Kipnis et al., 2004).  In 
contrast, we observed no effect on the total  numbers of either CD4+ T cell sub­
population in the spleen following aerosol infection (data not shown).
4.4.  The role of naturally occurring CD25+ Tregs during MTb infection:
4.4.1.  Anti-CD25 mAb treatment of mice before MTb infection does not affect 
bacterial load but enhances IFN-gamma production:
As  discussed  previously,  we  observed  an  increase in  lung CD4+CD25+FoxP3+
Tregs following aerosol exposure to MTb.  To address a functional role for CD25+
Tregs  as  negative  regulators  of the  immune  response to  early  MTb,  mice  were
treated  on  day  -4,  2  and  0  before  infection,  with  anti-CD25  mAb  (PC61;
0.5mg/mouse) or control IgG (GL113) to  specifically deplete  naturally occurring
CD25+ Tregs.  On day 0 before infection the depletion of Tregs was confirmed by
flow cytometry and was greater than 80% (Fig. 4.3).  We adopted this early anti-
CD25  mAb  treatment  schedule,  as  anti-CD25  mAb  will  also  deplete  recently
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activated CD4+CD25+ effector T cells, since naive CD4+ T cells up-regulate CD25 
shortly after activation (Shevach, 2006).  This approach has been widely used to 
address  the  role  of Tregs  in  infections  such  as  Listeria  (Kursar  et  al.,  2002), 
Plasmodium (Hisaeda et al., 2004), Leishmania  (Mendez  et al.,  2004)  and more 
recently BCG (Quinn et al., 2006).
In addition to CD25+ Tregs, we also sought to determine a role for TGF-beta during 
MTb  infection.  As  discussed  earlier,  TGF-beta  is  a  widely  distributed 
immunosuppressive cytokine that is important in the down-regulation of Thl  and 
Th2 cell mediated immune responses (Letterio et al.,  1998).  Studies in mice have 
reported that Treg derived TGF-beta plays a key role in regulating T cell mediated 
colitis (Powrie et al., 1996, Maloy et al., 2003) and is essential in the maintenance of 
the Treg population (Marie et al., 2005).  The role of TGF-beta during TB infection 
has not been well documented.  In human studies it has been reported that TGF-beta 
is elevated in the serum of TB patients compared to healthy controls (Fiorenza et al., 
2004 and Guyot-Revol et al., 2006).  To address the roles of TGF-beta in MTb we 
used in vivo antibody neutralisation as it is well documented that Tgf-Bl’1 ' mice die at 
3-4 weeks of age due to an overwhelming lymphoproliferative disorder (Shull et al., 
1992).
BALB/c mice were treated with anti-CD25 mAb (0.5mg/mouse) at day -4, -2 and
day 0 before infection as described above (Fig. 4.3).  Similarly, as IL-10 and TGF-
beta also function as immune-regulators, some mice were also administered with
anti-IL-lOR mAb (0.5mg/mouse), anti-TGF-beta antibody (1.5mg/mouse) or control
IgG  before  I.V.  H37Rv  infection,  then  once  weekly  during  the  course  of the
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infection.  On the day of infection, the efficiency of Treg depletion in mice that 
received anti-CD25 mAb as determined by flow cytometry for expression of CD4, 
CD25 and FoxP3 in the spleen was greater than 80% (Fig. 4.3).  Following infection 
mice were killed at day  1   or 22 (Fig. 4.4) to determine the bacterial growth within 
mice, then at day 33 final bacterial burdens in the spleen (Fig. 4.4B) and lung (Fig. 
4.4C) were determined.  Treatment of mice with anti-CD25 mAb alone or anti-TGF- 
beta antibody  alone had no effect on bacterial burdens  during the early  stage of 
infection.  As demonstrated previously (chapter 3; Fig. 3.8), treatment of mice with 
anti-IL-lOR mAb alone had a significant effect on bacterial burdens in the spleen at 
day 33  (Fig. 4.4.B).  Strikingly, co-administration of both anti-CD25 and anti-IL- 
10R mAb’s significantly enhanced bacterial clearance in the spleen (Fig. 4.4B) but 
not  lung  (Fig.  4.4C)  compared  to  single  treatment  controls  at  the  time-points 
investigated.  The  observed  decrease  in  bacterial  burdens  following  combined 
treatment of mice with both anti-CD25  mAb and anti-IL-lOR mAb could not be 
further enhanced in the presence of anti-TGF-beta antibody (Fig. 4.4B and C).  Our 
findings suggest only a minor effect when depleting CD25+ cells during early MTb 
infection except when administered in the presence of anti-IL-lOR mAb.
In addition, we also examined the effect of anti-CD25 mAb treatment of mice during 
aerosol MTb infection (Fig. 4.5), however treatment of mice under the same regimen 
as described above, with anti-CD25 mAb alone or combined with anti-IL-lOR mAb 
did not affect bacterial burdens in either the spleen (Fig. 4.5B) or lungs (Fig. 4.5C) at 
days 27, 35 or 60 post infection.  Our findings illustrate that CD25+ Tregs do not 
have  dominant  role  in  regulating  the  early  innate  immune  response  to  MTb  as
treatment with anti-CD25 mAb alone is not sufficient to enhance bacterial clearance.
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We postulate that in the absence of CD25+ cells, other regulatory factors such as IL- 
10 can still regulate the immune response.
To address whether anti-CD25 mAb treatment enhanced T-cell responses during I.V. 
MTb  infection,  whole  splenocytes  from infected anti-CD25  mAb or control  IgG 
treated mice were re-stimulated for 72 hours in the presence of PPD (Fig 4.6).  Re­
stimulation of whole splenocyte cell suspensions ex vivo with PPD gave an increase 
in production of IFN-gamma (P <0.01; Fig 4.6A), as compared to infected control 
IgG treated mice.  Similarly, IL-12p40 (Fig. 4.6B) and TNF (Fig 4.6C) were also 
enhanced in mice that were treated in vivo with anti-CD25 (P < 0.05), but this could 
only be observed when the re-stimulation was performed in the presence of IL-10 
neutralising antibodies.  Our data implies that the increase in IFN-gamma production 
in re-stimulations from anti-CD25 mAb alone treated mice is probably not sufficient 
to mediate bacterial clearance in vivo.
4.5.  Immuno-compromised Rag1  mice as a model for determining the role of 
Tregs during early MTb infection:
4.5.1.  Determining the kinetics of MTb infection in Ragl4 ' mice:
When  addressing a role for CD4+CD25+Tregs during MTb infection using anti- 
CD25  mAb depletion we observed no effect on bacterial load.  It is  known that 
treatment  of  mice  with  anti-CD25  mAb  not  only  depletes  naturally  occurring 
CD4+CD25+Tregs but can also deplete recently activated CD4+ effector T cells.  In 
accordance with this,  not  all  Tregs express  the  marker CD25, therefore  a small
subset of CD4+CD25-FoxP3+ Tregs - approximately 20-30%, cannot be depleted
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and will persist with regulatory capacity.  With this in mind we used an adoptive 
transfer model  as a complimentary approach to address the role of CD4+CD25+ 
Tregs during early MTb  infection.  The Rag'1 ' adoptive transfer model has been 
widely used in determining the role of Tregs in murine models of colitis (Powrie et 
al.,  1996,  Asseman  et  al., 2003)  and Leishmania  major  (Belkaid  et al., 2002; 
Mendez et al., 2004).
We  first  sought  to  define  the  kinetics  of  I.V.  MTb  infection  in  immuno­
compromised Rag'1 ' mice.  Wild-type B6 and B6.Ragl' mice were infected I.V. with 
H37Rv LSHTM (Fig. 4.7A) with bacterial burdens being determined in the spleen 
(Fig.  4.7B)  and  lung  (Fig.  4.7C)  at  the  time  points  indicated.  Following  I.V. 
infection there was no difference in bacterial load between B6 and B6.Ragl‘  mice 
until day 14 post infection, where B6.Ragl/' displayed a 10-fold higher bacterial load 
that was further increased by day 21  as the infection progressed (Fig. 4.7B).  In the 
lung,  the  infection  progressed  more  slowly  with  B6.Ragl'1 ' mice  displaying  an 
increased  bacterial  load  at  day  21  compared  to  B6  mice  (Fig.  4.7C).  For  the 
subsequent adoptive transfer studies we chose day 21  as a suitable end-point for 
experiments due to the observed correlation between protection and bacterial load in 
both the spleen and lungs.
4.5.2.  CD4+CD25+ Tregs have a limited effect on bacterial clearance:
Furthermore,  to  address  the  potential  role  of  Tregs  during  MTb  infection, 
BALBIc.Rag2''' mice were reconstituted the day before infection with either naive 
CD4+CD25-  T  cells  alone  or  together  with  increasing  numbers  of  naive
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CD4+CD25+  Tregs.  The  following  day  mice  were  infected  I.V.  with  H37Rv 
LSHTM.  Immuno-compromised  BALB/c./to^'  recipients  (no  cells)  and 
BALB/c.Rag2 '' mice receiving CD4+CD25+ Tregs failed to control MTb infection 
with bacterial burdens  significantly higher compared to wild-type BALB/c.  Re­
constitution of BALB/c./tag2‘A   with  CD4+CD25-  T  cells  conferred  significant 
protection to infection with H37Rv in both the spleen (Fig. 4.8A) and lung (Fig. 
4.8B).  There  was  evidence  to  suggest  that  the  presence  of  Treg  at  a  non- 
physiological ratio of 1:1  (Naive CD4+CD25- T cell: CD4+CD25+ Treg), limited 
the immune response to H37Rv infection in the spleen (Fig. 4.8A) and lungs (Fig. 
4.8B), however this finding failed to reach statistical significance.
We have demonstrated that treatment of mice with anti-CD25 mAb alone has no 
effect on bacterial clearance unless  it is  administered together with  anti-IL-lOR 
mAb.  We sought to verify our findings  above using an adoptive transfer model 
using CD4+CD25- T cells from wild-type and III Or1 ' mice.  BALB/c .Rag?1 ' mice 
were  re-constituted  with  either  whole  CD4+  T  cells  (as  reported  previously  in 
Chapter 3; Fig 3.13) or Treg depleted CD4+CD25- T cells from either wild-type or 
III O'1 ' mice (Fig. 4.9).  When CD4+CD25+ Tregs were removed from whole CD4+ T 
cell populations to yield CD4+CD25- T cells, there  was  no enhanced protective 
effect as compared to whole CD4+ T cells in either the spleen (Fig 4.9A), or the 
lungs (Fig. 4.9B).  This observation is in accordance with our earlier findings, when 
depletion of CD25+ cells via mAb treatment had no effect on bacterial clearance 
suggesting that CD25+ Tregs play a minimal role in the immune response to MTb at 
this stage.  The data suggests that CD4+ T cell derived IL-10 and more specifically
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CD4+CD25+ Treg derived IL-10 plays only a limited role at this stage during early 
infection with H37Rv LSHTM.
4.5.3.  Transfer of CD4+ CD25+  T cells from MTb  infected donors mediates 
protection not suppression to subsequent MTb infection:
Since we did not observe any significant effect following reconstitution of mice with 
Tregs  at  non-physiological  levels,  we  wished to  determine based on  our FACS 
analysis  (Fig.  4.1),  whether  MTb  expanded  Tregs  would  be  more  effective  in 
regulating the immune response to MTb.  To address this we infected mice for 14 
days before we attempted to enrich antigen specific Tregs, as at this time-point our 
FACS analysis revealed that the ratio of Tregs to effectors was significantly higher.
To address this BALB/c.JRag?1 ' mice received either a) CD4+CD25- T cells from 
naive donors or b) CD4+CD25+ T cells from MTb infected donors (from mice that 
had been infected for 14 days).  Mice were then infected I.V. with H37Rv LSHTM 
for 22 days before bacterial burdens were determined in the spleen (Fig. 4.10A) and 
lungs (Fig. 4.10B), in comparison to infected wild-type BALB/c.  As predicted, MTb 
infection of BALB/c.Rag2 '' recipients  (no cells) or mice receiving CD4+CD25+ 
Tregs  (from  naive  donors)  failed  to  control  infection.  However,  transfer  of 
CD4+CD25- T cells (from naive mice) or CD4+CD25+ T cells (from MTb donors), 
conferred protection in the spleen (Fig. 4.10A) and lung (Fig. 4.10B).  This effect 
was comparable to wild-type BALB/c as shown by a significant decrease in bacterial 
burdens.  Our data demonstrates that in the first  14 days following I.V.  infection 
CD4+CD25+ effector T cells are generated that mediate protection to infection with
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MTb which may explain why anti-CD25 mAb treatment during in vivo infection was 
not effective.
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Figure 4.1: Regulatory T cells accumulate in the lungs of mice shortly after MTb infection.
BALB/c mice were infected with approximately  100 CFU H37Rv LSHTM strain via the aerosol route.  At the time points indicated post infection 
the lungs were removed and stained for CD4, CD25 and FoxP3 expression as described in Materials and Methods.  Viable cells were selected on 
their FSC / SSC profile (A) to define the CD4+ cells and CD4+FoxP3+ Tregs.  At the time-points indicated, CD4+ cells  were selected then 
©  analysed  for expression  of CD25  and  FoxP3 £C}.  The  percentage  values  indicated on the  plots for CD4+ cells  are of total  live cells and  the
expression of CD25 and FoxP3 are shown as a percentage of total CD4+ T cells.  Each plot is representative of 3 individual  mice and the data 
shown is representative of 2 independent experiments
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Figure 4 2 : The absolute numbers of Tregs increase in the lungs of mice shortly after MTb infection.
BALB/c mice were infected with approximately 100 CFU H37Rv LSHTM strain via the aerosol route and the bacterial load was monitored 
during the course of infection (A).  Total numbers of CD25+ effector (B), CD25+FoxP3+ Treg (C] and CD25-FoxP3+ Treg (D) during the 
infection time course are shown.  Each data point represents the value obtained from one mouse lung with the horizontal lines representing 
the geometric means.  The influx of Tregs during infection was tested statistically using a Students t test (*, P <0.05; **, P <0.01).  The data 
shown is representative of 2 independent experiments.
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Figure 4.4: Depletion of CD25+ cells only has an effect on bacterial clearance 
during the early immune response to MTb unless administered in the presence of 
anti-IL-lOR mAb.
(A) Female BALB/c mice were infected I.V. with 2.2xl05  CFU H37Rv LSHTM and 
bacterial burdens were monitored in the spleen and lungs throughout the time course. 
Mice were injected I.P. once weekly from the day of infection with either anti-TGF- 
beta (1D11;  1.5mg/mouse) or TC31  (control IgG).  Mice also received anti-CD25 
mAb  (PC61;  0.5mg/mouse  at  days  -4,  -2,  0  and  7),  anti-ILlOR  mAb  (1B1.3A; 
0.5mg/mouse once weekly) or control IgG (GL113).  At day 33 post infection mice 
were killed and bacterial burdens were determined in the spleen {B} and lung  as 
described in Materials and Methods (number of mice per group = 5).  Each point 
represents the CFU value from one mouse with the horizontal lines representing the 
geometric means.  The effect of mAb treatment was tested statistically using a One- 
Way  ANOVA combined with  a  Bonferroni  multiple  comparison  post-test  (*,  P 
<0.05; **, P <0.01).
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Figure 4.5: Depletion of CD25+ cells does not alter protection during early aerosol 
MTb infection.
(A)  Female BALB/c mice were infected via the aerosol route with approximately 
100 CFU H37Rv LSHTM strain and the bacterial burdens were monitored in the 
spleen and lungs throughout the time course.  Mice were injected I.P. at days -4, -2, 
0  and  7  post  infection  with  GL113  (control  IgG)  or  anti-CD25  (PC61; 
0.5mg/mouse).  Mice  receiving  anti-IL-lOR  mAb  (1B1.3A;  0.5mg/mouse)  were 
injected I.P.  once weekly from the day of infection.  At days 27,  35  and 60 post 
infection mice were killed by cervical dislocation and CFU were determined in the 
spleen  and lung (CL as described in Materials and Methods (number of mice per 
group  =  5).  Each  point  represents  the  CFU  value  from  one  mouse  with  the 
horizontal lines representing the geometric means.
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Figure 4.6: Despite no effect on bacterial load, depletion of CD25+ cells enhances 
pro-inflammatory cytokine responses to mycobacterial PPD.
Whole  splenocytes  were pooled from anti-CD25  treated  mice or GL113  (control 
IgG)  and re-stimulated ex vivo  with  PPD  alone  (lOpg/ml)  or in  the  presence or 
absence of anti-IL-lOR mAb (both  lOpg/ml).  Supernatants were collected after 72 
hours post stimulation and assayed by ELISA for (A). IFN-gamma, £B) IL-12p40, 
and ££) and TNF production.  The effect of in vivo anti-CD25 mAb treatment was 
tested statistically using a One-Way ANOVA combined with a Bonferroni multiple 
comparison post-test (*, P <0.05; **, P <0.01).
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Figure 4.7:  Determining the kinetics ofH37Rv LSHTM infection in wild-type and 
B6.RagV'' mice.
(A) Wild-type B6 or B6.Ragl'1 ' mice were infected with 1x106CFU via the I.V. route 
and bacterial burdens were monitored in the spleen and lungs throughout the time 
course.  Mice were killed at the time-points indicated and bacterial load in the spleen
(B) and lung (CL were determined as described in Materials and Methods (number 
of mice per group = 8).  Each point represents the CFU value from one mouse with 
the  horizontal  lines  representing  the  geometric  means.  The  difference  in  CFU 
between B6  and B6.Ragl '' was  tested  statistically  using  a  Students  t test (**, P 
<0.01; ***, P <0.001).
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Figure  4.8:  Increasing  the  natural  ratio  of naive  CD4+CD25-  T  cells  to 
CD4+CD25+ Tregs plays a minimal role in regulating bacterial clearance.
CD25-  and CD25+ T cells  (All  CD4+)  were purified from the  spleens  of naive 
BALB/c  donors  as  described  in  materials  and  methods.  BALB/c./tag2‘A  were 
reconstituted I.V. on day -1 before infection (cell number in brackets): i) PBS  (no 
cells), ii) CD25- alone (4xl05), Hi) CD25+ alone (4xl05), or combinations of CD25-: 
CD25+ iv) 10:1; (4xl05:4xl04), v)  1:1; (4xl05:4xl05), vi)  1:2; (4xl05:8xl05).  Mice 
were infected I.V. with approximately 4xl04 CFU H37Rv LSHTM.  At day 22 post 
infection mice were killed and CFU were determined in the spleen {A} and lung £B), 
as described in Materials and Methods (number of mice per group = 5).  The effect 
of Treg transfer was tested statistically using a One-Way ANOVA combined with a 
Bonferroni multiple comparison post-test (*** P <0.001; NS = non-significant, «  = 
below  lxlO4  CFU).  Results  shown  are  representative  of  two  independent 
experiments.
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Figure 4.9: Whole CD4+ or CD4+CD25+ Treg derived IL-10 plays a minimal role 
in regulating the protective immune response to early MTb infection.
CD4+CD25-  T  cells  were  purified  from  the  spleens  of naive  WT  BALB/c  or 
BALB/cJllO'1 ' mice as described in materials and methods.  BALB/c,Rag2 /  mice 
were reconstituted I.V. the day before infection with 4xl05:  i)  no cells  (PBS), ii) 
whole  WT  CD4+,  iii)  whole  IL107 '  CD4+,  iv)  WT  CD4+CD25-,  v)  IL10A  
CD4+CD25-.  Mice  were  infected  I.V.  with  approximately  1x10s  CFU  H37Rv 
LSHTM.  At day 22 post infection mice were killed and CFU were determined in the 
spleen £A) and lung (B). as described in materials and methods (number of mice per 
group = 8).  The effect of IL-10 was tested statistically using a One-Way ANOVA 
combined with  a  Bonferroni  multiple  comparison  post-test  (*,  P  <0.05;  ***,  P 
<0.001;  NS  =  non-significant,  «   =  below  lxlO4  CFU).  Results  shown  are 
representative of two independent experiments.
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Figure 4.10: Antigen experienced CD4+CD25+ effector T cells mediate protection 
during early I.V. MTb infection.
To generate antigen experienced CD4+CD25+ T cells, BALB/c mice were infected 
I.V. with  1x10s CFU H37Rv LSHTM strain.  After  14 days, mice were killed by 
cervical dislocation, spleens removed and CD4+CD25+ T cells purified.  For naive 
donor  cells,  CD4+CD25+  and  CD4+CD25-  T  cells  were  obtained  from  naive 
BALB/c.  For the transfer, BALB/c.RagZ1 ' mice  were reconstituted I.V.  the  day 
before infection with 4xl05: i) no cells (PBS), ii) naive CD25-, iii) naive CD25+, iv) 
antigen experienced CD25+.  Mice  were infected I.V.  with  approximately 4xl04 
CFU H37Rv LSHTM strain.  At day 22 post infection mice were killed and CFU 
were  determined in the  spleen  (A)  and lung (B},  as  described  in  Materials  and 
Methods (number of mice per group = 5).  The effect of T cell transfer was tested 
statistically  using  a  One-Way  ANOVA  combined  with  a  Bonferroni  multiple 
comparison post-test  (***, p <0.001).  Results  shown  are representative of two 
independent experiments.
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4.7.  Discussion:
Tregs mediate suppressive activity either via cell-cell contact or through production 
of suppressive cytokines such as IL-10 (Asseman et al., 2003) or TGF-beta (Powrie 
et al.,  1996).  The outcome limits aberrant autoimmune responses or may dampen 
over-exuberant and potentially pathological innate or adaptive immune responses to 
antigen or infectious challenge (Belkaid et al., 2005).  The presence of regulatory 
factors may benefit the host by limiting collateral damage but may inadvertently 
promote pathogen persistence as  demonstrated in mouse models of Toxoplasma 
(Gazzinelli et al., 1996) and Trypanosomiasis (Hunter et al., 1997).  Tregs have been 
subdivided into a) naturally occurring Tregs derived from the thymus or b) antigen 
driven  IL-10 producing  CD4+  Tregs  (IL-10 Tregs)  that result  after exposure to 
specific stimulatory conditions during infection or antigen exposure (Mills, 2004, 
O'Garra et al., 2004, Belkaid et al., 2005).  We sought to address the role of naturally 
occurring Tregs as regulators of the protective immune response to MTb by three 
different approaches.  Firstly, by flow cytometry of the Tregs specific transcription 
factor  FoxP3.  Secondly,  by  antibody  treatment  of  mice  to  deplete  naturally 
occurring Tregs.  Thirdly, using adoptive transfer of specific T cell populations into 
empty immuno-compromised hosts.
CD4+FoxP3+ Tregs increase in the lung following aerosol MTb infection:
To date a role for Tregs in regulating the immune response during murine MTb has 
not been defined.  Our data demonstrates that Tregs play a limited role during early 
MTb infection.  In agreement with the findings in human TB studies by Guyot-Revol 
et al., (2006) and Ribeiro-Rodrigues et al., (2006), we have identified an increase in
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the percentage and absolute numbers of lung Tregs following aerosol exposure of 
mice to MTb.  The numbers of lung CD4+FoxP3+ Tregs increased from day 8 post 
infection until day 29 post infection and was independent of the marker CD25 (Fig. 
4.2C and D).  The opposite kinetics were apparent for CD4+CD25+FoxP3- effector 
T cells (Fig. 4.2B), that started to increase during the latter stages of infection from 
day 29 to day 50 as reported by others (Junqueira-Kipnis et al., 2004).
Treatment  of mice  with  anti-CD25  mAb  enhances  pro-inflammatory  cytokine 
production but does not correlate with enhanced bacterial clearance:
When using an antibody depletion model to address the involvement of Tregs in 
suppression of protective immunity to MTb thus promoting bacterial persistence and 
survival, we could assign no such role (Fig. 4.4).  This finding is in accordance with 
the  studies  of Quinn  et al.,  (2006),  who  have  also  shown  that  anti-CD25  mAb 
treatment of mice following aerosol  MTb  (and BCG)  infection had no effect on 
disease progression.  In the same study treatment of mice with anti-CD25 during 
BCG infection enhanced IFN-gamma production.  Similarly, in mice treated with 
anti-CD25 we observed an increase in IFN-gamma following ex vivo re-stimulation 
of cell suspensions with PPD.
As discussed earlier, depletion of CD4+CD25+ Tregs via anti-CD25 mAb therapy
leaves a minor population of CD4+CD25-FoxP3+ Tregs that cannot be depleted.
This  subset of CD4+CD25-FoxP3+ Tregs  will persist following  anti-CD25  mAb
treatment with the potential to regulate the immune response at the site of infection,
thus  masking  any  potential  subtle  effects  on  bacterial  load.  Whether  or  not
CD4+CD25-FoxP3+ Tregs have a specific function in comparison to CD25+FoxP3+
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Tregs during infection at this stage is not known.  In addition, treatment of mice with 
anti-CD25  mAb  may,  depending  on  the  half-life  the  antibody,  distort  the 
development later during infection of protective CD4+CD25+ effector T cells.  We 
have  demonstrated  that  during  the  first  14  days  following  I.V.  infection 
CD4+CD25+ effector T cells are generated that mediate protection when adoptively 
transferred into naive recipients and subsequently infected with MTb (Fig 4.10).  In 
addition,  we have recently  acquired a FoxP3  knock-in  green fluorescent protein 
(GFP) mouse thus enabling us to identify and track the development of FoxP3+ Treg 
populations including the cytokines they are producing during infection.  Similarly 
this  FoxP3-GFP  mouse  will  enable  us  to  obtain  an  ultra-pure  population  of 
CD4+FoxP3+ Tregs for our adoptive transfer studies, instead of enriching solely on 
the markers CD4 and CD25.
In contrast to anti-CD25 treatment alone, we were able to see an effect on bacterial
load when mice were treated with a combination of both anti-CD25 mAb and anti-
IL-10R mAb (Fig. 4.4B and C).  This effect on bacterial load when both anti-CD25
and anti-ILlOR were combined was enhanced compared to either mAb treatment
alone (Chapter 3; Fig. 3.8).  However, treatment of mice with both anti-CD25 mAb
and anti-IL-10 mAb during aerosol MTb infection had no effect on bacterial load.
The  exact  mechanism  underlying  the  enhanced  effect  seen  when  combining
treatment of anti-CD25 with anti-ILlOR mAb during I.V. infection is at present not
known.  We originally postulated that in the absence of CD4+CD25+FoxP3+ Tregs
IL-10 was  still being produced by a minor subset of CD4+CD25-FoxP3+ Tregs.
However, this hypothesis was disproved when transfer of CD4+ T cells from I110'1 '
mice in to Rag1 ' recipients, failed to influence bacterial burdens.  IL-10 could be
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from a non-T cell source such as macrophages and DC.  As discussed in chapter 3, to 
address the possibility of the innate immune response as a source for IL-10 we are 
currently breeding B6.7tog7'/\7/70'/'mice.
TGF-beta as a potential immunosuppressive factor limiting the immune response to 
MTb:
Suppression  of  the  immune  response  by  TGF-beta  is  important  in  the  down 
regulation of T cell mediated immune responses such as those that are needed to 
combat MTb infection.  In mouse models of colitis TGF-beta has been shown to be 
an  essential  regulator of Treg  activity  and  immune  cells  that  express  dominant 
negative TGF-beta receptors can escape regulatory control (Fahlen et al., 2005).  In 
mouse studies by Mogga et al., (2003) it has been shown that TGF-beta expression 
was  increased  in the lungs  of mice  12  weeks  following  aerosol  MTb  infection. 
When addressing the above roles for TGF-beta by antibody neutralisation, we found 
no such affect in a mouse model of early MTb infection.  When anti-TGF-beta was 
administered in the presence of anti-CD25 mAb and anti-IL-lOR mAb, no additive 
benefit on bacterial load was observed compared to mice that received combined 
anti-CD25 and anti-IL-lOR mAb.  The lack of effect observed by neutralisation of 
TGF-beta may reflect the complexity  and context of its  action, as TGF-beta can 
down-regulate Thl  and Th2 responses which may explain many of its suppressive 
effects (Li et al., 2006b).
However, recent reports have demonstrated a pro-inflammatory role for TGF-beta
plays in the derivation of pro-inflammatory Th-17 (IL-17 producing) T cells.  It has
been reported that stimulation of CD4+ T-cells in the presence of TGF-beta, IL-6
118- Chapter 4: The potential role for Tregs as mediators of MTb survival and persistence -
and TLR signalling drives the generation of Th-17 producing T cells (Veldhoen et 
al.,  2006,  Bettelli  et al.,  2006).  To  date,  reports  on  the  role  of IL-17  in  pro- 
inflammatory responses has drawn much attention in diseases including EAE (Park 
et al., 2005; Langrish et al., 2005) and MTb (Khader et al., 2005).  Furthermore, 
recent reports  during  BCG  infection  have  shown  that  IL-17  production  can  be 
regulated by the presence of IFN-gamma (Cruz et al., 2006).  During murine MTb 
infection, gamma/delta T cells but not CD4+ T cells are the predominant producers 
of IL-17.  In  summary,  the  role  of Th-17  in  either  protection  or pathology  in 
infectious disease is at present unclear.
Addressing the role of Tregs during MTb infection using an adoptive transfer model: 
Treatment  of  mice  with  an  antibody  against  the  marker  CD25  to  deplete 
CD4+CD25+Tregs did not appear to influence bacterial burdens, this finding was 
also reported previously in MTb by Quinn et al., (2006).  With this in mind, we used 
an  adoptive transfer model to  address the role of Tregs in MTb infection as this 
model has been extensively used in murine colitis.  We firstly established a suitable 
infection system in order to determine the kinetics of bacterial growth in the absence 
of the adaptive immune response.  Following high does MTb infection, B6 mice 
controlled bacterial  growth  by  day  7  showing  no  signs  of disease.  In  contrast 
B6.Rag  I'*'  mice  exhibited  a  dramatic  increase  in  bacterial  burdens  that  grew 
uncontrollably  during  the  21  days  of infection.  However,  following  adoptive 
transfer  of CD4+CD25-  T  cells  into  B6.Rag I'1 '  mice,  infection  was  controlled 
comparable to that observed in wild type mice.  When CD4+CD25- T cells were 
transferred in the presence of increasing numbers of CD4+CD25+ Tregs (Fig. 4.8),
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this had a limited effect on enhancing bacterial load that failed to reach statistical 
significance.
The negative effect seen on bacterial clearance was only observed when the Tregs 
were seeded at non-physiological ratios.  In summary, our data implies that despite 
the  observed increase  in  the  number  of lung Tregs  following  aerosol  infection. 
Depletion  of  CD25+  cells  and  adoptive  transfer  studies  failed  to  confirm  a 
suppressive role  for this  regulatory  subset  at this  early  stage  in MTb  infection. 
Furthermore, during MTb infection Tregs may play  a role in  an antigen specific 
manner to inhibit the anti-mycobacterial response as demonstrated in murine studies 
of Leishmania (Belkaid et al., 2002, Mendez et al., 2004).
120- Chapter 5: The role of plasmacytoid pDC in anti-mycobacterial immunity -
Chapter 5: The Role of Plasmacvtoid pDC in Anti- 
Mycobacterial Immunity.
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5.1.  The role of plasmacvtoid pDC in anti-mvcobacterial immunity, aims of the 
investigation;
To address the role of plasmacytoid pDC in MTb we sought to:
1) Determine whether plasmacytoid pDC can become infected with MTb in vitro and 
induced to produce cytokines.
2) Identify the kinetics of plasmacytoid pDC influx to infected tissues following 
aerosol and I.V. MTb infection.
3) During the early stages of MTb infection, does the absence of plasmacytoid pDC 
alter the course of infection?
5t2.  Background;
The importance of macrophages (Hart 1975; Schlesinger et al., 1990; Gomes et al., 
1999; Underhill et al., 1999, Gonzalez-Juerrero et al., 2003) and more recently DC 
(Gonzalez-Juerrero  et al.,  2001;  Bodnar et al.,  2001;  Tian et al.,  2005)  in  the 
immune response to MTb has been well documented.  In contrast to macrophages, 
following phagocytosis  of MTb  DC  are  not able to  mediate  intracellular killing 
(Bodnar  et al.,  2001).  However,  DC  play  a  key  role  in  uptake  and  antigen 
processing, migration to local draining lymph nodes and initiation of adaptive T- 
helper responses.  The role of specific DC subsets in the immune response to MTb 
has to date not been documented.
Plasmacytoid pDC were originally described in human PBMC by Ronnblom et al.,
(1983) as cells with a plasma cell like morphology. Recent studies in the mouse also
identified a similar DC  subset with identical morphology  (Asselin-Paturel et al.,
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2001;  Nakano et al.,  2001;  Bjork et al.,  2001).  To date, numerous studies have 
shown that plasmacytoid pDC play a pivotal role in anti-viral immune response, as 
stimulation with Influenza A, murine CMV, or HSV resulted in the production of 
large quantities of type IIFN (Liu et al., 2005).  In the mouse, plasmacytoid pDC are 
considered  immature  DC  because  of  their  low  expression  of  co-stimulatory 
molecules and the limited ability to stimulate naive T-helper cells (Asselin-Paturel et 
al., 2001).  Because of this observation plasmacytoid pDC are regarded as classic 
innate  cells.  However,  upon  activation  plasmacytoid  pDC  up-regulate  co­
stimulatory molecules and can present antigen.  On the other hand plasmacytoid 
pDC have been shown to play a regulatory role under conditions such as allergy (de 
Heer et al., 2004) or as mediators of vascularised graft tolerance (Ochando et al., 
2006).  Furthermore, no studies at present have reported the ability of plasmacytoid 
pDC to either phagocytose bacteria or contribute during bacterial infection.
Interestingly, stimulation of mouse but not human plasmacytoid pDC with CpG-
DNA  induces the  production  of high  levels  of IL-12,  IFN-alpha,  but  not IL-10
(Boonstra et al., 2006).  CpG-DNA is non-methylated (unlike human DNA) and is
present in MTb as well as viruses and other organisms, therefore making it a potent
inducer  of  pro-inflammatory  cytokines  such  as  IL-12.  The  involvement  of
plasmacytoid pDC may be important for inducing strong Thl  responses.  Whilst
Type I IFN’s can co-operate in the Thl  response (Gautier et al.,  2005), they can
sometimes  be  suppressive  (Cousens  et al.,  1997).  Recent  studies  have  shown
enhanced immune responses to the intracellular pathogen Listeria monocytogenes, in
the  absence  of  Type  I  IFN  (Auerbach  et al.,  2004;  Carrero  et al.,  2004  and
O’Connell et al., 2004).  The findings by Auerbach et al., (2004) indicated that in the
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absence of IFN-beta production, TNF production by phagocytic cells at the site of 
infection was  increased thus promoting bacterial killing.  Therefore the interplay 
between IL-12 and type I IFN’s during infection may influence the disease outcome.
At present, no data is available on the ability of plasmacytoid pDC to be infected or 
activated by MTb or its products.  In human studies plasmacytoid pDC have been 
shown by Celia et al., (1999) to be present in the lymph nodes of TB patients and 
Lichtner et al., (2005) have observed a decrease in the number of both classical DC 
and plasmacytoid pDC in the blood of active TB patients.  Findings by Blasius et al., 
(2004) demonstrated that following injection of mice in the footpad with heat-killed 
MTb, plasmacytoid pDC accumulated at the local draining knee lymph nodes.  In 
addition, Manca et al., (2001) have suggested that the hyper-virulent phenotype of 
the clinical isolate MTb HN878 in mice is due to induction of type I IFN. However, 
the source of Type I IFN was not examined.
The involvement of plasmacytoid pDC in immunity to pathogens can be direct as 
shown by its potent anti-viral effects mediated by Type I IFN, or indirectly via IFN- 
alpha/beta inhibition of IL-12, as discussed above.  Similarly as discussed above, 
Plasmacytoid pDC may also play a regulatory role under certain conditions e.g. in 
allergy (de Heer et al., 2004), although at present through unknown mechanisms.  In 
this  study,  we  examined  whether  plasmacytoid  pDC  play  a  role  during  MTb 
infection in vivo as well as in vitro.
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5.3.  Does MTb infect plasmacvtoid pDC?
5.3.1.  In vitro infection of BM macrophages and BM myeloid DC but not 
plasmacytoid pDC induces pro-inflammatory cytokine production:
To determine whether plasmacytoid pDC could be infected with MTb in vitro and 
induced to  produce  cytokines,  plasmacytoid  pDC  were  infected  alongside  BM 
macrophages and myeloid DC as these cell types have already been shown to be 
infected with MTb and subsequently produce pro-inflammatory cytokines.  Before 
we could address this, we firstly established an in vitro infection system whereby the 
infection dose of MTb on BM myeloid DC was titrated at MOI of 1:1, 5:1 and 10:1 
(MTb:DC).  The titration of MTb indicated that the optimal MOI for infection of DC 
was 5:1  as it gave significant infection, strong cytokine induction but with low DC 
death.  This finding was in contrast to infections using an MOI of 1:1  where only 
low levels of cytokine were induced, or an MOI of 10:1, where 90% of DC where 
non-viable within 24 hours.  Macrophages (Fig. 5.1 A), myeloid DC (Fig. 5.IB) and 
Flt-3L  cultured  plasmacytoid  pDC  (Fig.  5.1C)  were  derived  from  the  BM  or 
alternatively organ derived plasmacytoid pDC were freshly isolated from the spleen 
(Fig. 5.ID), as described in Materials and Methods.
Following cultures of BM and splenic derived plasmacytoid pDC for 24 hours in the 
presence of MTb, no detectable levels of IL-12p70, IL-12p40, TNF and IFN-alpha 
were produced (Fig. 5.2A).  However, in response to CpG-B DNA stimulation, both 
splenic and BM derived plasmacytoid pDC produced substantial levels of IL-12p70, 
IL-12p40,  TNF  and  IFN-alpha,  but no  IL-10  (Fig.  5.2B),  as reported by  others 
(Asselin-Paturel  et al.,  2001;  Boonstra et al.,  2006).  In contrast to plasmacytoid
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pDC, culture of BM macrophages  and BM myeloid DC in  the presence of MTb 
induced the pro-inflammatory cytokines  IL-12p40  and TNF after 24 hours  (Fig. 
5.2A) as reported by others (Bodnar et al., 2001).  CpG-B DNA stimulation of BM 
macrophages and BM myeloid DC produced high levels of IL-12p40, low levels of 
TNF and no detectable IL-12p70 or IFN-alpha (Fig. 5.2B).
To determine if plasmacytoid pDC were able to phagocytose and consequently be 
infected by MTb, the growth of bacilli  was determined after 24 hours of culture 
following infection  at an MOI of 5:1  (MTb:APC).  When  intracellular bacterial 
counts were determined, progressive growth within BM macrophages (Fig.5.3A) and 
BM  myeloid DC  (Fig.5.3B)  was  observed  as  reported by  others  (Bodnar et al., 
2001).  In contrast, plasmacytoid pDC were only minimally infected with MTb (Fig. 
5.3C).
5.4.  Tracking  the  kinetics  of  plasmacytoid  pDC  in  vivo  following  MTb 
infection:
5.4.1.  Plasmacytoid pDC are detected in spleen and lung suspensions by the mAb 
120G8:
Our data from in  vitro  studies  thus  far suggests  that plasmacytoid pDC  are  not
infected with  MTb in  vitro  and produce  no  detectable  levels  of cytokine.  We
therefore examined the kinetics of plasmacytoid pDC following in vivo infection of
mice using flow cytometry by tracking expression of the plasmacytoid pDC specific
marker 120G8.  We wanted to determine if plasmacytoid pDC were attracted to the
site  of infection  and  inflammation  as  previously  suggested for heat-killed MTb
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(Blasius et al., 2004) and in human MTb studies (Celia et al., 1999).  Asselin-Paturel 
et al., (2003) described the  120G8 mAb that recognises an unknown epitope that is 
highly expressed on the surface of murine plasmacytoid pDC.  In addition, 120G8 is 
also expressed on activated B  cells  and  some CDllc+ populations  albeit at low 
expression levels.
Prior to our  studies,  we firstly  conjugated the  120G8  mAb  to the  fluorochrome 
Alexa-488, before it was tested in vitro and used in vivo for flow cytometry studies. 
To identify plasmacytoid pDC, whole splenocytes from  129/Sv mice were stained 
for expression of B220+, CDllc+, GR1+ (Fig.  5.4A), or with CDllc and  120G8 
(Fig. 5.4B). The percentages of splenic plasmacytoid pDC using these two different 
staining procedures were identical  (Fig.  5.3B).  Similar to the  spleen,  a defined 
population of plasmacytoid pDC (CD1 lc+120G8+) were identified in the lung (Fig. 
5.4C).  Upon  closer  examination  of  the  lung  CDllc  high  population 
(CDllc+120G8-), we observed that these constituted a heterogeneous population 
consisting potentially of both large alveolar macrophages and smaller lung DC as 
determined by the forward scatter (FSC) and side scatter profiles (SSC) (Fig. 5.4C). 
This observation is in keeping with the detailed phenotypic analysis of lung CD1 lc+ 
populations performed by de Heer et al., (2004).
Interestingly, the percentage of plasmacytoid pDC  varies between mouse species
with  129/Sv  mice  having  the  highest  percentage  of plasmacytoid  pDC  when
compared to BALB/c and B6 as reported by others (Asselin-Paturel et al., 2003).
We  therefore  confirmed  this  finding  by  analyzing  the  percentage  of  splenic
plasmacytoid pDC in the  129/Sv, BALB/c and C57B1/6 (Fig 5.5A).  In addition to
127- Chapter 5: The role of plasmacytoid pDC in anti-mycobacterial immunity -
the  129/Sv mouse having the highest percentage of plasmacytoid pDC, this finding 
was also reflected in the serum levels of IFN-alpha induced following I.V. challenge 
with CpG-B DNA (Fig 5.5B).
5.4.2.  The number of  plasmacytoid pDC do not increase in the spleen or lung 
following early I.V. MTb infection:
We identified whether plasmacytoid pDC  accumulated at the  site(s) of infection 
following MTb infection.  To address this, mice were infected I.V. with 10,000 CFU 
H37Rv and the lungs (Fig. 5.6A) and spleen (Fig. 5.6B) were prepared and analysed 
on day 0,  1,  12, 21  and 43 after infection by flow cytometry for the expression of 
120G8 and CD1 lc and compared to non-infected control mice.  Dyuring the course 
of infection (Fig. 5.7A), the absolute numbers of plasmacytoid pDC in both the lungs 
(Fig.  5.7B) and spleen (Fig. 5.7C), remained unchanged during the course of I.V. 
infection as compared to non-infected control animals.  However, during the latter 
stages of infection (day 43), a minor increase in the numbers of total plasmacytoid 
pDC (CD1 lc+120G8+) in both the lungs (Fig. 5.7B) and spleen (Fig. 5.7C) became 
apparent.  Our findings suggest that following I.V. infection; the small increase in 
plasmacytoid pDC at day 43  suggests that they may play a role during the latter 
stages of MTb infection.
5.4.3.  Plasmacytoid pDC do not accumulate in the lung following aerosol 
infection:
MTb infection of mice by the I.V. route did not result in an increase of plasmacytoid
pDC in the lung or spleen during the early stages of infection.  This finding may be a
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reflection on i) the I.V. route of MTb infection in mice (that reflects a model of 
disseminated TB  rather than pulmonary  TB)  and  ii)  the  large  numbers  of MTb 
injected  I.V.  Both  these  factors  may  mask  any  subtle  responses  or  role  for 
plasmacytoid pDC during infection. We therefore infected mice via the aerosol route 
with a low dose of MTb in order to establish a model of pulmonary TB.
BALB/c mice were infected via the aerosol route with approximately 100 CFU MTb, 
and at specific time-points post infection bacterial burdens were determined (Fig. 
5.8A).  The percentages (Fig. 5.8) and absolute numbers of lung CDllc high cells 
(Fig 5.9A) and plasmacytoid pDC (Fig. 5.9B) did not change on day 2, 8, 14 and 29 
post infection.  In contrast to the lung APC populations, the number of lung CD4+ T 
cells  increased  from  day  8  post  infection  (Fig.  5.9C)  and  remained  elevated 
throughout the infection time course.  In the  spleen,  we observed no increase in 
splenic  plasmacytoid  pDC  (CDllc+120G8+),  splenic  DC  (CD1 lc+120G8-)  or 
CD4+ T cells during the course of infection (data not shown).  This observation may 
reflect the slow dissemination of MTb from the site of infection to secondary organs 
following infection via the aerosol route.
Our data suggests that plasmacytoid pDC do not accumulate in the lung following 
early aerosol infection, but the accumulation of plasmacytoid pDC may occur during 
the latter stages of infection as seen from day 43 post I.V. infection (Fig. 5.7).  In 
addition, our approach focused specifically on DC influx into the lungs or spleen, it 
did not however take into account the potential influx of this DC subset to the local 
draining lymph nodes.
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5.5.  The immune response to MTb infection is unaffected in the absence of 
plasmacytoid pDC:
5.5.1.  The antibody 120G8 depletes steady state splenic plasmacytoid pDC:
Depletion studies in the mouse by de Heer et al., (2004) have shown a regulatory 
role for lung plasmacytoid pDC in limiting asthmatic responses to harmless inhaled 
antigen.  Therefore to address a role for plasmacytoid pDC in regulating the immune 
response at the site of MTb infection, we treated  129/Sv mice in vivo with  120G8 
mAb.  As others and we have shown (Asselin-Paturel et al., 2003),  129/Sv mice 
possess a higher percentage of plasmacytoid pDC than other mouse strains including 
BALB/c and B6 mice (Fig. 5.5A).  This observation was reflected by the level of 
serum Type IIFN induced following I.V. challenge with CpG-B DNA (Fig. 5.5B). 
With this difference in mind, we postulated that depletion of plasmacytoid pDC in 
129/Sv mice, as opposed to BALB/c or B6 mice, would potentially have a greater 
influence on bacterial burdens.
To  test the  efficacy  of plasmacytoid pDC  depletion  in vivo,  naive  129/Sv  mice 
received two injections I.P. at 24 hour intervals of either 120G8 mAb (1 mg/mouse) 
or control IgG (GL113).  Six hours following the second injection the mice were 
killed  and  spleens  were  analysed  by  flow  cytometry  for  the  percentage  of 
plasmacytoid pDC.  Flow cytometric analysis of B220+CD1 lc+GRl+ plasmacytoid 
pDC in control treated mice (Fig. 5.10A) and 120G8 mAb treated mice (Fig. 5.10B), 
revealed an >80% depletion in splenic plasmacytoid pDC.
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5.5.2.  Depletion of  plasmacytoid pDC in vivo has no effect on regulating bacterial 
clearance during early MTb infection:
Next, we examined if plasmacytoid pDC play a regulatory role during MTb infection 
in mice by in vivo antibody depletion during the early immune response to MTb. 
Prior  to  infection  129/Sv  mice  were  treated  I.P.  with  either  120G8  mAb 
(1 mg/mouse) or control IgG (GL113) at day -1  and day 0.  Mice were then infected 
I.V. with either 50,000 CFU (Fig 5.11 A) or 250,000 CFU (Fig 5.1 IB) MTb.  Mice 
continued receiving once weekly I.P. injections of 120G8 mAb until the end of the 
infection time course.  At day  18 post  infection, mice  were killed and bacterial 
burdens  in  the  spleen  (Fig.  5.11C)  and  lungs  (Fig.  5.1 ID)  were  determined. 
Following 120G8 depletion of plasmacytoid pDC there was no apparent effect on the 
course of infection in either the spleen or lung compared to control IgG treated mice 
irrespective of the initial infection dose.
The lack of effect seen on bacterial loads  may reflect the route of infection.  As 
discussed above, I.V. injection with large non-physiological MTb doses may mask 
any subtle effects that plasmacytoid pDC may have on regulating bacterial clearance. 
Therefore to further address the role of plasmacytoid pDC during early infection, 
similar experiments need to be repeated in mice infected with a low dose of MTb via 
the more physiological aerosol route to reflect pulmonary TB.
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Figure 5.1:  Phenotypic analysis of macrophages and DC cultured either from the 
BM or freshly isolated  from the spleen.
£AJ BM macrophages (CD1 lb+F4/80+), (B) BM myeloid DC (CDllc+),  and £Q 
plasmacytoid  pDC  (CD1 lc+120G8+)  were  either  cultured  from  the  BM  or 
alternatively (D) plasmacytoid pDC (CDllc+120G8+) were freshly isolated form 
the spleen.  The cells were stained with the appropriate flow cytometry antibodies as 
described in Materials and Methods.  The BM macrophages and BM myeloid DC 
were not FACS sorted and used in infections straight from cell culture due to high 
cell purity.  However, the BM plasmacytoid pDC were FACS sorted after culture in 
order to  obtain  an  ultra-pure  population  of homogenous  DC.  Similarly,  splenic 
plasmacytoid pDC were freshly isolated from the spleen by FACS sorting.
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Figure 5.2: Plasmacytoid pDC are not triggered by MTb to produce IL-12p40, IL-12p70, TNF or IFN-alpha.
BM myeloid DC, BM macrophages, BM derived plasmacytoid pDC or freshly isolated plasmacytoid pDC were
obtained  as  described  in  Materials  and  Methods.  Cells  were  stimulated  in  vitro  with  either  (A)  live  MTb
H37Rv at a multiplicity of infection of 5:1 (MTb:DC) or (B) CpG-B DNA (1668ISS;  l pM) for 24 hours. After
24 hours  supernatants  were  harvested and  analyzed  by immunoassay. Results  shown  are representative  of 3
^   independent experiments.
u> u>
-
 
C
h
a
p
t
e
r
 
5
:
 
T
h
e
 
r
o
l
e
 
o
f
 
p
l
a
s
m
a
c
y
t
o
i
d
 
p
D
C
 
i
n
 
a
n
t
i
-
m
y
c
o
b
a
c
t
e
r
i
a
l
 
i
m
m
u
n
i
t
y
 
-- Chapter 5: The role of plasmacytoid pDC in anti-mycobacterial immunity -
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Figure 5.3: BM macrophages, BM myeloid DC but not BM plasmacytoid pDC are 
infected with MTb in vitro.
(A) BM macrophages or (B) BM myeloid DC and {Q BM plasmacytoid pDC were 
derived from BALB/c  mice  as  described  in Materials  and Methods.  Following 
culture, APC (5xl06 APC) were infected with H37Rv at an MOI of 5:1 (MTb:APC). 
After 24 hours cells were harvested and CFU performed in as described in Materials 
and Methods.
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Figure 5.4: Plasmacytoid pDC are dectected in both spleen and lung suspensions by 120G8 mAb.
Whole  splenocytes  or lung  cells  from  naive  129/Sv  mice  were  prepared  and  stained  as  described  in  Materials  and 
Methods.  Expression  of plasmacytoid  pDC  in the  spleen  was  shown  by  analysis  of (A) B220,  C D llc  and  GR1  or 
(B1120G8,  C D llc  and  GR1.  Plasmacytoid  pDC  were  also  analysed  in  the  lung  by  expression  of  (O120G8  and 
CD1 lc.  All percentages shown are of total live cells and are representative of 3 individual mice.
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Figure 5.5:  129/Sv mice have the highest percentage of splenic plasmacytoid pDC 
and respond to CpG-B DNA  challenge by producing large quantities of Type I 
IFN.
(A)  Whole  splenocyte  suspensions  were  prepared  from  129/Sv,  BALB/c  and 
C57B1/6 mice and stained for plasmacytoid pDC (CDllc+120G8+) as described in 
Materials and Methods.  £JH Mice were challenged I.V.  with 5jxM  CpG-B  DNA 
(1018 ISS; 5pM), for a period of 6 hours before serum was taken and analysed by 
ELISA for IFN-alpha.  Each point represents the serum level of IFN-alpha from one 
mouse with the horizontal lines representing the geometric means.
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Figure 5.6: Following early I.V. MTb infection, plasmacytoid pDC do not accumulate in infected organs.
u> '-J
129/Sv mice were infected I.V. with  10,000 CFU H37Rv.  At the time points indicated the level of CD1 lc and  120G8 
expression in the (A l lungs  and (B) spleen were analysed by flow cytometry). All percentages shown are of total live 
cells and are representative of 3 individual mice.
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Figure 5.7: Following early I.V. MTb infection, the total number of plasmacytoid 
pDC does not increase in infected organs until day 43.
(A)  129/Sv  mice  were  infected  I.V.  with  10,000  CFU  H37Rv  and  the  bacterial 
burdens  were  monitored  during  the  course  of  infection.  The  total  levels  of 
plasmacytoid pDC were determined from flow cytometric analysis at the time-points 
indicated in the lungs £BJ. and spleen (C).
138- Chapter 5: The role of plasmacytoid pDC in anti-mycobacterial immunity -
A
B
w
a> o
.c
O) 1.0x1 OS
2
o 8.0x105-
Q
O 6.0x105-
O 4.0x105-
V
-Q
E 2.0x105-
3
C 0-
1
0
£
CD11c high cells
■Non  infected 
■  M Tb infected
— I-------------------------- 1 --------------------------1
10  20  30
Days post infection
Plasmacytoid pDC
2.0x10
5.0x103-
0 10 20 30
■  Non-infected
■  MTb infected
Days post infection
CD4+ T cells
Days post infection
■Non-infected 
■  M Tb  infected
Figure 5.9:  The absolute numbers of plasmacytoid pDC do not increase in the 
lung following aerosol MTb infection.
BALB/c  mice  were  infected  via  the  aerosol route  with  approximately  100  CFU 
H37Rv.  At  the  time  points  indicated  the  total  numbers  of {A) classical  DC 
(CD1 lc+120G8-),  plasmacytoid pDC (CD1 lc+120G8+) and (Q  CD4+ T cells 
were determined from flow cytometric data.
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Figure 5.10: 120.G8 depletes steady state plasmacytoid pDC.
To deplete plasmacytoid pDC; naive  129/Sv mice were treated twice I.P. 24 hours apart with either 1  mg/mouse of 
control IgG (GL113) (A) or  120G8 (B). Mice were  sacrificed 6 hours  after the second mAb injection.  Spleen cell 
suspensions were analyzed for plasmacytoid pDC levels by flow cytometry. All percentages shown are of total live 
cells and are representative of 3 individual mice.  Results shown are representative of 3 independent experiments.
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Figure 5.11: Depletion of plasmacytoid pDC during early in vivo MTb infection 
shows no apparent effect on bacterial clearance.
129/Sv mice were infected I.V. with either: {A) 50,000 or (B) 250,000 CFU H37Rv. 
To deplete plasmacytoid pDC in vivo, mice were treated I.P. at day -1, 0, 7 and  14 
post infection with either 1 mg/mouse of 120G8 mAb or control IgG (GL113). Mice 
were killed at day  18 post infection and bacterial burdens in the spleen and lungs 
were determined at either infection dose of (XL) 50,000 or (D) 250,000 CFU MTb 
H37Rv  (number  of  mice  per  group  =  5).  Results  are  representative  of  two 
independent  experiments.  Results  shown  are  representative  of  2  independent 
experiments.
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5.7.  Discussion:
Recent studies in the human (Celia et al.,  1999; Lichtner et al., 2005) and mouse 
(Blasius et al., 2004) have suggested a potential role for plasmacytoid pDC during 
the  immune  response  to  MTb.  Our  study  demonstrates  a  minimal  role  for 
plasmacytoid pDC during the primary immune response to MTb.
Plasmacytoid pDC are not triggered to produce cytokines in vitro:
When BM and splenic plasmacytoid pDC were cultured in vitro with MTb for 24 
hours, we could not observe any detectable levels of IL-12, TNF or IFN-alpha.  In 
contrast, when BM and  splenic plasmacytoid pDC  were stimulated in vitro with 
CpG-B DNA, we observed high production of the cytokines IL-12p40, IL-12p70, 
TNF and IFN-alpha, as reported by others (Asselin-Paturel et al., 2001; Boonstra et 
al., 2003).  In response to MTb infection, BM macrophages and BM myeloid DC 
were readily  infected in  vitro  but  BM  plasmacytoid  pDC  were  only  minimally 
infected after 24  hours.  Our observations  suggest that MTb  is  unable  to infect 
plasmacytoid pDC,  however,  this  is  difficult to prove conclusively  because  the 
viability  of plasmacytoid  pDC  decreases  profoundly  from  around  12  hours  in 
culture, which was independent of the stimulus.  It has been reported by Asselin- 
Paturel et al., (2001) that plasmacytoid pDC undergo apoptosis in the absence of a 
strong activation signal, such as that afforded by CpG-DNA.  It is therefore possible 
that MTb (or its CpG-DNA) may sub-optimally activate plasmacytoid pDC, but this 
activation is not strong enough to induce cytokine production or inhibit the apoptosis 
pathway.  Furthermore,  due to  the difficulties  encountered  with  the  viability  of 
plasmacytoid pDC  in culture,  Ziehl Nielsen  staining of plasmacytoid pDC  from
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infection cultures did not allow us to determine whether this DC subset could be 
infected in vitro.  With this observation in mind and the findings by Celia et al., 
(1999) that plasmacytoid pDC were present in human tonsil tissue, we addressed the 
role of plasmacytoid pDC during in vivo MTb infection by antibody depletion
The kinetics of  plasmacytoid pDC following MTb infection:
During  aerosol  MTb  infection,  the  numbers  of  plasmacytoid  pDC  and 
CDllc+120G8- populations in the lungs and spleen did not significantly increase. 
However,  levels  of lung  CD4+  T  cells  increased  after day  8  following aerosol 
infection as previously published by others (Feng et al.,  1999, Serbina and Flynn, 
1999, Lazarevic et al., 2005).  During I.V. MTb infection the levels of plasmacytoid 
pDC did not appear to increase until day 43 post infection.  In our studies, we did try 
to  address  the  potential  role  for plasmacytoid pDC  migrating to  the  local  lung 
draining lymph nodes, but due to the constraints of working under bio-safety level 3 
conditions,  this  made  accurately  dissecting  the  lung  draining lymph  nodes  very 
difficult and was therefore not assessed.
Our findings are in contrast with studies by Blasius et al., (2004), when injection of
heat-killed MTb  into the footpad  subsequently gave rise  to the  accumulation  of
plasmacytoid pDC in the local draining lymph nodes.  The differences observed
between the studies of Blasius et al.,  (2004)  and our own  may be linked to key
differences in immunogenicity between heat-killed and live virulent MTb, the site of
infection (e.g. lung or lymph node), and the route of MTb administration.  Another
hypothesis for the accumulation of plasmacytoid pDC observed by Blasius et al.,
(2004)  may be the presence of CpG-DNA  or other contaminating  immunogenic
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pathogen related products present in the heat-killed MTb preparation which were not 
readily accessible in the live organism.
There are a number of reasons that in our studies APC did not increase in the lung 
following aerosol MTb  infection, these factors  include the site of infection  (e.g. 
draining lymph node)  and the time following infection.  Following aerosol MTb 
infection Gonzalez-Juarrero et al., (2003), have reported a minor increase in lung DC 
and macrophage populations in the first 20 days post infection.  In addition, studies 
by Humphreys et al., (2006) by infecting mice intra-nasally with a GFP-tagged BCG 
have shown that lung DC play a central role in the dissemination of bacteria from the 
site of infection to the draining mediastinal lymph nodes.  In our study, lung DC may 
have been constantly cycling between the lung and draining lymph nodes potentially 
masking any observed increase or decrease on total cell numbers.
Depletion studies did not address a role for plasmacytoid pDC in vivo:
As  we were unable to infect or induce cytokines following infection in vitro,  or
observe  any  increase  in  the  total  number of plasmacytoid pDC  following  MTb
infection in vivo, we further evaluated the role of plasmacytoid pDC during MTb
infection by antibody depletion in vivo.  In line with this, studies in the mouse by de
Heer et al.,  (2004) have  shown  a regulatory role  for lung plasmacytoid pDC  in
limiting asthmatic responses to harmless inhaled antigen.  In contrast, in this study
depletion of plasmacytoid pDC before MTb infection, revealed no regulatory role for
this DC subset during the primary immune response to MTb in the lung.  We did not
address whether plasmacytoid pDC play a role during chronic infection when death
of bacteria may be greater,  i.e.  during memory responses or following antibiotic
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treatment.  Indeed, it has been shown that MTb contains CpG-DNA that can activate 
DC in vitro (Bafica et al., (2005), and during bacterial killing the presence of CpG- 
DNA could activate plasmacytoid pDC via interaction with endosomally expressed 
TLR-9.  Therefore, the role of plasmacytoid pDC needs to be examined during late 
infection by use of flow cytometry of infected organs and in vivo antibody depletion, 
as our data however, did not address this possibility.
In summary, MTb did not appear to activate or infect pDC in vitro.  In vivo, no 
increase of plasmacytoid pDC was observed in lung and spleen following infection 
via the I.V.  or aerosol route,  and depletion of pDC during I.V.  infection did not 
result in modulation of bacterial burdens in lung or spleen. Therefore, we conclude 
that plasmacytoid pDC do not play a role during the early phase of infection with 
MTb.
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Chapter 6: General Discussion and Future Perspectives.
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6.1.  General discussion and future perspectives:
Immune homeostasis requires the harmonious interplay between specialised immune 
cells  and  their  secreted  soluble  factors  in  order  to  regulate  host  inflammatory 
responses  whilst  promoting  pathogen  eradication  without  causing  detrimental 
pathology.  As  observed  in  humans  with  naturally  occurring  mutations  or gene 
deficient mice,  the  absence or an  imbalance between  any  of these cells or their 
cytokines  can  have  pathological  or  fatal  consequences.  Following  infection,  a 
pathogen  may  seek  to  survive  and  persist  within  a  host  by  exploiting  specific 
regulatory pathways normally associated with immune homeostasis.  Similarly, the 
host may inadvertently promote pathogen persistence by limiting effector responses 
to invading organisms in order to limit damage to self.  MTb could be described as a 
master of evasion by utilising a wide array of mechanisms for immune evasion in 
order to establish life-long latency in 90% of infected individuals.  With this in mind, 
we sought to address the role of three potential regulatory pathways (IL-10, Tregs 
and plasmacytoid pDC), which may function either independently or in concert to 
promote persistence following infection with the bacterium MTb.
6.1.1.  The role of IL-10 in regulating protective immunity to MTb infection:
The data we present in this thesis supports a role for IL-10 as a negative regulator of
the  immune  response  during  both  early  and  late  stages  of MTb  infection.  We
demonstrate that during the early stages of infection IL-10 plays a role in regulating
bacterial  clearance  that  can  be  further enhanced  in  the  absence  of Tregs.  This
observation may highlight an important regulatory relationship on bacterial clearance
between IL-10  and Tregs that has not been reported during infection with MTb.
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During the latter stages of MTb infection, IL-10 is still present and plays a regulatory 
function to control cytokine production.  Thus we postulate that IL-lO’s function 
switches from being a regulator of bacterial clearance to become a regulator of host 
immune-pathology in order to blunt over-exuberant effector responses.
The role of IL-10 in limiting detrimental host immune-pathology:
We have shown that IL-10 appears to be regulating cytokine production both during 
early  and  late MTb  infection  as demonstrated by  ex vivo re-stimulations  of cell 
suspensions from MTb infected mice.  In contrast, using the approaches possible our 
data suggests that IL-10 only appears to be functioning to limit pathogen clearance 
during the early immune response to MTb.  Therefore we postulate that IL-10 may 
be functioning during late MTb infection to regulate the immune response to limit 
host immune-pathology.  In mouse models of Toxoplasma gondii (Gazzinelli et al., 
1996, Suzuki et al., 2000), Trypanosoma cruzi (Hunter et al., 1997) and malaria (Li 
et al.,  1999),  in the absence of IL-10 parasite clearance is enhanced but leads to 
detrimental host immune-pathology and mortality.  To date there is no published 
data on a role for IL-10 in limiting immune-pathology following either early  or 
late/chronic  MTb  infection.  We  are  currently  addressing  the role  of IL-10  on 
immune-pathology during MTb infection by using histological analysis of infected 
organs such as the lung, spleen and liver.  Examining the immune response in the 
absence of IL-10 at different stages of infection will provide insight into whether IL- 
10 affects the architecture of the granuloma including lymphocyte infiltration.  We 
are also interested in determining other features of immune-pathology during MTb 
infection in the absence of IL-10, including weight loss.
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Anti-IL-lOR  mAh  as  a  potential  adjuvant  to  enhance  the  efficacy  of anti- 
mycobacterial chemotherapy:
We are currently examining whether treatment of mice with anti-ILlOR mAb after 
the initiation of drug treatment during chronic MTb, may enhance bacterial killing 
and thus potentially speeding up the time to MTb clearance.  The potential for using 
anti-IL-lOR mAb during chemotherapy has  already been demonstrated in murine 
visceral  Leishmaniasis,  as  neutralisation  of  IL-10  activity  during  Pentostam 
chemotherapy, in order to lower parasite load, led to increased production of IFN- 
gamma and reduced time to parasite clearance (Murray et al., 2002, Murray, 2005). 
Similarly,  studies  by  Silva  et al.,  (2001)  in Mycobacterium  avium  have  also 
demonstrated a therapeutic role for anti-IL-lOR mAb when administered at the time 
of chemotherapy, greatly enhancing its efficacy.
IL-10 mediated suppression of macrophage activation and MTb killing during in 
vitro infection:
Our  studies  have  demonstrated  that  following  in  vitro MTb  infection  of  BM 
macrophages,  endogenous  IL-10  appears  to  inhibit  the  induction  of  pro- 
inflammatory cytokines, namely IL-12p70, IL-12p40 and TNF (Fig. 3.11), but does 
not affect MTb killing (Fig. 3.12).  With this in mind, we are currently determining 
whether in the absence of IL-10, IFN-gamma activation of macrophages (to mimic 
the T cell signal) enhances MTb killing.  It has been shown by Shi et al., (2003), that 
IFN-gamma activation of BM macrophages activates the expression of many genes 
encoding reactive  oxygen  and nitrogen  intermediates  and was  dependent on the 
signalling molecule MyD88.  However, in the same study it was also demonstrated
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that macrophages activated via infection with live MTb also up-regulated genes to 
mediate bacterial killing that was independent of MyD88.
Macrophages and DC as sources for IL-10 during early MTb infection:
To address an in vivo role for macrophages and DC as sources of IL-10 during early 
MTb infection, we are currently breeding a Ragl, IL-10 double knockout mouse on 
the B6 background (B6.Rag  1' .Ill O '* ').  Our rationale that macrophage-derived IL-10 
may limit the response to MTb is based on our findings that the protection afforded 
by CD4+ T cells when adoptively transferred into BALB/c .Rag?1 ’ mice appeared to 
be independent of the action of T cell-derived IL-10 (Fig.  3.13).  However in this 
Rag'7 ' transfer model, IL-10 could still have been coming a non-T cell source such as 
DC  or  macrophages;  thus  inhibiting  any  potential  protective  T  cell  immunity. 
Therefore we will repeat the adoptive transfers into B6.Rag'7 './/70'7 ' mice to address 
the role of non-T cell derived IL-10.
6.1.2.  The potential role for naturally occurring Tregs in mediating MTb 
survival and persistence;
Despite observing a negative role for IL-10 in limiting anti-mycobacterial immunity, 
we could not isolate its cellular source.  The advancement of reagents to study the 
role of Tregs during MTb infection has facilitated great interest in the role of this 
regulatory  subset  during  chronic  infections.  We  hypothesised  that  Tregs  may 
regulate the immune response to MTb by production of IL-10 or other suppressive 
mediators as described in other experimental models such as colitis (Asseman et al., 
1999), Leishmania (Belkaid et al., 2002) and Helicobacter hepaticus (Malloy et al.,
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2003).  The number of lung CD4+FoxP3+ Tregs increased significantly following 
aerosol challenge that suggested they maybe regulating the immune response early 
during infection.  However, depletion of Tregs during MTb infection or adoptive 
transfer of Tregs into immuno-compromised hosts failed to confirm their regulatory 
role.  As discussed earlier however, our data suggests that Tregs and IL-10 may 
function together in order to limit protective immunity during early MTb infection.
Tracking Treg activity in mice expressing a GFP tagged FoxP3:
We have shown in two independent experiments that CD4+FoxP3+ Tregs increase 
in the  lung  following  aerosol  MTb  infection  (Fig.  4.1  and  Fig.  4.2).  We  have 
recently received  a transgenic mouse  expressing  a GFP  tagged FoxP3  (from B. 
Malissen).  This transgenic mouse will enable us to as we performed previously to 
visualise the influx of FoxP3+ Tregs by flow cytometry, but in addition, we will also 
be  able  to  sort  an  ultra-pure  population  of CD4+FoxP3+ Tregs  for  use  in  our 
adoptive transfer studies that may have greater regulatory potential since they will be 
completely devoid of any contaminating CD25+ effectors.  Furthermore, the Tregs 
used in transfer models were purified on CD4+ and CD25+ expression alone thus 
eliminating a minor CD4+CD25-FoxP3+ Treg population.
Does adoptive transfer of Tregs into immuno-compromised mice regulate the early 
immune response to aerosol infection?
The adoptive transfer model used in our studies focused primarily on mice being 
infected by the I.V. route.  This route of infection can be interpreted as a model for 
disseminated TB disease; therefore we intend to repeat our transfer studies using an 
aerosol infection model to mimic pulmonary TB.
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6.1.3.  The role of plasmacvtoid pDC in anti-mycobacterial immunity;
To date,  there  is no  direct evidence implicating  a role for plasmacytoid pDC in 
regulating immunity to MTb infection, in contrast numerous reports have identified 
this DC subset as an essential player in the anti-viral response.  In human studies, 
plasmacytoid pDC have been reported in the inflamed tonsil tissue of a TB patient 
(Celia et al.,  1999) and in the mouse the percentage of plasmacytoid pDC increases 
in  the  local  draining  lymph  nodes  in  response  to  injection  of heat-killed  MTb 
(Blasius et al., 2004).  In our studies we demonstrate the plasmacytoid pDC were not 
infected with MTb or produced any pro-inflammatory cytokines in response to the 
bacterium.  In  addition,  plasmacytoid pDC  did  not accumulate  in MTb  infected 
organs and depletion studies could not assign any regulatory role for this DC subset.
The role of  plasmacytoid pDC following aerosol MTb infection:
Depletion  studies  during  early  I.V.  infection  revealed  no  apparent  role  for 
plasmacytoid pDC in regulating bacterial clearance.  However, the study should be 
repeated using aerosol  infection to  address the role of plasmacytoid pDC during 
pulmonary TB.
The potential  role for plasmacytoid pDC  during  the  chronic  stages  of MTb 
infection:
During the latter stages of I.V. infection (Day 43) we observed a small increase in 
the absolute numbers of plasmacytoid pDC (Fig. 5.7).  We hypothesise that during 
the latter stages of infection (or following antibiotic treatment), plasmacytoid pDC 
may become activated by pathogen related products e.g. non-methylated CpG-DNA,
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that may be released into the local milieu by dead bacteria.  Therefore we would like 
to assess the influx of plasmacytoid pDC to the lung and draining lymph nodes by 
flow  cytometry  during  the  course  of  MTb  infection  and  in  the  presence  of 
antibiotics.  In addition,  120G8 mAb depletion of plasmacytoid pDC late after MTb 
infection  will  allow us to  confirm if this DC subset plays  any regulatory role as 
suggested previously in models of allergy (de Heer et al., 2004) and graft tolerance 
(Orchando et al, 2006).
In summary, our studies suggest that IL-10 and Tregs both function together in order 
to regulate bacterial clearance during the immune response to MTb.  In contrast to 
murine studies in asthma, we could assign no regulatory role for plasmacytoid pDC 
on bacterial clearance.  Our findings highlight an important regulatory pathway that 
MTb could be exploiting in order to survive and persist within infected hosts that 
may have important clinical implications for the design of novel immune therapies.
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The  role  of  plasmacvtoid  precursor  dendritic  cells  in  anti-mvcobacterial 
immunity,
Paul Redford1 . Andre Boonstra1 , Mary Holman1, Giorgio Trinchieri, Greg Bancroft2  
and Anne O’ Garra1.
division of Immunoregulation, National Institute for Medical Research (NIMR), 
London, NW7 1AA, United Kingdom.
2Dept. of Immunology, London School of Hygiene and Tropical Medicine, London, 
UK.
Plasmacytoid precursor dendritic cells (pDC) play a pivotal role in anti-viral 
immune responses through the production of large quantities of type I interferon 
(primarily  IFN-alpha).  Numerous  studies  to  date  have  focused  on  the  role  of 
plasmacytoid pDC during viral infections; however, the relative contribution of this 
DC  subset during bacterial  infections  is  largely unknown.  We have  previously 
reported that plasmacytoid pDC activated in vitro with un-methylated CpG DNA 
produce  high  levels  of  IL-12p70  and  IFN-alpha,  whilst  inducing  strong  Thl 
responses.  IL-12  is  well  known  to  promote  protective  Thl  responses,  and  its 
production can be inhibited under certain conditions, by IFN-alpha.  In line with this, 
recent studies have shown enhanced immune responses to Listeria monocytogenes in 
the absence of IFN-alpha/beta signalling.  The balance of IL-12 versus IFN-alpha 
during  infections  may  therefore  be  important  for  the  outcome  of the  immune 
response.
The  immune  response  to  Mycobacterium  tuberculosis  (MTb)  strongly 
depends on protective Thl  responses, in which IFN-gamma and TNF play pivotal 
roles.  To date,  there is little published data on plasmacytoid pDC or type IIFN 
during in vivo MTb infection.  One study has shown the presence of plasmacytoid 
pDC in human MTb infected tonsil tissue. Another study in a murine model of MTb, 
has postulated that the hyper-virulent phenotype of the clinical isolate HN878 in 
mice is due to induction of type I IFN.  To examine whether Thl responses during 
MTb infection are suboptimal due to the inhibitory effect of IFN-alpha we studied 
the role of plasmacytoid pDC during MTb infection in mice.  In vitro MTb infection 
of bone-marrow-derived myeloid DC resulted in the production of IL-12p40, IL-10 
and TNF, as previously reported by others.  In contrast, in vitro MTb infection of 
freshly isolated plasmacytoid pDC from the spleen did not produce detectable levels 
of  the  cytokines  IL-12p40,  TNF,  IL-10  or  IFN-alpha.  Other  markers  of 
plasmacytoid  pDC  activation  following  in  vitro  MTb  infection  are  under 
investigation.  Currently, we are assessing the role of plasmacytoid pDC in vivo by 
studying the potential  influx of this  DC  subset into  sites of MTb infection, their 
activation state, as well  as the effect of specific depletion of plasmacytoid pDC. 
Determining the role of plasmacytoid pDC during MTb infection will further our 
understanding of the role of type I IFN in the immunology of MTb and in addition 
may highlight important implications for future vaccine design.
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Regulatory  mechanisms  inhibiting  anti-mvcobacterial  immunity  following 
Mycobacterium tuberculosis infection:
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and Anne O’ Garra1.
1  Division of Immunoregulation, National Institute for Medical Research, London, 
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Control and clearance of intracellular pathogens  such  as M.  tuberculosis 
(MTb) is dependent on TNF and the induction of the T-helper 1  (Thl) cytokine IFN- 
gamma  by  IL-12.  Conversely,  IL-10  is  a  suppressive  cytokine  essential  for 
dampening the immune response to a number of intracellular pathogens to limit host 
immune  pathology.  During  infection  with  pathogens  such  as  T.  gondii,  IL-10 
prevents pathogen clearance  but  is  critical  for blocking  immune  pathology.  In 
patients with chronic tuberculosis (TB), T cells are present that produce both IL-10 
and IFN-gamma and stimulation  of MTb-antigen  specific T cells ex-vivo  in  the 
presence of anti-IL-10 antibodies results in their increased proliferation and IFN- 
gamma production.  Although this suggests a role for IL-10 in the regulation of the 
response to MTb, this has not been demonstrated and it is possible that a major role 
at this stage is to limit immune pathology in chronic disease.
To date in murine models of MTb,  a role for IL-10  is controversial.  To 
determine a regulatory role for IL-10 following murine infection, we examined its 
function during both  acute and  chronic  stages of infection with the MTb  strain: 
H37Rv  obtained  from  the  London  School  of  Hygiene  and  Tropical  Medicine 
(LSHTM).  IL-10 receptor blockade during the chronic phase of MTb infection with 
H37Rv (LSHTM) did not affect bacterial levels, even when the number of bacilli 
used to infect mice was decreased.  Despite the lack of effect of IL-10 blockade on 
the bacterial load, during chronic infection with H37Rv (LSHTM), immune cells 
obtained from MTb infected mice produced elevated levels of IFN-gamma when 
stimulated in vitro in the presence of anti-IL-lOR antibodies.  Most importantly, 
neutralisation  of  IL-10  before  and  during  acute  MTb  infection  with  H37Rv 
(LSHTM) resulted in a transient reduction in bacteraemia and enhanced IFN-gamma 
production, suggesting that IL-10 plays a role in regulating the immune response to 
MTb at a very early stage of the innate immune response.  With these findings in 
mind, we hypothesise that IL-10 plays a role to limit the early protective response to 
MTb,  but  may  function  later  to  contain  the  immune  response  and  inhibit  host 
pathology, which we are currently investigating.
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